#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Increased habenular connectivity in opioid users is associated with an α5 subunit nicotinic receptor genetic variant
#Text=Background and Objectives
#Text=Opioid use disorder (OUD) is a chronic disorder with relapse based on both desire for reinforcement (craving) and avoidance of withdrawal.
1-1	0-9	Increased	_	
1-2	10-19	habenular	_	
1-3	20-32	connectivity	_	
1-4	33-35	in	_	
1-5	36-42	opioid	_	
1-6	43-48	users	_	
1-7	49-51	is	_	
1-8	52-62	associated	_	
1-9	63-67	with	_	
1-10	68-70	an	_	
1-11	71-73	α5	_	
1-12	74-81	subunit	_	
1-13	82-91	nicotinic	_	
1-14	92-100	receptor	_	
1-15	101-108	genetic	_	
1-16	109-116	variant	_	
1-17	117-127	Background	_	
1-18	128-131	and	_	
1-19	132-142	Objectives	_	
1-20	143-149	Opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-21	150-153	use	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-22	154-162	disorder	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-23	163-164	(	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-24	164-167	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-25	167-168	)	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-26	169-171	is	_	
1-27	172-173	a	_	
1-28	174-181	chronic	_	
1-29	182-190	disorder	_	
1-30	191-195	with	_	
1-31	196-203	relapse	_	
1-32	204-209	based	_	
1-33	210-212	on	_	
1-34	213-217	both	_	
1-35	218-224	desire	_	
1-36	225-228	for	_	
1-37	229-242	reinforcement	_	
1-38	243-244	(	_	
1-39	244-251	craving	_	
1-40	251-252	)	_	
1-41	253-256	and	_	
1-42	257-266	avoidance	_	
1-43	267-269	of	_	
1-44	270-280	withdrawal	_	
1-45	280-281	.	_	

#Text=The aversive aspect of dependence and relapse has been associated with a small brain structure called the habenula, which expresses large numbers of both opioid and nicotinic receptors.
2-1	282-285	The	_	
2-2	286-294	aversive	_	
2-3	295-301	aspect	_	
2-4	302-304	of	_	
2-5	305-315	dependence	_	
2-6	316-319	and	_	
2-7	320-327	relapse	_	
2-8	328-331	has	_	
2-9	332-336	been	_	
2-10	337-347	associated	_	
2-11	348-352	with	_	
2-12	353-354	a	_	
2-13	355-360	small	_	
2-14	361-366	brain	_	
2-15	367-376	structure	_	
2-16	377-383	called	_	
2-17	384-387	the	_	
2-18	388-396	habenula	_	
2-19	396-397	,	_	
2-20	398-403	which	_	
2-21	404-413	expresses	_	
2-22	414-419	large	_	
2-23	420-427	numbers	_	
2-24	428-430	of	_	
2-25	431-435	both	_	
2-26	436-442	opioid	_	
2-27	443-446	and	_	
2-28	447-456	nicotinic	_	
2-29	457-466	receptors	_	
2-30	466-467	.	_	

#Text=Additionally, opioid withdrawal symptoms can be induced in opioid-treated rodents by blocking not only opioid, but also nicotinic receptors.
3-1	468-480	Additionally	_	
3-2	480-481	,	_	
3-3	482-488	opioid	_	
3-4	489-499	withdrawal	_	
3-5	500-508	symptoms	_	
3-6	509-512	can	_	
3-7	513-515	be	_	
3-8	516-523	induced	_	
3-9	524-526	in	_	
3-10	527-541	opioid-treated	_	
3-11	542-549	rodents	_	
3-12	550-552	by	_	
3-13	553-561	blocking	_	
3-14	562-565	not	_	
3-15	566-570	only	_	
3-16	571-577	opioid	_	
3-17	577-578	,	_	
3-18	579-582	but	_	
3-19	583-587	also	_	
3-20	588-597	nicotinic	_	
3-21	598-607	receptors	_	
3-22	607-608	.	_	

#Text=This receptor co-localization and cross-induction of withdrawal therefore might lead to genetic variation in the nicotinic receptor influencing development of human opioid dependence through its impact on the aversive components of opioid dependence.
4-1	609-613	This	_	
4-2	614-622	receptor	_	
4-3	623-638	co-localization	_	
4-4	639-642	and	_	
4-5	643-658	cross-induction	_	
4-6	659-661	of	_	
4-7	662-672	withdrawal	_	
4-8	673-682	therefore	_	
4-9	683-688	might	_	
4-10	689-693	lead	_	
4-11	694-696	to	_	
4-12	697-704	genetic	_	
4-13	705-714	variation	_	
4-14	715-717	in	_	
4-15	718-721	the	_	
4-16	722-731	nicotinic	_	
4-17	732-740	receptor	_	
4-18	741-752	influencing	_	
4-19	753-764	development	_	
4-20	765-767	of	_	
4-21	768-773	human	_	
4-22	774-780	opioid	_	
4-23	781-791	dependence	_	
4-24	792-799	through	_	
4-25	800-803	its	_	
4-26	804-810	impact	_	
4-27	811-813	on	_	
4-28	814-817	the	_	
4-29	818-826	aversive	_	
4-30	827-837	components	_	
4-31	838-840	of	_	
4-32	841-847	opioid	_	
4-33	848-858	dependence	_	
4-34	858-859	.	_	

#Text=Methods
#Text=We studied habenular resting state functional connectivity with related brain structures, specifically the striatum.
5-1	860-867	Methods	_	
5-2	868-870	We	_	
5-3	871-878	studied	_	
5-4	879-888	habenular	_	
5-5	889-896	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
5-6	897-902	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
5-7	903-913	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
5-8	914-926	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
5-9	927-931	with	_	
5-10	932-939	related	_	
5-11	940-945	brain	_	
5-12	946-956	structures	_	
5-13	956-957	,	_	
5-14	958-970	specifically	_	
5-15	971-974	the	_	
5-16	975-983	striatum	_	
5-17	983-984	.	_	

#Text=We compared abstinent psychiatric patients who use opioids (N=51) to psychiatric patients who don’t (N=254) to identify an endophenotype of opioid use that focused on withdrawal avoidance and aversion rather than the more commonly examined craving aspects of relapse.
6-1	985-987	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-2	988-996	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-3	997-1006	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[4]	
6-4	1007-1018	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-5	1019-1027	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[5]	
6-6	1028-1031	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[5]	
6-7	1032-1035	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[5]	
6-8	1036-1043	opioids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[5]	
6-9	1044-1045	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-10	1045-1046	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-11	1046-1047	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-12	1047-1049	51	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-13	1049-1050	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-14	1051-1053	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-15	1054-1065	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-16	1066-1074	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
6-17	1075-1078	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
6-18	1079-1082	don	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
6-19	1082-1083	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
6-20	1083-1084	t	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
6-21	1085-1086	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-22	1086-1087	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-23	1087-1088	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-24	1088-1091	254	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-25	1091-1092	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-26	1093-1095	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-27	1096-1104	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-28	1105-1107	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-29	1108-1121	endophenotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-30	1122-1124	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-31	1125-1131	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-32	1132-1135	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-33	1136-1140	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-34	1141-1148	focused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-35	1149-1151	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-36	1152-1162	withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-37	1163-1172	avoidance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-38	1173-1176	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-39	1177-1185	aversion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-40	1186-1192	rather	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-41	1193-1197	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-42	1198-1201	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-43	1202-1206	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-44	1207-1215	commonly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-45	1216-1224	examined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-46	1225-1232	craving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-47	1233-1240	aspects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-48	1241-1243	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-49	1244-1251	relapse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
6-50	1251-1252	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Results
#Text=We found that habenula – striatal connectivity was stronger in opioid-using patients.
7-1	1253-1260	Results	_	
7-2	1261-1263	We	_	
7-3	1264-1269	found	_	
7-4	1270-1274	that	_	
7-5	1275-1283	habenula	_	
7-6	1284-1285	–	_	
7-7	1286-1294	striatal	_	
7-8	1295-1307	connectivity	_	
7-9	1308-1311	was	_	
7-10	1312-1320	stronger	_	
7-11	1321-1323	in	_	
7-12	1324-1336	opioid-using	_	
7-13	1337-1345	patients	_	
7-14	1345-1346	.	_	

#Text=Increased habenula-striatum connectivity was observed in opioid-using patients with the low risk rs16969968 GG genotype, but not in patients carrying the high risk AG or AA genotypes.
8-1	1347-1356	Increased	_	
8-2	1357-1374	habenula-striatum	_	
8-3	1375-1387	connectivity	_	
8-4	1388-1391	was	_	
8-5	1392-1400	observed	_	
8-6	1401-1403	in	_	
8-7	1404-1416	opioid-using	_	
8-8	1417-1425	patients	_	
8-9	1426-1430	with	_	
8-10	1431-1434	the	_	
8-11	1435-1438	low	_	
8-12	1439-1443	risk	_	
8-13	1444-1454	rs16969968	_	
8-14	1455-1457	GG	_	
8-15	1458-1466	genotype	_	
8-16	1466-1467	,	_	
8-17	1468-1471	but	_	
8-18	1472-1475	not	_	
8-19	1476-1478	in	_	
8-20	1479-1487	patients	_	
8-21	1488-1496	carrying	_	
8-22	1497-1500	the	_	
8-23	1501-1505	high	_	
8-24	1506-1510	risk	_	
8-25	1511-1513	AG	_	
8-26	1514-1516	or	_	
8-27	1517-1519	AA	_	
8-28	1520-1529	genotypes	_	
8-29	1529-1530	.	_	

#Text=Conclusions
#Text=We propose that increased habenula – striatum functional connectivity may be modulated by the nicotinic receptor variant rs16969968 and may lead to increased opioid use.
9-1	1531-1542	Conclusions	_	
9-2	1543-1545	We	_	
9-3	1546-1553	propose	_	
9-4	1554-1558	that	_	
9-5	1559-1568	increased	_	
9-6	1569-1577	habenula	_	
9-7	1578-1579	–	_	
9-8	1580-1588	striatum	_	
9-9	1589-1599	functional	_	
9-10	1600-1612	connectivity	_	
9-11	1613-1616	may	_	
9-12	1617-1619	be	_	
9-13	1620-1629	modulated	_	
9-14	1630-1632	by	_	
9-15	1633-1636	the	_	
9-16	1637-1646	nicotinic	_	
9-17	1647-1655	receptor	_	
9-18	1656-1663	variant	_	
9-19	1664-1674	rs16969968	_	
9-20	1675-1678	and	_	
9-21	1679-1682	may	_	
9-22	1683-1687	lead	_	
9-23	1688-1690	to	_	
9-24	1691-1700	increased	_	
9-25	1701-1707	opioid	_	
9-26	1708-1711	use	_	
9-27	1711-1712	.	_	

#Text=Scientific Significance
#Text=Our data uncovered a promising brain target for development of novel anti-addiction therapies and may help the development of personalized therapies against opioid abuse.
10-1	1713-1723	Scientific	_	
10-2	1724-1736	Significance	_	
10-3	1737-1740	Our	_	
10-4	1741-1745	data	_	
10-5	1746-1755	uncovered	_	
10-6	1756-1757	a	_	
10-7	1758-1767	promising	_	
10-8	1768-1773	brain	_	
10-9	1774-1780	target	_	
10-10	1781-1784	for	_	
10-11	1785-1796	development	_	
10-12	1797-1799	of	_	
10-13	1800-1805	novel	_	
10-14	1806-1820	anti-addiction	_	
10-15	1821-1830	therapies	_	
10-16	1831-1834	and	_	
10-17	1835-1838	may	_	
10-18	1839-1843	help	_	
10-19	1844-1847	the	_	
10-20	1848-1859	development	_	
10-21	1860-1862	of	_	
10-22	1863-1875	personalized	_	
10-23	1876-1885	therapies	_	
10-24	1886-1893	against	_	
10-25	1894-1900	opioid	_	
10-26	1901-1906	abuse	_	
10-27	1906-1907	.	_	

#Text=Introduction
#Text=Abuse of both prescription opioids and heroin has increased over the last several years, leading to more reported cases of Opioid Use Disorder (OUD).
11-1	1908-1920	Introduction	_	
11-2	1921-1926	Abuse	_	
11-3	1927-1929	of	_	
11-4	1930-1934	both	_	
11-5	1935-1947	prescription	_	
11-6	1948-1955	opioids	_	
11-7	1956-1959	and	_	
11-8	1960-1966	heroin	_	
11-9	1967-1970	has	_	
11-10	1971-1980	increased	_	
11-11	1981-1985	over	_	
11-12	1986-1989	the	_	
11-13	1990-1994	last	_	
11-14	1995-2002	several	_	
11-15	2003-2008	years	_	
11-16	2008-2009	,	_	
11-17	2010-2017	leading	_	
11-18	2018-2020	to	_	
11-19	2021-2025	more	_	
11-20	2026-2034	reported	_	
11-21	2035-2040	cases	_	
11-22	2041-2043	of	_	
11-23	2044-2050	Opioid	_	
11-24	2051-2054	Use	_	
11-25	2055-2063	Disorder	_	
11-26	2064-2065	(	_	
11-27	2065-2068	OUD	_	
11-28	2068-2069	)	_	
11-29	2069-2070	.	_	

#Text=Between 2000 and 2014, annual deaths from abuse of prescription opioids increased from 4,400 to 18,900, while the number of deaths due to heroin overdose increased from 1,800 to 10,600 in the USA.
12-1	2071-2078	Between	_	
12-2	2079-2083	2000	_	
12-3	2084-2087	and	_	
12-4	2088-2092	2014	_	
12-5	2092-2093	,	_	
12-6	2094-2100	annual	_	
12-7	2101-2107	deaths	_	
12-8	2108-2112	from	_	
12-9	2113-2118	abuse	_	
12-10	2119-2121	of	_	
12-11	2122-2134	prescription	_	
12-12	2135-2142	opioids	_	
12-13	2143-2152	increased	_	
12-14	2153-2157	from	_	
12-15	2158-2163	4,400	_	
12-16	2164-2166	to	_	
12-17	2167-2173	18,900	_	
12-18	2173-2174	,	_	
12-19	2175-2180	while	_	
12-20	2181-2184	the	_	
12-21	2185-2191	number	_	
12-22	2192-2194	of	_	
12-23	2195-2201	deaths	_	
12-24	2202-2205	due	_	
12-25	2206-2208	to	_	
12-26	2209-2215	heroin	_	
12-27	2216-2224	overdose	_	
12-28	2225-2234	increased	_	
12-29	2235-2239	from	_	
12-30	2240-2245	1,800	_	
12-31	2246-2248	to	_	
12-32	2249-2255	10,600	_	
12-33	2256-2258	in	_	
12-34	2259-2262	the	_	
12-35	2263-2266	USA	_	
12-36	2266-2267	.	_	

#Text=Motivational drivers for continued opioid use include first, seeking the rewards and positive reinforcement of acute opioid use and second, avoiding withdrawal and its negative reinforcement after dependence has developed.
13-1	2268-2280	Motivational	_	
13-2	2281-2288	drivers	_	
13-3	2289-2292	for	_	
13-4	2293-2302	continued	_	
13-5	2303-2309	opioid	_	
13-6	2310-2313	use	_	
13-7	2314-2321	include	_	
13-8	2322-2327	first	_	
13-9	2327-2328	,	_	
13-10	2329-2336	seeking	_	
13-11	2337-2340	the	_	
13-12	2341-2348	rewards	_	
13-13	2349-2352	and	_	
13-14	2353-2361	positive	_	
13-15	2362-2375	reinforcement	_	
13-16	2376-2378	of	_	
13-17	2379-2384	acute	_	
13-18	2385-2391	opioid	_	
13-19	2392-2395	use	_	
13-20	2396-2399	and	_	
13-21	2400-2406	second	_	
13-22	2406-2407	,	_	
13-23	2408-2416	avoiding	_	
13-24	2417-2427	withdrawal	_	
13-25	2428-2431	and	_	
13-26	2432-2435	its	_	
13-27	2436-2444	negative	_	
13-28	2445-2458	reinforcement	_	
13-29	2459-2464	after	_	
13-30	2465-2475	dependence	_	
13-31	2476-2479	has	_	
13-32	2480-2489	developed	_	
13-33	2489-2490	.	_	

#Text=The second component, withdrawal avoidance, can include both acute opioid withdrawal syndrome (1–2 weeks) and protracted withdrawal that can persist for months after discontinuation.
14-1	2491-2494	The	_	
14-2	2495-2501	second	_	
14-3	2502-2511	component	_	
14-4	2511-2512	,	_	
14-5	2513-2523	withdrawal	_	
14-6	2524-2533	avoidance	_	
14-7	2533-2534	,	_	
14-8	2535-2538	can	_	
14-9	2539-2546	include	_	
14-10	2547-2551	both	_	
14-11	2552-2557	acute	_	
14-12	2558-2564	opioid	_	
14-13	2565-2575	withdrawal	_	
14-14	2576-2584	syndrome	_	
14-15	2585-2586	(	_	
14-16	2586-2587	1	_	
14-17	2587-2588	–	_	
14-18	2588-2589	2	_	
14-19	2590-2595	weeks	_	
14-20	2595-2596	)	_	
14-21	2597-2600	and	_	
14-22	2601-2611	protracted	_	
14-23	2612-2622	withdrawal	_	
14-24	2623-2627	that	_	
14-25	2628-2631	can	_	
14-26	2632-2639	persist	_	
14-27	2640-2643	for	_	
14-28	2644-2650	months	_	
14-29	2651-2656	after	_	
14-30	2657-2672	discontinuation	_	
14-31	2672-2673	.	_	

#Text=While there are no good animal models of protracted withdrawal and negative reinforcement, precipitated opioid withdrawal in rodents serves as an animal model of acute withdrawal.
15-1	2674-2679	While	_	
15-2	2680-2685	there	_	
15-3	2686-2689	are	_	
15-4	2690-2692	no	_	
15-5	2693-2697	good	_	
15-6	2698-2704	animal	_	
15-7	2705-2711	models	_	
15-8	2712-2714	of	_	
15-9	2715-2725	protracted	_	
15-10	2726-2736	withdrawal	_	
15-11	2737-2740	and	_	
15-12	2741-2749	negative	_	
15-13	2750-2763	reinforcement	_	
15-14	2763-2764	,	_	
15-15	2765-2777	precipitated	_	
15-16	2778-2784	opioid	_	
15-17	2785-2795	withdrawal	_	
15-18	2796-2798	in	_	
15-19	2799-2806	rodents	_	
15-20	2807-2813	serves	_	
15-21	2814-2816	as	_	
15-22	2817-2819	an	_	
15-23	2820-2826	animal	_	
15-24	2827-2832	model	_	
15-25	2833-2835	of	_	
15-26	2836-2841	acute	_	
15-27	2842-2852	withdrawal	_	
15-28	2852-2853	.	_	

#Text=In this model, a mouse or rat is semi-chronically treated with morphine, followed by precipitated withdrawal using an opioid receptor antagonist, such as naloxone.
16-1	2854-2856	In	_	
16-2	2857-2861	this	_	
16-3	2862-2867	model	_	
16-4	2867-2868	,	_	
16-5	2869-2870	a	_	
16-6	2871-2876	mouse	_	
16-7	2877-2879	or	_	
16-8	2880-2883	rat	_	
16-9	2884-2886	is	_	
16-10	2887-2903	semi-chronically	_	
16-11	2904-2911	treated	_	
16-12	2912-2916	with	_	
16-13	2917-2925	morphine	_	
16-14	2925-2926	,	_	
16-15	2927-2935	followed	_	
16-16	2936-2938	by	_	
16-17	2939-2951	precipitated	_	
16-18	2952-2962	withdrawal	_	
16-19	2963-2968	using	_	
16-20	2969-2971	an	_	
16-21	2972-2978	opioid	_	
16-22	2979-2987	receptor	_	
16-23	2988-2998	antagonist	_	
16-24	2998-2999	,	_	
16-25	3000-3004	such	_	
16-26	3005-3007	as	_	
16-27	3008-3016	naloxone	_	
16-28	3016-3017	.	_	

#Text=A rodent model of withdrawal also has been successfully used for nicotine, precipitating withdrawal following semi-chronic nicotine treatment with the nicotinic receptor blocker mecamylamine.
17-1	3018-3019	A	_	
17-2	3020-3026	rodent	_	
17-3	3027-3032	model	_	
17-4	3033-3035	of	_	
17-5	3036-3046	withdrawal	_	
17-6	3047-3051	also	_	
17-7	3052-3055	has	_	
17-8	3056-3060	been	_	
17-9	3061-3073	successfully	_	
17-10	3074-3078	used	_	
17-11	3079-3082	for	_	
17-12	3083-3091	nicotine	_	
17-13	3091-3092	,	_	
17-14	3093-3106	precipitating	_	
17-15	3107-3117	withdrawal	_	
17-16	3118-3127	following	_	
17-17	3128-3140	semi-chronic	_	
17-18	3141-3149	nicotine	_	
17-19	3150-3159	treatment	_	
17-20	3160-3164	with	_	
17-21	3165-3168	the	_	
17-22	3169-3178	nicotinic	_	
17-23	3179-3187	receptor	_	
17-24	3188-3195	blocker	_	
17-25	3196-3208	mecamylamine	_	
17-26	3208-3209	.	_	

#Text=Interestingly, in rodents nicotine withdrawal can be precipitated with naloxone, while morphine withdrawal can be modified by mecamylamine.
18-1	3210-3223	Interestingly	_	
18-2	3223-3224	,	_	
18-3	3225-3227	in	_	
18-4	3228-3235	rodents	_	
18-5	3236-3244	nicotine	_	
18-6	3245-3255	withdrawal	_	
18-7	3256-3259	can	_	
18-8	3260-3262	be	_	
18-9	3263-3275	precipitated	_	
18-10	3276-3280	with	_	
18-11	3281-3289	naloxone	_	
18-12	3289-3290	,	_	
18-13	3291-3296	while	_	
18-14	3297-3305	morphine	_	
18-15	3306-3316	withdrawal	_	
18-16	3317-3320	can	_	
18-17	3321-3323	be	_	
18-18	3324-3332	modified	_	
18-19	3333-3335	by	_	
18-20	3336-3348	mecamylamine	_	
18-21	3348-3349	.	_	

#Text=This opioid/nicotine cross-talk is likely to occur within a brain region expressing high numbers of receptors responsive to both drugs, such as the habenula.
19-1	3350-3354	This	_	
19-2	3355-3361	opioid	_	
19-3	3361-3362	/	_	
19-4	3362-3370	nicotine	_	
19-5	3371-3381	cross-talk	_	
19-6	3382-3384	is	_	
19-7	3385-3391	likely	_	
19-8	3392-3394	to	_	
19-9	3395-3400	occur	_	
19-10	3401-3407	within	_	
19-11	3408-3409	a	_	
19-12	3410-3415	brain	_	
19-13	3416-3422	region	_	
19-14	3423-3433	expressing	_	
19-15	3434-3438	high	_	
19-16	3439-3446	numbers	_	
19-17	3447-3449	of	_	
19-18	3450-3459	receptors	_	
19-19	3460-3470	responsive	_	
19-20	3471-3473	to	_	
19-21	3474-3478	both	_	
19-22	3479-3484	drugs	_	
19-23	3484-3485	,	_	
19-24	3486-3490	such	_	
19-25	3491-3493	as	_	
19-26	3494-3497	the	_	
19-27	3498-3506	habenula	_	
19-28	3506-3507	.	_	

#Text=The habenula is a small brain region activated by negative reinforcers, such as lack of expected reward.
20-1	3508-3511	The	_	
20-2	3512-3520	habenula	_	
20-3	3521-3523	is	_	
20-4	3524-3525	a	_	
20-5	3526-3531	small	_	
20-6	3532-3537	brain	_	
20-7	3538-3544	region	_	
20-8	3545-3554	activated	_	
20-9	3555-3557	by	_	
20-10	3558-3566	negative	_	
20-11	3567-3578	reinforcers	_	
20-12	3578-3579	,	_	
20-13	3580-3584	such	_	
20-14	3585-3587	as	_	
20-15	3588-3592	lack	_	
20-16	3593-3595	of	_	
20-17	3596-3604	expected	_	
20-18	3605-3611	reward	_	
20-19	3611-3612	.	_	

#Text=The habenula has substantial concentrations of both µ-opioid and α5 and β4 subunits of the nicotinic receptors (Allen Brain Atlas, www.brain-map.org).
21-1	3613-3616	The	_	
21-2	3617-3625	habenula	_	
21-3	3626-3629	has	_	
21-4	3630-3641	substantial	_	
21-5	3642-3656	concentrations	_	
21-6	3657-3659	of	_	
21-7	3660-3664	both	_	
21-8	3665-3673	µ-opioid	_	
21-9	3674-3677	and	_	
21-10	3678-3680	α5	_	
21-11	3681-3684	and	_	
21-12	3685-3687	β4	_	
21-13	3688-3696	subunits	_	
21-14	3697-3699	of	_	
21-15	3700-3703	the	_	
21-16	3704-3713	nicotinic	_	
21-17	3714-3723	receptors	_	
21-18	3724-3725	(	_	
21-19	3725-3730	Allen	_	
21-20	3731-3736	Brain	_	
21-21	3737-3742	Atlas	_	
21-22	3742-3743	,	_	
21-23	3744-3761	www.brain-map.org	_	
21-24	3761-3762	)	_	
21-25	3762-3763	.	_	

#Text=We previously showed that blocking nicotinic receptors with mecamylamine in the habenula precipitates nicotine withdrawal, and that the α5 and β4 nicotinic receptor subunits are both expressed in the habenula and necessary to observe nicotine withdrawal.
22-1	3764-3766	We	_	
22-2	3767-3777	previously	_	
22-3	3778-3784	showed	_	
22-4	3785-3789	that	_	
22-5	3790-3798	blocking	_	
22-6	3799-3808	nicotinic	_	
22-7	3809-3818	receptors	_	
22-8	3819-3823	with	_	
22-9	3824-3836	mecamylamine	_	
22-10	3837-3839	in	_	
22-11	3840-3843	the	_	
22-12	3844-3852	habenula	_	
22-13	3853-3865	precipitates	_	
22-14	3866-3874	nicotine	_	
22-15	3875-3885	withdrawal	_	
22-16	3885-3886	,	_	
22-17	3887-3890	and	_	
22-18	3891-3895	that	_	
22-19	3896-3899	the	_	
22-20	3900-3902	α5	_	
22-21	3903-3906	and	_	
22-22	3907-3909	β4	_	
22-23	3910-3919	nicotinic	_	
22-24	3920-3928	receptor	_	
22-25	3929-3937	subunits	_	
22-26	3938-3941	are	_	
22-27	3942-3946	both	_	
22-28	3947-3956	expressed	_	
22-29	3957-3959	in	_	
22-30	3960-3963	the	_	
22-31	3964-3972	habenula	_	
22-32	3973-3976	and	_	
22-33	3977-3986	necessary	_	
22-34	3987-3989	to	_	
22-35	3990-3997	observe	_	
22-36	3998-4006	nicotine	_	
22-37	4007-4017	withdrawal	_	
22-38	4017-4018	.	_	

#Text=One of the habenula’s main downstream targets, the interpeduncular nucleus, also expresses the α2 nicotinic receptor subunit, which may also be important for nicotine withdrawal.
23-1	4019-4022	One	_	
23-2	4023-4025	of	_	
23-3	4026-4029	the	_	
23-4	4030-4038	habenula	_	
23-5	4038-4039	’	_	
23-6	4039-4040	s	_	
23-7	4041-4045	main	_	
23-8	4046-4056	downstream	_	
23-9	4057-4064	targets	_	
23-10	4064-4065	,	_	
23-11	4066-4069	the	_	
23-12	4070-4085	interpeduncular	_	
23-13	4086-4093	nucleus	_	
23-14	4093-4094	,	_	
23-15	4095-4099	also	_	
23-16	4100-4109	expresses	_	
23-17	4110-4113	the	_	
23-18	4114-4116	α2	_	
23-19	4117-4126	nicotinic	_	
23-20	4127-4135	receptor	_	
23-21	4136-4143	subunit	_	
23-22	4143-4144	,	_	
23-23	4145-4150	which	_	
23-24	4151-4154	may	_	
23-25	4155-4159	also	_	
23-26	4160-4162	be	_	
23-27	4163-4172	important	_	
23-28	4173-4176	for	_	
23-29	4177-4185	nicotine	_	
23-30	4186-4196	withdrawal	_	
23-31	4196-4197	.	_	

#Text=Thus, we hypothesize that cross-talk between the nicotinic and the opioid systems may occur within the habenula.
24-1	4198-4202	Thus	_	
24-2	4202-4203	,	_	
24-3	4204-4206	we	_	
24-4	4207-4218	hypothesize	_	
24-5	4219-4223	that	_	
24-6	4224-4234	cross-talk	_	
24-7	4235-4242	between	_	
24-8	4243-4246	the	_	
24-9	4247-4256	nicotinic	_	
24-10	4257-4260	and	_	
24-11	4261-4264	the	_	
24-12	4265-4271	opioid	_	
24-13	4272-4279	systems	_	
24-14	4280-4283	may	_	
24-15	4284-4289	occur	_	
24-16	4290-4296	within	_	
24-17	4297-4300	the	_	
24-18	4301-4309	habenula	_	
24-19	4309-4310	.	_	

#Text=Three of the nicotinic receptor subunits necessary for mouse nicotine withdrawal and other nicotine-induced behaviors (α3, α5, β4) were later shown to be important for tobacco abuse and related diseases in humans.
25-1	4311-4316	Three	_	
25-2	4317-4319	of	_	
25-3	4320-4323	the	_	
25-4	4324-4333	nicotinic	_	
25-5	4334-4342	receptor	_	
25-6	4343-4351	subunits	_	
25-7	4352-4361	necessary	_	
25-8	4362-4365	for	_	
25-9	4366-4371	mouse	_	
25-10	4372-4380	nicotine	_	
25-11	4381-4391	withdrawal	_	
25-12	4392-4395	and	_	
25-13	4396-4401	other	_	
25-14	4402-4418	nicotine-induced	_	
25-15	4419-4428	behaviors	_	
25-16	4429-4430	(	_	
25-17	4430-4432	α3	_	
25-18	4432-4433	,	_	
25-19	4434-4436	α5	_	
25-20	4436-4437	,	_	
25-21	4438-4440	β4	_	
25-22	4440-4441	)	_	
25-23	4442-4446	were	_	
25-24	4447-4452	later	_	
25-25	4453-4458	shown	_	
25-26	4459-4461	to	_	
25-27	4462-4464	be	_	
25-28	4465-4474	important	_	
25-29	4475-4478	for	_	
25-30	4479-4486	tobacco	_	
25-31	4487-4492	abuse	_	
25-32	4493-4496	and	_	
25-33	4497-4504	related	_	
25-34	4505-4513	diseases	_	
25-35	4514-4516	in	_	
25-36	4517-4523	humans	_	
25-37	4523-4524	.	_	

#Text=The genes coding for the α3, α5, and β4 nicotinic receptors are clustered on the human chromosome 15q25.1, where a large number of single nucleotide polymorphisms (SNPs) in high linkage disequilibrium have been found to be associated with tobacco abuse, terminal lung cancer, and other tobacco-related phenotypes.
26-1	4525-4528	The	_	
26-2	4529-4534	genes	_	
26-3	4535-4541	coding	_	
26-4	4542-4545	for	_	
26-5	4546-4549	the	_	
26-6	4550-4552	α3	_	
26-7	4552-4553	,	_	
26-8	4554-4556	α5	_	
26-9	4556-4557	,	_	
26-10	4558-4561	and	_	
26-11	4562-4564	β4	_	
26-12	4565-4574	nicotinic	_	
26-13	4575-4584	receptors	_	
26-14	4585-4588	are	_	
26-15	4589-4598	clustered	_	
26-16	4599-4601	on	_	
26-17	4602-4605	the	_	
26-18	4606-4611	human	_	
26-19	4612-4622	chromosome	_	
26-20	4623-4630	15q25.1	_	
26-21	4630-4631	,	_	
26-22	4632-4637	where	_	
26-23	4638-4639	a	_	
26-24	4640-4645	large	_	
26-25	4646-4652	number	_	
26-26	4653-4655	of	_	
26-27	4656-4662	single	_	
26-28	4663-4673	nucleotide	_	
26-29	4674-4687	polymorphisms	_	
26-30	4688-4689	(	_	
26-31	4689-4693	SNPs	_	
26-32	4693-4694	)	_	
26-33	4695-4697	in	_	
26-34	4698-4702	high	_	
26-35	4703-4710	linkage	_	
26-36	4711-4725	disequilibrium	_	
26-37	4726-4730	have	_	
26-38	4731-4735	been	_	
26-39	4736-4741	found	_	
26-40	4742-4744	to	_	
26-41	4745-4747	be	_	
26-42	4748-4758	associated	_	
26-43	4759-4763	with	_	
26-44	4764-4771	tobacco	_	
26-45	4772-4777	abuse	_	
26-46	4777-4778	,	_	
26-47	4779-4787	terminal	_	
26-48	4788-4792	lung	_	
26-49	4793-4799	cancer	_	
26-50	4799-4800	,	_	
26-51	4801-4804	and	_	
26-52	4805-4810	other	_	
26-53	4811-4826	tobacco-related	_	
26-54	4827-4837	phenotypes	_	
26-55	4837-4838	.	_	

#Text=The rs16969968 SNP is located in the α5 subunit of the nicotinic acetylcholine receptor gene and has been linked not only to tobacco, but also to opioid, alcohol, and cocaine use disorders.
27-1	4839-4842	The	_	
27-2	4843-4853	rs16969968	_	
27-3	4854-4857	SNP	_	
27-4	4858-4860	is	_	
27-5	4861-4868	located	_	
27-6	4869-4871	in	_	
27-7	4872-4875	the	_	
27-8	4876-4878	α5	_	
27-9	4879-4886	subunit	_	
27-10	4887-4889	of	_	
27-11	4890-4893	the	_	
27-12	4894-4903	nicotinic	_	
27-13	4904-4917	acetylcholine	_	
27-14	4918-4926	receptor	_	
27-15	4927-4931	gene	_	
27-16	4932-4935	and	_	
27-17	4936-4939	has	_	
27-18	4940-4944	been	_	
27-19	4945-4951	linked	_	
27-20	4952-4955	not	_	
27-21	4956-4960	only	_	
27-22	4961-4963	to	_	
27-23	4964-4971	tobacco	_	
27-24	4971-4972	,	_	
27-25	4973-4976	but	_	
27-26	4977-4981	also	_	
27-27	4982-4984	to	_	
27-28	4985-4991	opioid	_	
27-29	4991-4992	,	_	
27-30	4993-5000	alcohol	_	
27-31	5000-5001	,	_	
27-32	5002-5005	and	_	
27-33	5006-5013	cocaine	_	
27-34	5014-5017	use	_	
27-35	5018-5027	disorders	_	
27-36	5027-5028	.	_	

#Text=Presence of the rs16969968 A allele increases risk of use and disease related to tobacco and alcohol while also increasing risk of high severity dependence for opioid users.
28-1	5029-5037	Presence	_	
28-2	5038-5040	of	_	
28-3	5041-5044	the	_	
28-4	5045-5055	rs16969968	_	
28-5	5056-5057	A	_	
28-6	5058-5064	allele	_	
28-7	5065-5074	increases	_	
28-8	5075-5079	risk	_	
28-9	5080-5082	of	_	
28-10	5083-5086	use	_	
28-11	5087-5090	and	_	
28-12	5091-5098	disease	_	
28-13	5099-5106	related	_	
28-14	5107-5109	to	_	
28-15	5110-5117	tobacco	_	
28-16	5118-5121	and	_	
28-17	5122-5129	alcohol	_	
28-18	5130-5135	while	_	
28-19	5136-5140	also	_	
28-20	5141-5151	increasing	_	
28-21	5152-5156	risk	_	
28-22	5157-5159	of	_	
28-23	5160-5164	high	_	
28-24	5165-5173	severity	_	
28-25	5174-5184	dependence	_	
28-26	5185-5188	for	_	
28-27	5189-5195	opioid	_	
28-28	5196-5201	users	_	
28-29	5201-5202	.	_	

#Text=A allele carriers, however, have a decreased risk of abuse of cocaine.
29-1	5203-5204	A	_	
29-2	5205-5211	allele	_	
29-3	5212-5220	carriers	_	
29-4	5220-5221	,	_	
29-5	5222-5229	however	_	
29-6	5229-5230	,	_	
29-7	5231-5235	have	_	
29-8	5236-5237	a	_	
29-9	5238-5247	decreased	_	
29-10	5248-5252	risk	_	
29-11	5253-5255	of	_	
29-12	5256-5261	abuse	_	
29-13	5262-5264	of	_	
29-14	5265-5272	cocaine	_	
29-15	5272-5273	.	_	

#Text=The habenula indirectly decreases dopamine availability in downstream striatal areas.
30-1	5274-5277	The	_	
30-2	5278-5286	habenula	_	
30-3	5287-5297	indirectly	_	
30-4	5298-5307	decreases	_	
30-5	5308-5316	dopamine	_	
30-6	5317-5329	availability	_	
30-7	5330-5332	in	_	
30-8	5333-5343	downstream	_	
30-9	5344-5352	striatal	_	
30-10	5353-5358	areas	_	
30-11	5358-5359	.	_	

#Text=Activation of the habenula following negative events results in inhibition of midbrain dopaminergic cells, ultimately affecting dopamine levels in the striatum.
31-1	5360-5370	Activation	_	
31-2	5371-5373	of	_	
31-3	5374-5377	the	_	
31-4	5378-5386	habenula	_	
31-5	5387-5396	following	_	
31-6	5397-5405	negative	_	
31-7	5406-5412	events	_	
31-8	5413-5420	results	_	
31-9	5421-5423	in	_	
31-10	5424-5434	inhibition	_	
31-11	5435-5437	of	_	
31-12	5438-5446	midbrain	_	
31-13	5447-5459	dopaminergic	_	
31-14	5460-5465	cells	_	
31-15	5465-5466	,	_	
31-16	5467-5477	ultimately	_	
31-17	5478-5487	affecting	_	
31-18	5488-5496	dopamine	_	
31-19	5497-5503	levels	_	
31-20	5504-5506	in	_	
31-21	5507-5510	the	_	
31-22	5511-5519	striatum	_	
31-23	5519-5520	.	_	

#Text=Given the role dopamine plays in reward, habenula-striatum connectivity is likely to be a major player in OUD.
32-1	5521-5526	Given	_	
32-2	5527-5530	the	_	
32-3	5531-5535	role	_	
32-4	5536-5544	dopamine	_	
32-5	5545-5550	plays	_	
32-6	5551-5553	in	_	
32-7	5554-5560	reward	_	
32-8	5560-5561	,	_	
32-9	5562-5579	habenula-striatum	_	
32-10	5580-5592	connectivity	_	
32-11	5593-5595	is	_	
32-12	5596-5602	likely	_	
32-13	5603-5605	to	_	
32-14	5606-5608	be	_	
32-15	5609-5610	a	_	
32-16	5611-5616	major	_	
32-17	5617-5623	player	_	
32-18	5624-5626	in	_	
32-19	5627-5630	OUD	_	
32-20	5630-5631	.	_	

#Text=The habenula also affects the noradrenergic, serotonergic, and cholinergic systems via its anatomical connections to the locus coeruleus, raphe nucleus, and interpeduncular nucleus, respectively.
33-1	5632-5635	The	_	
33-2	5636-5644	habenula	_	
33-3	5645-5649	also	_	
33-4	5650-5657	affects	_	
33-5	5658-5661	the	_	
33-6	5662-5675	noradrenergic	_	
33-7	5675-5676	,	_	
33-8	5677-5689	serotonergic	_	
33-9	5689-5690	,	_	
33-10	5691-5694	and	_	
33-11	5695-5706	cholinergic	_	
33-12	5707-5714	systems	_	
33-13	5715-5718	via	_	
33-14	5719-5722	its	_	
33-15	5723-5733	anatomical	_	
33-16	5734-5745	connections	_	
33-17	5746-5748	to	_	
33-18	5749-5752	the	_	
33-19	5753-5758	locus	_	
33-20	5759-5768	coeruleus	_	
33-21	5768-5769	,	_	
33-22	5770-5775	raphe	_	
33-23	5776-5783	nucleus	_	
33-24	5783-5784	,	_	
33-25	5785-5788	and	_	
33-26	5789-5804	interpeduncular	_	
33-27	5805-5812	nucleus	_	
33-28	5812-5813	,	_	
33-29	5814-5826	respectively	_	
33-30	5826-5827	.	_	

#Text=In addition to modulating the brain’s response to drugs of abuse, the habenula regulates affect and has been implicated in mood disorders and anxiety-like behaviors.
34-1	5828-5830	In	_	
34-2	5831-5839	addition	_	
34-3	5840-5842	to	_	
34-4	5843-5853	modulating	_	
34-5	5854-5857	the	_	
34-6	5858-5863	brain	_	
34-7	5863-5864	’	_	
34-8	5864-5865	s	_	
34-9	5866-5874	response	_	
34-10	5875-5877	to	_	
34-11	5878-5883	drugs	_	
34-12	5884-5886	of	_	
34-13	5887-5892	abuse	_	
34-14	5892-5893	,	_	
34-15	5894-5897	the	_	
34-16	5898-5906	habenula	_	
34-17	5907-5916	regulates	_	
34-18	5917-5923	affect	_	
34-19	5924-5927	and	_	
34-20	5928-5931	has	_	
34-21	5932-5936	been	_	
34-22	5937-5947	implicated	_	
34-23	5948-5950	in	_	
34-24	5951-5955	mood	_	
34-25	5956-5965	disorders	_	
34-26	5966-5969	and	_	
34-27	5970-5982	anxiety-like	_	
34-28	5983-5992	behaviors	_	
34-29	5992-5993	.	_	

#Text=In addition, the habenula is an important locus for pain signaling and sensitivity, likely due to high µ-opioid receptor expression.
35-1	5994-5996	In	_	
35-2	5997-6005	addition	_	
35-3	6005-6006	,	_	
35-4	6007-6010	the	_	
35-5	6011-6019	habenula	_	
35-6	6020-6022	is	_	
35-7	6023-6025	an	_	
35-8	6026-6035	important	_	
35-9	6036-6041	locus	_	
35-10	6042-6045	for	_	
35-11	6046-6050	pain	_	
35-12	6051-6060	signaling	_	
35-13	6061-6064	and	_	
35-14	6065-6076	sensitivity	_	
35-15	6076-6077	,	_	
35-16	6078-6084	likely	_	
35-17	6085-6088	due	_	
35-18	6089-6091	to	_	
35-19	6092-6096	high	_	
35-20	6097-6105	µ-opioid	_	
35-21	6106-6114	receptor	_	
35-22	6115-6125	expression	_	
35-23	6125-6126	.	_	

#Text=To determine the role of the habenula in opioid use and whether the α5 nicotinic acetylcholine receptor SNP rs16969968 is associated with the possible habenular mechanisms of opioid use, we studied the resting state functional connectivity (RSFC) between the habenula and the striatum using functional MRI (fMRI) in psychiatric inpatients with and without opioid use at The Menninger Clinic, a psychiatric clinic in Houston, TX.
36-1	6127-6129	To	_	
36-2	6130-6139	determine	_	
36-3	6140-6143	the	_	
36-4	6144-6148	role	_	
36-5	6149-6151	of	_	
36-6	6152-6155	the	_	
36-7	6156-6164	habenula	_	
36-8	6165-6167	in	_	
36-9	6168-6174	opioid	_	
36-10	6175-6178	use	_	
36-11	6179-6182	and	_	
36-12	6183-6190	whether	_	
36-13	6191-6194	the	_	
36-14	6195-6197	α5	_	
36-15	6198-6207	nicotinic	_	
36-16	6208-6221	acetylcholine	_	
36-17	6222-6230	receptor	_	
36-18	6231-6234	SNP	_	
36-19	6235-6245	rs16969968	_	
36-20	6246-6248	is	_	
36-21	6249-6259	associated	_	
36-22	6260-6264	with	_	
36-23	6265-6268	the	_	
36-24	6269-6277	possible	_	
36-25	6278-6287	habenular	_	
36-26	6288-6298	mechanisms	_	
36-27	6299-6301	of	_	
36-28	6302-6308	opioid	_	
36-29	6309-6312	use	_	
36-30	6312-6313	,	_	
36-31	6314-6316	we	_	
36-32	6317-6324	studied	_	
36-33	6325-6328	the	_	
36-34	6329-6336	resting	_	
36-35	6337-6342	state	_	
36-36	6343-6353	functional	_	
36-37	6354-6366	connectivity	_	
36-38	6367-6368	(	_	
36-39	6368-6372	RSFC	_	
36-40	6372-6373	)	_	
36-41	6374-6381	between	_	
36-42	6382-6385	the	_	
36-43	6386-6394	habenula	_	
36-44	6395-6398	and	_	
36-45	6399-6402	the	_	
36-46	6403-6411	striatum	_	
36-47	6412-6417	using	_	
36-48	6418-6428	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
36-49	6429-6432	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
36-50	6433-6434	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
36-51	6434-6438	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
36-52	6438-6439	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
36-53	6440-6442	in	_	
36-54	6443-6454	psychiatric	_	
36-55	6455-6465	inpatients	_	
36-56	6466-6470	with	_	
36-57	6471-6474	and	_	
36-58	6475-6482	without	_	
36-59	6483-6489	opioid	_	
36-60	6490-6493	use	_	
36-61	6494-6496	at	_	
36-62	6497-6500	The	_	
36-63	6501-6510	Menninger	_	
36-64	6511-6517	Clinic	_	
36-65	6517-6518	,	_	
36-66	6519-6520	a	_	
36-67	6521-6532	psychiatric	_	
36-68	6533-6539	clinic	_	
36-69	6540-6542	in	_	
36-70	6543-6550	Houston	_	
36-71	6550-6551	,	_	
36-72	6552-6554	TX	_	
36-73	6554-6555	.	_	

#Text=Methods
#Text=Participants
#Text=Participants were psychiatric inpatients from a larger study at the Menninger Clinic in Houston, TX, USA (McNair Initiative for Neuroscience Discovery – Menninger/Baylor, or MIND-MB project.
37-1	6556-6563	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
37-2	6564-6576	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-3	6577-6589	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-4	6590-6594	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-5	6595-6606	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-6	6607-6617	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-7	6618-6622	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-8	6623-6624	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-9	6625-6631	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-10	6632-6637	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-11	6638-6640	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-12	6641-6644	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-13	6645-6654	Menninger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-14	6655-6661	Clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-15	6662-6664	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-16	6665-6672	Houston	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-17	6672-6673	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-18	6674-6676	TX	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-19	6676-6677	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-20	6678-6681	USA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-21	6682-6683	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-22	6683-6689	McNair	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-23	6690-6700	Initiative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-24	6701-6704	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-25	6705-6717	Neuroscience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-26	6718-6727	Discovery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-27	6728-6729	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-28	6730-6739	Menninger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-29	6739-6740	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-30	6740-6746	Baylor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-31	6746-6747	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-32	6748-6750	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-33	6751-6758	MIND-MB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-34	6759-6766	project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
37-35	6766-6767	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=All participation was voluntary with approximately 72% of eligible patients consenting to participate.
38-1	6768-6771	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-2	6772-6785	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-3	6786-6789	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-4	6790-6799	voluntary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-5	6800-6804	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-6	6805-6818	approximately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-7	6819-6822	72%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-8	6823-6825	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-9	6826-6834	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-10	6835-6843	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-11	6844-6854	consenting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-12	6855-6857	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-13	6858-6869	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-14	6869-6870	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Psychiatric disorder diagnoses were assessed using the research versions of the Structured Clinical Interview for DSM-IV Disorders (SCID-I/II).
39-1	6871-6882	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-2	6883-6891	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-3	6892-6901	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-4	6902-6906	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-5	6907-6915	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-6	6916-6921	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-7	6922-6925	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-8	6926-6934	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-9	6935-6943	versions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-10	6944-6946	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-11	6947-6950	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-12	6951-6961	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-13	6962-6970	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-14	6971-6980	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-15	6981-6984	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-16	6985-6991	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-17	6992-7001	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-18	7002-7003	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-19	7003-7009	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-20	7009-7010	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-21	7010-7012	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-22	7012-7013	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
39-23	7013-7014	.	_	

#Text=The SCID-I and SCID II were administered by master’s level researchers after reviewing pertinent psychiatric and psychosocial evaluations as well as consulting with the attending psychiatrist.
40-1	7015-7018	The	_	
40-2	7019-7025	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	
40-3	7026-7029	and	_	
40-4	7030-7034	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[9]	
40-5	7035-7037	II	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[9]	
40-6	7038-7042	were	_	
40-7	7043-7055	administered	_	
40-8	7056-7058	by	_	
40-9	7059-7065	master	_	
40-10	7065-7066	’	_	
40-11	7066-7067	s	_	
40-12	7068-7073	level	_	
40-13	7074-7085	researchers	_	
40-14	7086-7091	after	_	
40-15	7092-7101	reviewing	_	
40-16	7102-7111	pertinent	_	
40-17	7112-7123	psychiatric	_	
40-18	7124-7127	and	_	
40-19	7128-7140	psychosocial	_	
40-20	7141-7152	evaluations	_	
40-21	7153-7155	as	_	
40-22	7156-7160	well	_	
40-23	7161-7163	as	_	
40-24	7164-7174	consulting	_	
40-25	7175-7179	with	_	
40-26	7180-7183	the	_	
40-27	7184-7193	attending	_	
40-28	7194-7206	psychiatrist	_	
40-29	7206-7207	.	_	

#Text=Most inpatients showed co-occurring psychiatric illnesses, with the most common diagnoses being major depressive disorder (MDD), anxiety disorders (ANX), personality disorders (PD), and substance use disorders (SUD).
41-1	7208-7212	Most	_	
41-2	7213-7223	inpatients	_	
41-3	7224-7230	showed	_	
41-4	7231-7243	co-occurring	_	
41-5	7244-7255	psychiatric	_	
41-6	7256-7265	illnesses	_	
41-7	7265-7266	,	_	
41-8	7267-7271	with	_	
41-9	7272-7275	the	_	
41-10	7276-7280	most	_	
41-11	7281-7287	common	_	
41-12	7288-7297	diagnoses	_	
41-13	7298-7303	being	_	
41-14	7304-7309	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-15	7310-7320	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-16	7321-7329	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-17	7330-7331	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-18	7331-7334	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-19	7334-7335	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
41-20	7335-7336	,	_	
41-21	7337-7344	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[11]	
41-22	7345-7354	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[11]	
41-23	7355-7356	(	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[11]	
41-24	7356-7359	ANX	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[11]	
41-25	7359-7360	)	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[11]	
41-26	7360-7361	,	_	
41-27	7362-7373	personality	_	
41-28	7374-7383	disorders	_	
41-29	7384-7385	(	_	
41-30	7385-7387	PD	_	
41-31	7387-7388	)	_	
41-32	7388-7389	,	_	
41-33	7390-7393	and	_	
41-34	7394-7403	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-35	7404-7407	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-36	7408-7417	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-37	7418-7419	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-38	7419-7422	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-39	7422-7423	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
41-40	7423-7424	.	_	

#Text=We used the World Health Organization ASSIST scale, which contains 10 subscales for specific drugs to study opioid use.
42-1	7425-7427	We	_	
42-2	7428-7432	used	_	
42-3	7433-7436	the	_	
42-4	7437-7442	World	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[13]	
42-5	7443-7449	Health	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[13]	
42-6	7450-7462	Organization	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[13]	
42-7	7463-7469	ASSIST	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[13]	
42-8	7470-7475	scale	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[13]	
42-9	7475-7476	,	_	
42-10	7477-7482	which	_	
42-11	7483-7491	contains	_	
42-12	7492-7494	10	_	
42-13	7495-7504	subscales	_	
42-14	7505-7508	for	_	
42-15	7509-7517	specific	_	
42-16	7518-7523	drugs	_	
42-17	7524-7526	to	_	
42-18	7527-7532	study	_	
42-19	7533-7539	opioid	_	
42-20	7540-7543	use	_	
42-21	7543-7544	.	_	

#Text=We used the ASSIST scale to divide patients into two groups: low versus moderate/high opioid use (called non-users versus users from now on).
43-1	7545-7547	We	_	
43-2	7548-7552	used	_	
43-3	7553-7556	the	*[14]	
43-4	7557-7563	ASSIST	*[14]	
43-5	7564-7569	scale	*[14]	
43-6	7570-7572	to	_	
43-7	7573-7579	divide	_	
43-8	7580-7588	patients	_	
43-9	7589-7593	into	_	
43-10	7594-7597	two	_	
43-11	7598-7604	groups	_	
43-12	7604-7605	:	_	
43-13	7606-7609	low	_	
43-14	7610-7616	versus	_	
43-15	7617-7625	moderate	_	
43-16	7625-7626	/	_	
43-17	7626-7630	high	_	
43-18	7631-7637	opioid	_	
43-19	7638-7641	use	_	
43-20	7642-7643	(	_	
43-21	7643-7649	called	_	
43-22	7650-7659	non-users	_	
43-23	7660-7666	versus	_	
43-24	7667-7672	users	_	
43-25	7673-7677	from	_	
43-26	7678-7681	now	_	
43-27	7682-7684	on	_	
43-28	7684-7685	)	_	
43-29	7685-7686	.	_	

#Text=From an original group of 316 patients, two were removed for missing ASSIST scale data.
44-1	7687-7691	From	_	
44-2	7692-7694	an	_	
44-3	7695-7703	original	_	
44-4	7704-7709	group	_	
44-5	7710-7712	of	_	
44-6	7713-7716	316	_	
44-7	7717-7725	patients	_	
44-8	7725-7726	,	_	
44-9	7727-7730	two	_	
44-10	7731-7735	were	_	
44-11	7736-7743	removed	_	
44-12	7744-7747	for	_	
44-13	7748-7755	missing	_	
44-14	7756-7762	ASSIST	_	
44-15	7763-7768	scale	_	
44-16	7769-7773	data	_	
44-17	7773-7774	.	_	

#Text=Of the remaining 314 patients, nine patients were removed for missing or low quality MRI data, leaving a final sample of 305 patients (Table 1).
45-1	7775-7777	Of	_	
45-2	7778-7781	the	_	
45-3	7782-7791	remaining	_	
45-4	7792-7795	314	_	
45-5	7796-7804	patients	_	
45-6	7804-7805	,	_	
45-7	7806-7810	nine	_	
45-8	7811-7819	patients	_	
45-9	7820-7824	were	_	
45-10	7825-7832	removed	_	
45-11	7833-7836	for	_	
45-12	7837-7844	missing	_	
45-13	7845-7847	or	_	
45-14	7848-7851	low	_	
45-15	7852-7859	quality	_	
45-16	7860-7863	MRI	_	
45-17	7864-7868	data	_	
45-18	7868-7869	,	_	
45-19	7870-7877	leaving	_	
45-20	7878-7879	a	_	
45-21	7880-7885	final	_	
45-22	7886-7892	sample	_	
45-23	7893-7895	of	_	
45-24	7896-7899	305	_	
45-25	7900-7908	patients	_	
45-26	7909-7910	(	_	
45-27	7910-7915	Table	_	
45-28	7916-7917	1	_	
45-29	7917-7918	)	_	
45-30	7918-7919	.	_	

#Text=Procedures were approved by the Baylor College of Medicine Institutional Review Board and the Research and Development Committee of the MEDVAMC.
46-1	7920-7930	Procedures	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-2	7931-7935	were	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-3	7936-7944	approved	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-4	7945-7947	by	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-5	7948-7951	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-6	7952-7958	Baylor	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-7	7959-7966	College	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-8	7967-7969	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-9	7970-7978	Medicine	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-10	7979-7992	Institutional	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-11	7993-7999	Review	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-12	8000-8005	Board	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-13	8006-8009	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-14	8010-8013	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-15	8014-8022	Research	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-16	8023-8026	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-17	8027-8038	Development	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-18	8039-8048	Committee	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-19	8049-8051	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-20	8052-8055	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-21	8056-8063	MEDVAMC	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	
46-22	8063-8064	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[15]	

#Text=All patients had been drug-free at least since time of admission and were imaged an average of 4.3 days following clinic admission.
47-1	8065-8068	All	_	
47-2	8069-8077	patients	_	
47-3	8078-8081	had	_	
47-4	8082-8086	been	_	
47-5	8087-8096	drug-free	_	
47-6	8097-8099	at	_	
47-7	8100-8105	least	_	
47-8	8106-8111	since	_	
47-9	8112-8116	time	_	
47-10	8117-8119	of	_	
47-11	8120-8129	admission	_	
47-12	8130-8133	and	_	
47-13	8134-8138	were	_	
47-14	8139-8145	imaged	_	
47-15	8146-8148	an	_	
47-16	8149-8156	average	_	
47-17	8157-8159	of	_	
47-18	8160-8163	4.3	_	
47-19	8164-8168	days	_	
47-20	8169-8178	following	_	
47-21	8179-8185	clinic	_	
47-22	8186-8195	admission	_	
47-23	8195-8196	.	_	

#Text=Imaging
#Text=Informed consent was obtained prior to scanning in a 3T Siemens Trio MR scanner in the Core for Advanced MR Imaging at Baylor College of Medicine in Houston, TX, USA.
48-1	8197-8204	Imaging	_	
48-2	8205-8213	Informed	_	
48-3	8214-8221	consent	_	
48-4	8222-8225	was	_	
48-5	8226-8234	obtained	_	
48-6	8235-8240	prior	_	
48-7	8241-8243	to	_	
48-8	8244-8252	scanning	_	
48-9	8253-8255	in	_	
48-10	8256-8257	a	_	
48-11	8258-8260	3T	_	
48-12	8261-8268	Siemens	_	
48-13	8269-8273	Trio	_	
48-14	8274-8276	MR	_	
48-15	8277-8284	scanner	_	
48-16	8285-8287	in	_	
48-17	8288-8291	the	_	
48-18	8292-8296	Core	_	
48-19	8297-8300	for	_	
48-20	8301-8309	Advanced	_	
48-21	8310-8312	MR	_	
48-22	8313-8320	Imaging	_	
48-23	8321-8323	at	_	
48-24	8324-8330	Baylor	_	
48-25	8331-8338	College	_	
48-26	8339-8341	of	_	
48-27	8342-8350	Medicine	_	
48-28	8351-8353	in	_	
48-29	8354-8361	Houston	_	
48-30	8361-8362	,	_	
48-31	8363-8365	TX	_	
48-32	8365-8366	,	_	
48-33	8367-8370	USA	_	
48-34	8370-8371	.	_	

#Text=A 4.5 min structural MPRAGE sequence (TE = 2.66 ms, TR = 1200 ms, flip angle = 12°, 256 × 256 matrix, 160 one mm axial slices at 1×1×1 mm voxels) was collected, followed by a 5 min resting state scan (RSFC: TE = 40 ms, TR = 2 s, flip angle = 90, 3.4 × 3.4 × 4 mm voxels).
49-1	8372-8373	A	_	
49-2	8374-8377	4.5	_	
49-3	8378-8381	min	_	
49-4	8382-8392	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[16]	
49-5	8393-8399	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[16]	
49-6	8400-8408	sequence	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[16]	
49-7	8409-8410	(	_	
49-8	8410-8412	TE	_	
49-9	8413-8414	=	_	
49-10	8415-8419	2.66	_	
49-11	8420-8422	ms	_	
49-12	8422-8423	,	_	
49-13	8424-8426	TR	_	
49-14	8427-8428	=	_	
49-15	8429-8433	1200	_	
49-16	8434-8436	ms	_	
49-17	8436-8437	,	_	
49-18	8438-8442	flip	_	
49-19	8443-8448	angle	_	
49-20	8449-8450	=	_	
49-21	8451-8453	12	_	
49-22	8453-8454	°	_	
49-23	8454-8455	,	_	
49-24	8456-8459	256	_	
49-25	8460-8461	×	_	
49-26	8462-8465	256	_	
49-27	8466-8472	matrix	_	
49-28	8472-8473	,	_	
49-29	8474-8477	160	_	
49-30	8478-8481	one	_	
49-31	8482-8484	mm	_	
49-32	8485-8490	axial	_	
49-33	8491-8497	slices	_	
49-34	8498-8500	at	_	
49-35	8501-8502	1	_	
49-36	8502-8503	×	_	
49-37	8503-8504	1	_	
49-38	8504-8505	×	_	
49-39	8505-8506	1	_	
49-40	8507-8509	mm	_	
49-41	8510-8516	voxels	_	
49-42	8516-8517	)	_	
49-43	8518-8521	was	_	
49-44	8522-8531	collected	_	
49-45	8531-8532	,	_	
49-46	8533-8541	followed	_	
49-47	8542-8544	by	_	
49-48	8545-8546	a	_	
49-49	8547-8548	5	_	
49-50	8549-8552	min	_	
49-51	8553-8560	resting	_	
49-52	8561-8566	state	_	
49-53	8567-8571	scan	_	
49-54	8572-8573	(	_	
49-55	8573-8577	RSFC	_	
49-56	8577-8578	:	_	
49-57	8579-8581	TE	_	
49-58	8582-8583	=	_	
49-59	8584-8586	40	_	
49-60	8587-8589	ms	_	
49-61	8589-8590	,	_	
49-62	8591-8593	TR	_	
49-63	8594-8595	=	_	
49-64	8596-8597	2	_	
49-65	8598-8599	s	_	
49-66	8599-8600	,	_	
49-67	8601-8605	flip	_	
49-68	8606-8611	angle	_	
49-69	8612-8613	=	_	
49-70	8614-8616	90	_	
49-71	8616-8617	,	_	
49-72	8618-8621	3.4	_	
49-73	8622-8623	×	_	
49-74	8624-8627	3.4	_	
49-75	8628-8629	×	_	
49-76	8630-8631	4	_	
49-77	8632-8634	mm	_	
49-78	8635-8641	voxels	_	
49-79	8641-8642	)	_	
49-80	8642-8643	.	_	

#Text=During the resting state scan, subjects were instructed to relax.
50-1	8644-8650	During	_	
50-2	8651-8654	the	_	
50-3	8655-8662	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]	
50-4	8663-8668	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]	
50-5	8669-8673	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]	
50-6	8673-8674	,	_	
50-7	8675-8683	subjects	_	
50-8	8684-8688	were	_	
50-9	8689-8699	instructed	_	
50-10	8700-8702	to	_	
50-11	8703-8708	relax	_	
50-12	8708-8709	.	_	

#Text=A large “X” was displayed on the screen during the resting state scan.
51-1	8710-8711	A	_	
51-2	8712-8717	large	_	
51-3	8718-8719	“	_	
51-4	8719-8720	X	_	
51-5	8720-8721	”	_	
51-6	8722-8725	was	_	
51-7	8726-8735	displayed	_	
51-8	8736-8738	on	_	
51-9	8739-8742	the	_	
51-10	8743-8749	screen	_	
51-11	8750-8756	during	_	
51-12	8757-8760	the	_	
51-13	8761-8768	resting	_	
51-14	8769-8774	state	_	
51-15	8775-8779	scan	_	
51-16	8779-8780	.	_	

#Text=RSFC data were pre-processed using the CONN Functional Connectivity Toolbox.
52-1	8781-8785	RSFC	_	
52-2	8786-8790	data	_	
52-3	8791-8795	were	_	
52-4	8796-8809	pre-processed	_	
52-5	8810-8815	using	_	
52-6	8816-8819	the	_	
52-7	8820-8824	CONN	_	
52-8	8825-8835	Functional	_	
52-9	8836-8848	Connectivity	_	
52-10	8849-8856	Toolbox	_	
52-11	8856-8857	.	_	

#Text=The preprocessing pipeline consisted of realignment to the first time series image, slice-timing correction, structural segmentation and normalization to the MNI EPI template, functional normalization, ART-based outlier detection using default settings, and smoothing with an 8 mm full width at high maximum (FWHM) Gaussian smoothing kernel (although importantly, the habenula ROI was not smoothed).
53-1	8858-8861	The	_	
53-2	8862-8875	preprocessing	_	
53-3	8876-8884	pipeline	_	
53-4	8885-8894	consisted	_	
53-5	8895-8897	of	_	
53-6	8898-8909	realignment	_	
53-7	8910-8912	to	_	
53-8	8913-8916	the	_	
53-9	8917-8922	first	_	
53-10	8923-8927	time	_	
53-11	8928-8934	series	_	
53-12	8935-8940	image	_	
53-13	8940-8941	,	_	
53-14	8942-8954	slice-timing	_	
53-15	8955-8965	correction	_	
53-16	8965-8966	,	_	
53-17	8967-8977	structural	_	
53-18	8978-8990	segmentation	_	
53-19	8991-8994	and	_	
53-20	8995-9008	normalization	_	
53-21	9009-9011	to	_	
53-22	9012-9015	the	_	
53-23	9016-9019	MNI	_	
53-24	9020-9023	EPI	_	
53-25	9024-9032	template	_	
53-26	9032-9033	,	_	
53-27	9034-9044	functional	_	
53-28	9045-9058	normalization	_	
53-29	9058-9059	,	_	
53-30	9060-9069	ART-based	_	
53-31	9070-9077	outlier	_	
53-32	9078-9087	detection	_	
53-33	9088-9093	using	_	
53-34	9094-9101	default	_	
53-35	9102-9110	settings	_	
53-36	9110-9111	,	_	
53-37	9112-9115	and	_	
53-38	9116-9125	smoothing	_	
53-39	9126-9130	with	_	
53-40	9131-9133	an	_	
53-41	9134-9135	8	_	
53-42	9136-9138	mm	_	
53-43	9139-9143	full	_	
53-44	9144-9149	width	_	
53-45	9150-9152	at	_	
53-46	9153-9157	high	_	
53-47	9158-9165	maximum	_	
53-48	9166-9167	(	_	
53-49	9167-9171	FWHM	_	
53-50	9171-9172	)	_	
53-51	9173-9181	Gaussian	_	
53-52	9182-9191	smoothing	_	
53-53	9192-9198	kernel	_	
53-54	9199-9200	(	_	
53-55	9200-9208	although	_	
53-56	9209-9220	importantly	_	
53-57	9220-9221	,	_	
53-58	9222-9225	the	_	
53-59	9226-9234	habenula	_	
53-60	9235-9238	ROI	_	
53-61	9239-9242	was	_	
53-62	9243-9246	not	_	
53-63	9247-9255	smoothed	_	
53-64	9255-9256	)	_	
53-65	9256-9257	.	_	

#Text=The main region of interest (ROI) was the striatum, defined as the sum of caudate, putamen, and globus pallidus.
54-1	9258-9261	The	_	
54-2	9262-9266	main	_	
54-3	9267-9273	region	_	
54-4	9274-9276	of	_	
54-5	9277-9285	interest	_	
54-6	9286-9287	(	_	
54-7	9287-9290	ROI	_	
54-8	9290-9291	)	_	
54-9	9292-9295	was	_	
54-10	9296-9299	the	_	
54-11	9300-9308	striatum	_	
54-12	9308-9309	,	_	
54-13	9310-9317	defined	_	
54-14	9318-9320	as	_	
54-15	9321-9324	the	_	
54-16	9325-9328	sum	_	
54-17	9329-9331	of	_	
54-18	9332-9339	caudate	_	
54-19	9339-9340	,	_	
54-20	9341-9348	putamen	_	
54-21	9348-9349	,	_	
54-22	9350-9353	and	_	
54-23	9354-9360	globus	_	
54-24	9361-9369	pallidus	_	
54-25	9369-9370	.	_	

#Text=Additional ROIs for exploratory analyses included the inferior, medial, and superior frontal gyri (iFG, mFG, sFG), insula, nucleus accumbens, septum verum, locus coeruleus, amygdala, and anterior cingulate cortex (ACC) and were created in AFNI using the MNI atlas Figure 1A and C–E).
55-1	9371-9381	Additional	_	
55-2	9382-9386	ROIs	_	
55-3	9387-9390	for	_	
55-4	9391-9402	exploratory	_	
55-5	9403-9411	analyses	_	
55-6	9412-9420	included	_	
55-7	9421-9424	the	_	
55-8	9425-9433	inferior	_	
55-9	9433-9434	,	_	
55-10	9435-9441	medial	_	
55-11	9441-9442	,	_	
55-12	9443-9446	and	_	
55-13	9447-9455	superior	_	
55-14	9456-9463	frontal	_	
55-15	9464-9468	gyri	_	
55-16	9469-9470	(	_	
55-17	9470-9473	iFG	_	
55-18	9473-9474	,	_	
55-19	9475-9478	mFG	_	
55-20	9478-9479	,	_	
55-21	9480-9483	sFG	_	
55-22	9483-9484	)	_	
55-23	9484-9485	,	_	
55-24	9486-9492	insula	_	
55-25	9492-9493	,	_	
55-26	9494-9501	nucleus	_	
55-27	9502-9511	accumbens	_	
55-28	9511-9512	,	_	
55-29	9513-9519	septum	_	
55-30	9520-9525	verum	_	
55-31	9525-9526	,	_	
55-32	9527-9532	locus	_	
55-33	9533-9542	coeruleus	_	
55-34	9542-9543	,	_	
55-35	9544-9552	amygdala	_	
55-36	9552-9553	,	_	
55-37	9554-9557	and	_	
55-38	9558-9566	anterior	_	
55-39	9567-9576	cingulate	_	
55-40	9577-9583	cortex	_	
55-41	9584-9585	(	_	
55-42	9585-9588	ACC	_	
55-43	9588-9589	)	_	
55-44	9590-9593	and	_	
55-45	9594-9598	were	_	
55-46	9599-9606	created	_	
55-47	9607-9609	in	_	
55-48	9610-9614	AFNI	_	
55-49	9615-9620	using	_	
55-50	9621-9624	the	_	
55-51	9625-9628	MNI	_	
55-52	9629-9634	atlas	_	
55-53	9635-9641	Figure	_	
55-54	9642-9644	1A	_	
55-55	9645-9648	and	_	
55-56	9649-9652	C–E	_	
55-57	9652-9653	)	_	
55-58	9653-9654	.	_	

#Text=Those regions were chosen because they are known to be important for habenular circuits.
56-1	9655-9660	Those	_	
56-2	9661-9668	regions	_	
56-3	9669-9673	were	_	
56-4	9674-9680	chosen	_	
56-5	9681-9688	because	_	
56-6	9689-9693	they	_	
56-7	9694-9697	are	_	
56-8	9698-9703	known	_	
56-9	9704-9706	to	_	
56-10	9707-9709	be	_	
56-11	9710-9719	important	_	
56-12	9720-9723	for	_	
56-13	9724-9733	habenular	_	
56-14	9734-9742	circuits	_	
56-15	9742-9743	.	_	

#Text=Left and right habenula ROIs were generated for each subject using SPM 8 (http://imaging.mrc-cbu.cam.ac.uk/imaging).
57-1	9744-9748	Left	_	
57-2	9749-9752	and	_	
57-3	9753-9758	right	_	
57-4	9759-9767	habenula	_	
57-5	9768-9772	ROIs	_	
57-6	9773-9777	were	_	
57-7	9778-9787	generated	_	
57-8	9788-9791	for	_	
57-9	9792-9796	each	_	
57-10	9797-9804	subject	_	
57-11	9805-9810	using	_	
57-12	9811-9814	SPM	_	
57-13	9815-9816	8	_	
57-14	9817-9818	(	_	
57-15	9818-9822	http	_	
57-16	9822-9823	:	_	
57-17	9823-9824	/	_	
57-18	9824-9825	/	_	
57-19	9825-9850	imaging.mrc-cbu.cam.ac.uk	_	
57-20	9850-9851	/	_	
57-21	9851-9858	imaging	_	
57-22	9858-9859	)	_	
57-23	9859-9860	.	_	

#Text=Functional images were downsampled to 3×3×3 to try to mitigate partial volume issues derived from the habenula size being comparable to voxel size.
58-1	9861-9871	Functional	_	
58-2	9872-9878	images	_	
58-3	9879-9883	were	_	
58-4	9884-9895	downsampled	_	
58-5	9896-9898	to	_	
58-6	9899-9900	3	_	
58-7	9900-9901	×	_	
58-8	9901-9902	3	_	
58-9	9902-9903	×	_	
58-10	9903-9904	3	_	
58-11	9905-9907	to	_	
58-12	9908-9911	try	_	
58-13	9912-9914	to	_	
58-14	9915-9923	mitigate	_	
58-15	9924-9931	partial	_	
58-16	9932-9938	volume	_	
58-17	9939-9945	issues	_	
58-18	9946-9953	derived	_	
58-19	9954-9958	from	_	
58-20	9959-9962	the	_	
58-21	9963-9971	habenula	_	
58-22	9972-9976	size	_	
58-23	9977-9982	being	_	
58-24	9983-9993	comparable	_	
58-25	9994-9996	to	_	
58-26	9997-10002	voxel	_	
58-27	10003-10007	size	_	
58-28	10007-10008	.	_	

#Text=Each habenula was identified using brain landmarks and a 3×3×3 mm cube was manually placed for each individual subject (Figure 1B).
59-1	10009-10013	Each	_	
59-2	10014-10022	habenula	_	
59-3	10023-10026	was	_	
59-4	10027-10037	identified	_	
59-5	10038-10043	using	_	
59-6	10044-10049	brain	_	
59-7	10050-10059	landmarks	_	
59-8	10060-10063	and	_	
59-9	10064-10065	a	_	
59-10	10066-10067	3	_	
59-11	10067-10068	×	_	
59-12	10068-10069	3	_	
59-13	10069-10070	×	_	
59-14	10070-10071	3	_	
59-15	10072-10074	mm	_	
59-16	10075-10079	cube	_	
59-17	10080-10083	was	_	
59-18	10084-10092	manually	_	
59-19	10093-10099	placed	_	
59-20	10100-10103	for	_	
59-21	10104-10108	each	_	
59-22	10109-10119	individual	_	
59-23	10120-10127	subject	_	
59-24	10128-10129	(	_	
59-25	10129-10135	Figure	_	
59-26	10136-10138	1B	_	
59-27	10138-10139	)	_	
59-28	10139-10140	.	_	

#Text=RSFC data were then analyzed using the CONN functional connectivity toolbox.
60-1	10141-10145	RSFC	_	
60-2	10146-10150	data	_	
60-3	10151-10155	were	_	
60-4	10156-10160	then	_	
60-5	10161-10169	analyzed	_	
60-6	10170-10175	using	_	
60-7	10176-10179	the	_	
60-8	10180-10184	CONN	_	
60-9	10185-10195	functional	_	
60-10	10196-10208	connectivity	_	
60-11	10209-10216	toolbox	_	
60-12	10216-10217	.	_	

#Text=White matter, cerebrospinal fluid, realignment, and scrubbing were considered variables of no interest confounders.
61-1	10218-10223	White	_	
61-2	10224-10230	matter	_	
61-3	10230-10231	,	_	
61-4	10232-10245	cerebrospinal	_	
61-5	10246-10251	fluid	_	
61-6	10251-10252	,	_	
61-7	10253-10264	realignment	_	
61-8	10264-10265	,	_	
61-9	10266-10269	and	_	
61-10	10270-10279	scrubbing	_	
61-11	10280-10284	were	_	
61-12	10285-10295	considered	_	
61-13	10296-10305	variables	_	
61-14	10306-10308	of	_	
61-15	10309-10311	no	_	
61-16	10312-10320	interest	_	
61-17	10321-10332	confounders	_	
61-18	10332-10333	.	_	

#Text=Statistics
#Text=Fisher’s z-transformed correlation coefficients between the different seeds for each subject were used in statistical analyses.
62-1	10334-10344	Statistics	_	
62-2	10345-10351	Fisher	_	
62-3	10351-10352	’	_	
62-4	10352-10353	s	_	
62-5	10354-10367	z-transformed	_	
62-6	10368-10379	correlation	_	
62-7	10380-10392	coefficients	_	
62-8	10393-10400	between	_	
62-9	10401-10404	the	_	
62-10	10405-10414	different	_	
62-11	10415-10420	seeds	_	
62-12	10421-10424	for	_	
62-13	10425-10429	each	_	
62-14	10430-10437	subject	_	
62-15	10438-10442	were	_	
62-16	10443-10447	used	_	
62-17	10448-10450	in	_	
62-18	10451-10462	statistical	_	
62-19	10463-10471	analyses	_	
62-20	10471-10472	.	_	

#Text=ANOVA was used to test the primary outcome: RSFC between the habenula (separated in right and left) and the striatum.
63-1	10473-10478	ANOVA	_	
63-2	10479-10482	was	_	
63-3	10483-10487	used	_	
63-4	10488-10490	to	_	
63-5	10491-10495	test	_	
63-6	10496-10499	the	_	
63-7	10500-10507	primary	_	
63-8	10508-10515	outcome	_	
63-9	10515-10516	:	_	
63-10	10517-10521	RSFC	_	
63-11	10522-10529	between	_	
63-12	10530-10533	the	_	
63-13	10534-10542	habenula	_	
63-14	10543-10544	(	_	
63-15	10544-10553	separated	_	
63-16	10554-10556	in	_	
63-17	10557-10562	right	_	
63-18	10563-10566	and	_	
63-19	10567-10571	left	_	
63-20	10571-10572	)	_	
63-21	10573-10576	and	_	
63-22	10577-10580	the	_	
63-23	10581-10589	striatum	_	
63-24	10589-10590	.	_	

#Text=Next we subdivided the striatum into its constituent parts: right and left caudate, globus pallidus, and putamen.
64-1	10591-10595	Next	_	
64-2	10596-10598	we	_	
64-3	10599-10609	subdivided	_	
64-4	10610-10613	the	_	
64-5	10614-10622	striatum	_	
64-6	10623-10627	into	_	
64-7	10628-10631	its	_	
64-8	10632-10643	constituent	_	
64-9	10644-10649	parts	_	
64-10	10649-10650	:	_	
64-11	10651-10656	right	_	
64-12	10657-10660	and	_	
64-13	10661-10665	left	_	
64-14	10666-10673	caudate	_	
64-15	10673-10674	,	_	
64-16	10675-10681	globus	_	
64-17	10682-10690	pallidus	_	
64-18	10690-10691	,	_	
64-19	10692-10695	and	_	
64-20	10696-10703	putamen	_	
64-21	10703-10704	.	_	

#Text=Because gender was found to be different between groups, we then used ANCOVA to control for the effect of gender after finding initial differences in habenula-whole striatum.
65-1	10705-10712	Because	_	
65-2	10713-10719	gender	_	
65-3	10720-10723	was	_	
65-4	10724-10729	found	_	
65-5	10730-10732	to	_	
65-6	10733-10735	be	_	
65-7	10736-10745	different	_	
65-8	10746-10753	between	_	
65-9	10754-10760	groups	_	
65-10	10760-10761	,	_	
65-11	10762-10764	we	_	
65-12	10765-10769	then	_	
65-13	10770-10774	used	_	
65-14	10775-10781	ANCOVA	_	
65-15	10782-10784	to	_	
65-16	10785-10792	control	_	
65-17	10793-10796	for	_	
65-18	10797-10800	the	_	
65-19	10801-10807	effect	_	
65-20	10808-10810	of	_	
65-21	10811-10817	gender	_	
65-22	10818-10823	after	_	
65-23	10824-10831	finding	_	
65-24	10832-10839	initial	_	
65-25	10840-10851	differences	_	
65-26	10852-10854	in	_	
65-27	10855-10869	habenula-whole	_	
65-28	10870-10878	striatum	_	
65-29	10878-10879	.	_	

#Text=ANCOVA was also used to further explore differences in RSFC activation in striatal sub-regions.
66-1	10880-10886	ANCOVA	_	
66-2	10887-10890	was	_	
66-3	10891-10895	also	_	
66-4	10896-10900	used	_	
66-5	10901-10903	to	_	
66-6	10904-10911	further	_	
66-7	10912-10919	explore	_	
66-8	10920-10931	differences	_	
66-9	10932-10934	in	_	
66-10	10935-10939	RSFC	_	
66-11	10940-10950	activation	_	
66-12	10951-10953	in	_	
66-13	10954-10962	striatal	_	
66-14	10963-10974	sub-regions	_	
66-15	10974-10975	.	_	

#Text=Since we were interested in the possible relationship between opioid use and habenular connectivity, the high co-use of different drugs of abuse was dealt with by stepwise regression.
67-1	10976-10981	Since	_	
67-2	10982-10984	we	_	
67-3	10985-10989	were	_	
67-4	10990-11000	interested	_	
67-5	11001-11003	in	_	
67-6	11004-11007	the	_	
67-7	11008-11016	possible	_	
67-8	11017-11029	relationship	_	
67-9	11030-11037	between	_	
67-10	11038-11044	opioid	_	
67-11	11045-11048	use	_	
67-12	11049-11052	and	_	
67-13	11053-11062	habenular	_	
67-14	11063-11075	connectivity	_	
67-15	11075-11076	,	_	
67-16	11077-11080	the	_	
67-17	11081-11085	high	_	
67-18	11086-11092	co-use	_	
67-19	11093-11095	of	_	
67-20	11096-11105	different	_	
67-21	11106-11111	drugs	_	
67-22	11112-11114	of	_	
67-23	11115-11120	abuse	_	
67-24	11121-11124	was	_	
67-25	11125-11130	dealt	_	
67-26	11131-11135	with	_	
67-27	11136-11138	by	_	
67-28	11139-11147	stepwise	_	
67-29	11148-11158	regression	_	
67-30	11158-11159	.	_	

#Text=First, we separated patients into users and non-users of each drug.
68-1	11160-11165	First	_	
68-2	11165-11166	,	_	
68-3	11167-11169	we	_	
68-4	11170-11179	separated	_	
68-5	11180-11188	patients	_	
68-6	11189-11193	into	_	
68-7	11194-11199	users	_	
68-8	11200-11203	and	_	
68-9	11204-11213	non-users	_	
68-10	11214-11216	of	_	
68-11	11217-11221	each	_	
68-12	11222-11226	drug	_	
68-13	11226-11227	.	_	

#Text=The WHO-ASSIST questionnaire was used to assess drug use.
69-1	11228-11231	The	_	
69-2	11232-11242	WHO-ASSIST	_	
69-3	11243-11256	questionnaire	_	
69-4	11257-11260	was	_	
69-5	11261-11265	used	_	
69-6	11266-11268	to	_	
69-7	11269-11275	assess	_	
69-8	11276-11280	drug	_	
69-9	11281-11284	use	_	
69-10	11284-11285	.	_	

#Text=The ASSIST is divided into ten subcategories (tobacco, alcohol, cannabis, cocaine, amphetamine, inhalants, sedatives, hallucinogens, opioids, and other).
70-1	11286-11289	The	_	
70-2	11290-11296	ASSIST	_	
70-3	11297-11299	is	_	
70-4	11300-11307	divided	_	
70-5	11308-11312	into	_	
70-6	11313-11316	ten	_	
70-7	11317-11330	subcategories	_	
70-8	11331-11332	(	_	
70-9	11332-11339	tobacco	_	
70-10	11339-11340	,	_	
70-11	11341-11348	alcohol	_	
70-12	11348-11349	,	_	
70-13	11350-11358	cannabis	_	
70-14	11358-11359	,	_	
70-15	11360-11367	cocaine	_	
70-16	11367-11368	,	_	
70-17	11369-11380	amphetamine	_	
70-18	11380-11381	,	_	
70-19	11382-11391	inhalants	_	
70-20	11391-11392	,	_	
70-21	11393-11402	sedatives	_	
70-22	11402-11403	,	_	
70-23	11404-11417	hallucinogens	_	
70-24	11417-11418	,	_	
70-25	11419-11426	opioids	_	
70-26	11426-11427	,	_	
70-27	11428-11431	and	_	
70-28	11432-11437	other	_	
70-29	11437-11438	)	_	
70-30	11438-11439	.	_	

#Text=With the exception of alcohol, each sub-category of drug was divided into groups of low (scores of 0–3) and pooled moderate to high (4+) use.
71-1	11440-11444	With	_	
71-2	11445-11448	the	_	
71-3	11449-11458	exception	_	
71-4	11459-11461	of	_	
71-5	11462-11469	alcohol	_	
71-6	11469-11470	,	_	
71-7	11471-11475	each	_	
71-8	11476-11488	sub-category	_	
71-9	11489-11491	of	_	
71-10	11492-11496	drug	_	
71-11	11497-11500	was	_	
71-12	11501-11508	divided	_	
71-13	11509-11513	into	_	
71-14	11514-11520	groups	_	
71-15	11521-11523	of	_	
71-16	11524-11527	low	_	
71-17	11528-11529	(	_	
71-18	11529-11535	scores	_	
71-19	11536-11538	of	_	
71-20	11539-11540	0	_	
71-21	11540-11541	–	_	
71-22	11541-11542	3	_	
71-23	11542-11543	)	_	
71-24	11544-11547	and	_	
71-25	11548-11554	pooled	_	
71-26	11555-11563	moderate	_	
71-27	11564-11566	to	_	
71-28	11567-11571	high	_	
71-29	11572-11573	(	_	
71-30	11573-11574	4	_	
71-31	11574-11575	+	_	
71-32	11575-11576	)	_	
71-33	11577-11580	use	_	
71-34	11580-11581	.	_	

#Text=Alcohol use was scored as low (0–10) and moderate to high (11+), as defined in the ASSIST questionnaire.
72-1	11582-11589	Alcohol	_	
72-2	11590-11593	use	_	
72-3	11594-11597	was	_	
72-4	11598-11604	scored	_	
72-5	11605-11607	as	_	
72-6	11608-11611	low	_	
72-7	11612-11613	(	_	
72-8	11613-11614	0	_	
72-9	11614-11615	–	_	
72-10	11615-11617	10	_	
72-11	11617-11618	)	_	
72-12	11619-11622	and	_	
72-13	11623-11631	moderate	_	
72-14	11632-11634	to	_	
72-15	11635-11639	high	_	
72-16	11640-11641	(	_	
72-17	11641-11643	11	_	
72-18	11643-11644	+	_	
72-19	11644-11645	)	_	
72-20	11645-11646	,	_	
72-21	11647-11649	as	_	
72-22	11650-11657	defined	_	
72-23	11658-11660	in	_	
72-24	11661-11664	the	_	
72-25	11665-11671	ASSIST	_	
72-26	11672-11685	questionnaire	_	
72-27	11685-11686	.	_	

#Text=Individual patients could be a “user” of more than one drug.
73-1	11687-11697	Individual	_	
73-2	11698-11706	patients	_	
73-3	11707-11712	could	_	
73-4	11713-11715	be	_	
73-5	11716-11717	a	_	
73-6	11718-11719	“	_	
73-7	11719-11723	user	_	
73-8	11723-11724	”	_	
73-9	11725-11727	of	_	
73-10	11728-11732	more	_	
73-11	11733-11737	than	_	
73-12	11738-11741	one	_	
73-13	11742-11746	drug	_	
73-14	11746-11747	.	_	

#Text=We tested whether opioid use would predict the habenula-striatum RSFC when the effect of additional drugs was considered by entering each drug in a stepwise multiple regression analysis.
74-1	11748-11750	We	_	
74-2	11751-11757	tested	_	
74-3	11758-11765	whether	_	
74-4	11766-11772	opioid	_	
74-5	11773-11776	use	_	
74-6	11777-11782	would	_	
74-7	11783-11790	predict	_	
74-8	11791-11794	the	_	
74-9	11795-11812	habenula-striatum	_	
74-10	11813-11817	RSFC	_	
74-11	11818-11822	when	_	
74-12	11823-11826	the	_	
74-13	11827-11833	effect	_	
74-14	11834-11836	of	_	
74-15	11837-11847	additional	_	
74-16	11848-11853	drugs	_	
74-17	11854-11857	was	_	
74-18	11858-11868	considered	_	
74-19	11869-11871	by	_	
74-20	11872-11880	entering	_	
74-21	11881-11885	each	_	
74-22	11886-11890	drug	_	
74-23	11891-11893	in	_	
74-24	11894-11895	a	_	
74-25	11896-11904	stepwise	_	
74-26	11905-11913	multiple	_	
74-27	11914-11924	regression	_	
74-28	11925-11933	analysis	_	
74-29	11933-11934	.	_	

#Text=We then investigated possible genotype differences within the opioid users and non-users on the Right habenula/Left caudate RSFC.
75-1	11935-11937	We	_	
75-2	11938-11942	then	_	
75-3	11943-11955	investigated	_	
75-4	11956-11964	possible	_	
75-5	11965-11973	genotype	_	
75-6	11974-11985	differences	_	
75-7	11986-11992	within	_	
75-8	11993-11996	the	_	
75-9	11997-12003	opioid	_	
75-10	12004-12009	users	_	
75-11	12010-12013	and	_	
75-12	12014-12023	non-users	_	
75-13	12024-12026	on	_	
75-14	12027-12030	the	_	
75-15	12031-12036	Right	_	
75-16	12037-12045	habenula	_	
75-17	12045-12046	/	_	
75-18	12046-12050	Left	_	
75-19	12051-12058	caudate	_	
75-20	12059-12063	RSFC	_	
75-21	12063-12064	.	_	

#Text=We used ANCOVA to test Right habenula/Left caudate RSFC after separating participants according to their rs16969968 genotype.
76-1	12065-12067	We	_	
76-2	12068-12072	used	_	
76-3	12073-12079	ANCOVA	_	
76-4	12080-12082	to	_	
76-5	12083-12087	test	_	
76-6	12088-12093	Right	_	
76-7	12094-12102	habenula	_	
76-8	12102-12103	/	_	
76-9	12103-12107	Left	_	
76-10	12108-12115	caudate	_	
76-11	12116-12120	RSFC	_	
76-12	12121-12126	after	_	
76-13	12127-12137	separating	_	
76-14	12138-12150	participants	_	
76-15	12151-12160	according	_	
76-16	12161-12163	to	_	
76-17	12164-12169	their	_	
76-18	12170-12180	rs16969968	_	
76-19	12181-12189	genotype	_	
76-20	12189-12190	.	_	

#Text=We pooled those with an AG or AA genotype, since the phenotype seems to be dominant for the A allele.
77-1	12191-12193	We	_	
77-2	12194-12200	pooled	_	
77-3	12201-12206	those	_	
77-4	12207-12211	with	_	
77-5	12212-12214	an	_	
77-6	12215-12217	AG	_	
77-7	12218-12220	or	_	
77-8	12221-12223	AA	_	
77-9	12224-12232	genotype	_	
77-10	12232-12233	,	_	
77-11	12234-12239	since	_	
77-12	12240-12243	the	_	
77-13	12244-12253	phenotype	_	
77-14	12254-12259	seems	_	
77-15	12260-12262	to	_	
77-16	12263-12265	be	_	
77-17	12266-12274	dominant	_	
77-18	12275-12278	for	_	
77-19	12279-12282	the	_	
77-20	12283-12284	A	_	
77-21	12285-12291	allele	_	
77-22	12291-12292	.	_	

#Text=In this case, we used population structure, despite the patients being ethnically homogenous (97% Caucasian), and sex as covariates.
78-1	12293-12295	In	_	
78-2	12296-12300	this	_	
78-3	12301-12305	case	_	
78-4	12305-12306	,	_	
78-5	12307-12309	we	_	
78-6	12310-12314	used	_	
78-7	12315-12325	population	_	
78-8	12326-12335	structure	_	
78-9	12335-12336	,	_	
78-10	12337-12344	despite	_	
78-11	12345-12348	the	_	
78-12	12349-12357	patients	_	
78-13	12358-12363	being	_	
78-14	12364-12374	ethnically	_	
78-15	12375-12385	homogenous	_	
78-16	12386-12387	(	_	
78-17	12387-12390	97%	_	
78-18	12391-12400	Caucasian	_	
78-19	12400-12401	)	_	
78-20	12401-12402	,	_	
78-21	12403-12406	and	_	
78-22	12407-12410	sex	_	
78-23	12411-12413	as	_	
78-24	12414-12424	covariates	_	
78-25	12424-12425	.	_	

#Text=Ten ancestry informative markers (AIMs) were genotyped and used to calculate population structure.
79-1	12426-12429	Ten	_	
79-2	12430-12438	ancestry	_	
79-3	12439-12450	informative	_	
79-4	12451-12458	markers	_	
79-5	12459-12460	(	_	
79-6	12460-12464	AIMs	_	
79-7	12464-12465	)	_	
79-8	12466-12470	were	_	
79-9	12471-12480	genotyped	_	
79-10	12481-12484	and	_	
79-11	12485-12489	used	_	
79-12	12490-12492	to	_	
79-13	12493-12502	calculate	_	
79-14	12503-12513	population	_	
79-15	12514-12523	structure	_	
79-16	12523-12524	.	_	

#Text=Data from the current participant sample were compared to the Centre d'Etude du Polymorphisme Humain–Human Genome Diversity Panel (CEPH-HGDP) samples (1,035 subjects of 51 populations) as previously described.
80-1	12525-12529	Data	_	
80-2	12530-12534	from	_	
80-3	12535-12538	the	_	
80-4	12539-12546	current	_	
80-5	12547-12558	participant	_	
80-6	12559-12565	sample	_	
80-7	12566-12570	were	_	
80-8	12571-12579	compared	_	
80-9	12580-12582	to	_	
80-10	12583-12586	the	_	
80-11	12587-12593	Centre	_	
80-12	12594-12601	d'Etude	_	
80-13	12602-12604	du	_	
80-14	12605-12618	Polymorphisme	_	
80-15	12619-12631	Humain–Human	_	
80-16	12632-12638	Genome	_	
80-17	12639-12648	Diversity	_	
80-18	12649-12654	Panel	_	
80-19	12655-12656	(	_	
80-20	12656-12665	CEPH-HGDP	_	
80-21	12665-12666	)	_	
80-22	12667-12674	samples	_	
80-23	12675-12676	(	_	
80-24	12676-12681	1,035	_	
80-25	12682-12690	subjects	_	
80-26	12691-12693	of	_	
80-27	12694-12696	51	_	
80-28	12697-12708	populations	_	
80-29	12708-12709	)	_	
80-30	12710-12712	as	_	
80-31	12713-12723	previously	_	
80-32	12724-12733	described	_	
80-33	12733-12734	.	_	

#Text=It has been shown before that 94.6% of the maximum informativity value is obtained using these ten AIMs.
81-1	12735-12737	It	_	
81-2	12738-12741	has	_	
81-3	12742-12746	been	_	
81-4	12747-12752	shown	_	
81-5	12753-12759	before	_	
81-6	12760-12764	that	_	
81-7	12765-12770	94.6%	_	
81-8	12771-12773	of	_	
81-9	12774-12777	the	_	
81-10	12778-12785	maximum	_	
81-11	12786-12799	informativity	_	
81-12	12800-12805	value	_	
81-13	12806-12808	is	_	
81-14	12809-12817	obtained	_	
81-15	12818-12823	using	_	
81-16	12824-12829	these	_	
81-17	12830-12833	ten	_	
81-18	12834-12838	AIMs	_	
81-19	12838-12839	.	_	

#Text=Finally, in a series of exploratory experiments we studied the connectivity between the habenula and several brain regions known or hypothesized to be related to habenular activity (iFG, mFG, sFG, insula, striatum, nucleus accumbens, septum verum, locus coeruleus, amygdala, and ACC).
82-1	12840-12847	Finally	_	
82-2	12847-12848	,	_	
82-3	12849-12851	in	_	
82-4	12852-12853	a	_	
82-5	12854-12860	series	_	
82-6	12861-12863	of	_	
82-7	12864-12875	exploratory	_	
82-8	12876-12887	experiments	_	
82-9	12888-12890	we	_	
82-10	12891-12898	studied	_	
82-11	12899-12902	the	_	
82-12	12903-12915	connectivity	_	
82-13	12916-12923	between	_	
82-14	12924-12927	the	_	
82-15	12928-12936	habenula	_	
82-16	12937-12940	and	_	
82-17	12941-12948	several	_	
82-18	12949-12954	brain	_	
82-19	12955-12962	regions	_	
82-20	12963-12968	known	_	
82-21	12969-12971	or	_	
82-22	12972-12984	hypothesized	_	
82-23	12985-12987	to	_	
82-24	12988-12990	be	_	
82-25	12991-12998	related	_	
82-26	12999-13001	to	_	
82-27	13002-13011	habenular	_	
82-28	13012-13020	activity	_	
82-29	13021-13022	(	_	
82-30	13022-13025	iFG	_	
82-31	13025-13026	,	_	
82-32	13027-13030	mFG	_	
82-33	13030-13031	,	_	
82-34	13032-13035	sFG	_	
82-35	13035-13036	,	_	
82-36	13037-13043	insula	_	
82-37	13043-13044	,	_	
82-38	13045-13053	striatum	_	
82-39	13053-13054	,	_	
82-40	13055-13062	nucleus	_	
82-41	13063-13072	accumbens	_	
82-42	13072-13073	,	_	
82-43	13074-13080	septum	_	
82-44	13081-13086	verum	_	
82-45	13086-13087	,	_	
82-46	13088-13093	locus	_	
82-47	13094-13103	coeruleus	_	
82-48	13103-13104	,	_	
82-49	13105-13113	amygdala	_	
82-50	13113-13114	,	_	
82-51	13115-13118	and	_	
82-52	13119-13122	ACC	_	
82-53	13122-13123	)	_	
82-54	13123-13124	.	_	

#Text=These data are presented as exploratory since we did not perform any corrections for multiple comparisons.
83-1	13125-13130	These	_	
83-2	13131-13135	data	_	
83-3	13136-13139	are	_	
83-4	13140-13149	presented	_	
83-5	13150-13152	as	_	
83-6	13153-13164	exploratory	_	
83-7	13165-13170	since	_	
83-8	13171-13173	we	_	
83-9	13174-13177	did	_	
83-10	13178-13181	not	_	
83-11	13182-13189	perform	_	
83-12	13190-13193	any	_	
83-13	13194-13205	corrections	_	
83-14	13206-13209	for	_	
83-15	13210-13218	multiple	_	
83-16	13219-13230	comparisons	_	
83-17	13230-13231	.	_	

#Text=Results
#Text=Menninger inpatients show strong comorbidity
#Text=Figure 2A shows the number of patients who were positive (moderate or high) for use of each drug (solid bars) and the number of patients who were positive for only one individual drug (open bars).
84-1	13232-13239	Results	_	
84-2	13240-13249	Menninger	_	
84-3	13250-13260	inpatients	_	
84-4	13261-13265	show	_	
84-5	13266-13272	strong	_	
84-6	13273-13284	comorbidity	_	
84-7	13285-13291	Figure	_	
84-8	13292-13294	2A	_	
84-9	13295-13300	shows	_	
84-10	13301-13304	the	_	
84-11	13305-13311	number	_	
84-12	13312-13314	of	_	
84-13	13315-13323	patients	_	
84-14	13324-13327	who	_	
84-15	13328-13332	were	_	
84-16	13333-13341	positive	_	
84-17	13342-13343	(	_	
84-18	13343-13351	moderate	_	
84-19	13352-13354	or	_	
84-20	13355-13359	high	_	
84-21	13359-13360	)	_	
84-22	13361-13364	for	_	
84-23	13365-13368	use	_	
84-24	13369-13371	of	_	
84-25	13372-13376	each	_	
84-26	13377-13381	drug	_	
84-27	13382-13383	(	_	
84-28	13383-13388	solid	_	
84-29	13389-13393	bars	_	
84-30	13393-13394	)	_	
84-31	13395-13398	and	_	
84-32	13399-13402	the	_	
84-33	13403-13409	number	_	
84-34	13410-13412	of	_	
84-35	13413-13421	patients	_	
84-36	13422-13425	who	_	
84-37	13426-13430	were	_	
84-38	13431-13439	positive	_	
84-39	13440-13443	for	_	
84-40	13444-13448	only	_	
84-41	13449-13452	one	_	
84-42	13453-13463	individual	_	
84-43	13464-13468	drug	_	
84-44	13469-13470	(	_	
84-45	13470-13474	open	_	
84-46	13475-13479	bars	_	
84-47	13479-13480	)	_	
84-48	13480-13481	.	_	

#Text=Eight percent of the patients were exclusively positive for tobacco.
85-1	13482-13487	Eight	_	
85-2	13488-13495	percent	_	
85-3	13496-13498	of	_	
85-4	13499-13502	the	_	
85-5	13503-13511	patients	_	
85-6	13512-13516	were	_	
85-7	13517-13528	exclusively	_	
85-8	13529-13537	positive	_	
85-9	13538-13541	for	_	
85-10	13542-13549	tobacco	_	
85-11	13549-13550	.	_	

#Text=Interestingly, all opioid users also were positive for other drug use.
86-1	13551-13564	Interestingly	_	
86-2	13564-13565	,	_	
86-3	13566-13569	all	_	
86-4	13570-13576	opioid	_	
86-5	13577-13582	users	_	
86-6	13583-13587	also	_	
86-7	13588-13592	were	_	
86-8	13593-13601	positive	_	
86-9	13602-13605	for	_	
86-10	13606-13611	other	_	
86-11	13612-13616	drug	_	
86-12	13617-13620	use	_	
86-13	13620-13621	.	_	

#Text=Figure 2B shows the number of patients who were positive (according to ASSIST) for none, one, or more drugs of abuse.
87-1	13622-13628	Figure	_	
87-2	13629-13631	2B	_	
87-3	13632-13637	shows	_	
87-4	13638-13641	the	_	
87-5	13642-13648	number	_	
87-6	13649-13651	of	_	
87-7	13652-13660	patients	_	
87-8	13661-13664	who	_	
87-9	13665-13669	were	_	
87-10	13670-13678	positive	_	
87-11	13679-13680	(	_	
87-12	13680-13689	according	_	
87-13	13690-13692	to	_	
87-14	13693-13699	ASSIST	_	
87-15	13699-13700	)	_	
87-16	13701-13704	for	_	
87-17	13705-13709	none	_	
87-18	13709-13710	,	_	
87-19	13711-13714	one	_	
87-20	13714-13715	,	_	
87-21	13716-13718	or	_	
87-22	13719-13723	more	_	
87-23	13724-13729	drugs	_	
87-24	13730-13732	of	_	
87-25	13733-13738	abuse	_	
87-26	13738-13739	.	_	

#Text=Figure 2C shows the most common diagnoses (MDD, SUD, ANX, and PD).
88-1	13740-13746	Figure	_	
88-2	13747-13749	2C	_	
88-3	13750-13755	shows	_	
88-4	13756-13759	the	_	
88-5	13760-13764	most	_	
88-6	13765-13771	common	_	
88-7	13772-13781	diagnoses	_	
88-8	13782-13783	(	_	
88-9	13783-13786	MDD	_	
88-10	13786-13787	,	_	
88-11	13788-13791	SUD	_	
88-12	13791-13792	,	_	
88-13	13793-13796	ANX	_	
88-14	13796-13797	,	_	
88-15	13798-13801	and	_	
88-16	13802-13804	PD	_	
88-17	13804-13805	)	_	
88-18	13805-13806	.	_	

#Text=Solid bars show the total numbers of patients with each diagnosis, while open bars show the number of patients with only one diagnosis.
89-1	13807-13812	Solid	_	
89-2	13813-13817	bars	_	
89-3	13818-13822	show	_	
89-4	13823-13826	the	_	
89-5	13827-13832	total	_	
89-6	13833-13840	numbers	_	
89-7	13841-13843	of	_	
89-8	13844-13852	patients	_	
89-9	13853-13857	with	_	
89-10	13858-13862	each	_	
89-11	13863-13872	diagnosis	_	
89-12	13872-13873	,	_	
89-13	13874-13879	while	_	
89-14	13880-13884	open	_	
89-15	13885-13889	bars	_	
89-16	13890-13894	show	_	
89-17	13895-13898	the	_	
89-18	13899-13905	number	_	
89-19	13906-13908	of	_	
89-20	13909-13917	patients	_	
89-21	13918-13922	with	_	
89-22	13923-13927	only	_	
89-23	13928-13931	one	_	
89-24	13932-13941	diagnosis	_	
89-25	13941-13942	.	_	

#Text=Figure 2D shows the number of patients with none, one, or more of the most common diagnoses (MDD, SUD, ANX, PD).
90-1	13943-13949	Figure	_	
90-2	13950-13952	2D	_	
90-3	13953-13958	shows	_	
90-4	13959-13962	the	_	
90-5	13963-13969	number	_	
90-6	13970-13972	of	_	
90-7	13973-13981	patients	_	
90-8	13982-13986	with	_	
90-9	13987-13991	none	_	
90-10	13991-13992	,	_	
90-11	13993-13996	one	_	
90-12	13996-13997	,	_	
90-13	13998-14000	or	_	
90-14	14001-14005	more	_	
90-15	14006-14008	of	_	
90-16	14009-14012	the	_	
90-17	14013-14017	most	_	
90-18	14018-14024	common	_	
90-19	14025-14034	diagnoses	_	
90-20	14035-14036	(	_	
90-21	14036-14039	MDD	_	
90-22	14039-14040	,	_	
90-23	14041-14044	SUD	_	
90-24	14044-14045	,	_	
90-25	14046-14049	ANX	_	
90-26	14049-14050	,	_	
90-27	14051-14053	PD	_	
90-28	14053-14054	)	_	
90-29	14054-14055	.	_	

#Text=Comorbidities of two or more diagnoses were present in more than half of patients.
91-1	14056-14069	Comorbidities	_	
91-2	14070-14072	of	_	
91-3	14073-14076	two	_	
91-4	14077-14079	or	_	
91-5	14080-14084	more	_	
91-6	14085-14094	diagnoses	_	
91-7	14095-14099	were	_	
91-8	14100-14107	present	_	
91-9	14108-14110	in	_	
91-10	14111-14115	more	_	
91-11	14116-14120	than	_	
91-12	14121-14125	half	_	
91-13	14126-14128	of	_	
91-14	14129-14137	patients	_	
91-15	14137-14138	.	_	

#Text=Additional diagnoses included psychotic and bipolar patients who were not diagnosed with MDD, SUD, ANX, or PD.
92-1	14139-14149	Additional	_	
92-2	14150-14159	diagnoses	_	
92-3	14160-14168	included	_	
92-4	14169-14178	psychotic	_	
92-5	14179-14182	and	_	
92-6	14183-14190	bipolar	_	
92-7	14191-14199	patients	_	
92-8	14200-14203	who	_	
92-9	14204-14208	were	_	
92-10	14209-14212	not	_	
92-11	14213-14222	diagnosed	_	
92-12	14223-14227	with	_	
92-13	14228-14231	MDD	_	
92-14	14231-14232	,	_	
92-15	14233-14236	SUD	_	
92-16	14236-14237	,	_	
92-17	14238-14241	ANX	_	
92-18	14241-14242	,	_	
92-19	14243-14245	or	_	
92-20	14246-14248	PD	_	
92-21	14248-14249	.	_	

#Text=The right habenula shows increased striatal connectivity in opioid-dependent patients
#Text=In our initial analysis, we found a significant RSFC difference between the Right habenula/striatumopioid (0.13 ± 0.03) and Right habenula/striatumnon-opioid (0.06 ± 0.01) (F(304,1) = 5.152, p<0.03) (Nopioid = 51, Nnon-opioid = 254) (primary outcome, Figure 3A).
93-1	14250-14253	The	_	
93-2	14254-14259	right	_	
93-3	14260-14268	habenula	_	
93-4	14269-14274	shows	_	
93-5	14275-14284	increased	_	
93-6	14285-14293	striatal	_	
93-7	14294-14306	connectivity	_	
93-8	14307-14309	in	_	
93-9	14310-14326	opioid-dependent	_	
93-10	14327-14335	patients	_	
93-11	14336-14338	In	_	
93-12	14339-14342	our	_	
93-13	14343-14350	initial	_	
93-14	14351-14359	analysis	_	
93-15	14359-14360	,	_	
93-16	14361-14363	we	_	
93-17	14364-14369	found	_	
93-18	14370-14371	a	_	
93-19	14372-14383	significant	_	
93-20	14384-14388	RSFC	_	
93-21	14389-14399	difference	_	
93-22	14400-14407	between	_	
93-23	14408-14411	the	_	
93-24	14412-14417	Right	_	
93-25	14418-14426	habenula	_	
93-26	14426-14427	/	_	
93-27	14427-14441	striatumopioid	_	
93-28	14442-14443	(	_	
93-29	14443-14447	0.13	_	
93-30	14448-14449	±	_	
93-31	14450-14454	0.03	_	
93-32	14454-14455	)	_	
93-33	14456-14459	and	_	
93-34	14460-14465	Right	_	
93-35	14466-14474	habenula	_	
93-36	14474-14475	/	_	
93-37	14475-14493	striatumnon-opioid	_	
93-38	14494-14495	(	_	
93-39	14495-14499	0.06	_	
93-40	14500-14501	±	_	
93-41	14502-14506	0.01	_	
93-42	14506-14507	)	_	
93-43	14508-14509	(	_	
93-44	14509-14510	F	_	
93-45	14510-14511	(	_	
93-46	14511-14516	304,1	_	
93-47	14516-14517	)	_	
93-48	14518-14519	=	_	
93-49	14520-14525	5.152	_	
93-50	14525-14526	,	_	
93-51	14527-14528	p	_	
93-52	14528-14529	<	_	
93-53	14529-14533	0.03	_	
93-54	14533-14534	)	_	
93-55	14535-14536	(	_	
93-56	14536-14543	Nopioid	_	
93-57	14544-14545	=	_	
93-58	14546-14548	51	_	
93-59	14548-14549	,	_	
93-60	14550-14561	Nnon-opioid	_	
93-61	14562-14563	=	_	
93-62	14564-14567	254	_	
93-63	14567-14568	)	_	
93-64	14569-14570	(	_	
93-65	14570-14577	primary	_	
93-66	14578-14585	outcome	_	
93-67	14585-14586	,	_	
93-68	14587-14593	Figure	_	
93-69	14594-14596	3A	_	
93-70	14596-14597	)	_	
93-71	14597-14598	.	_	

#Text=After controlling for gender, a nearly significant difference between the Right habenula/striatum remained (F(304),1) = 3.694, p = 0.056).
94-1	14599-14604	After	_	
94-2	14605-14616	controlling	_	
94-3	14617-14620	for	_	
94-4	14621-14627	gender	_	
94-5	14627-14628	,	_	
94-6	14629-14630	a	_	
94-7	14631-14637	nearly	_	
94-8	14638-14649	significant	_	
94-9	14650-14660	difference	_	
94-10	14661-14668	between	_	
94-11	14669-14672	the	_	
94-12	14673-14678	Right	_	
94-13	14679-14687	habenula	_	
94-14	14687-14688	/	_	
94-15	14688-14696	striatum	_	
94-16	14697-14705	remained	_	
94-17	14706-14707	(	_	
94-18	14707-14708	F	_	
94-19	14708-14709	(	_	
94-20	14709-14712	304	_	
94-21	14712-14713	)	_	
94-22	14713-14714	,	_	
94-23	14714-14715	1	_	
94-24	14715-14716	)	_	
94-25	14717-14718	=	_	
94-26	14719-14724	3.694	_	
94-27	14724-14725	,	_	
94-28	14726-14727	p	_	
94-29	14728-14729	=	_	
94-30	14730-14735	0.056	_	
94-31	14735-14736	)	_	
94-32	14736-14737	.	_	

#Text=No difference was found for the left habenula.
95-1	14738-14740	No	_	
95-2	14741-14751	difference	_	
95-3	14752-14755	was	_	
95-4	14756-14761	found	_	
95-5	14762-14765	for	_	
95-6	14766-14769	the	_	
95-7	14770-14774	left	_	
95-8	14775-14783	habenula	_	
95-9	14783-14784	.	_	

#Text=No other drug showed a difference for the right habenula.
96-1	14785-14787	No	_	
96-2	14788-14793	other	_	
96-3	14794-14798	drug	_	
96-4	14799-14805	showed	_	
96-5	14806-14807	a	_	
96-6	14808-14818	difference	_	
96-7	14819-14822	for	_	
96-8	14823-14826	the	_	
96-9	14827-14832	right	_	
96-10	14833-14841	habenula	_	
96-11	14841-14842	.	_	

#Text=For Right habenula/striatum, the Cohen’s d effect size for users vs. non-users was 0.17.
97-1	14843-14846	For	_	
97-2	14847-14852	Right	_	
97-3	14853-14861	habenula	_	
97-4	14861-14862	/	_	
97-5	14862-14870	striatum	_	
97-6	14870-14871	,	_	
97-7	14872-14875	the	_	
97-8	14876-14881	Cohen	_	
97-9	14881-14882	’	_	
97-10	14882-14883	s	_	
97-11	14884-14885	d	_	
97-12	14886-14892	effect	_	
97-13	14893-14897	size	_	
97-14	14898-14901	for	_	
97-15	14902-14907	users	_	
97-16	14908-14910	vs	_	
97-17	14910-14911	.	_	
97-18	14912-14921	non-users	_	
97-19	14922-14925	was	_	
97-20	14926-14930	0.17	_	
97-21	14930-14931	.	_	

#Text=Given the initial result and strong trend toward significance after controlling for gender, we divided the striatum into its sub-components: right and left caudate, putamen, and globus pallidus.
98-1	14932-14937	Given	_	
98-2	14938-14941	the	_	
98-3	14942-14949	initial	_	
98-4	14950-14956	result	_	
98-5	14957-14960	and	_	
98-6	14961-14967	strong	_	
98-7	14968-14973	trend	_	
98-8	14974-14980	toward	_	
98-9	14981-14993	significance	_	
98-10	14994-14999	after	_	
98-11	15000-15011	controlling	_	
98-12	15012-15015	for	_	
98-13	15016-15022	gender	_	
98-14	15022-15023	,	_	
98-15	15024-15026	we	_	
98-16	15027-15034	divided	_	
98-17	15035-15038	the	_	
98-18	15039-15047	striatum	_	
98-19	15048-15052	into	_	
98-20	15053-15056	its	_	
98-21	15057-15071	sub-components	_	
98-22	15071-15072	:	_	
98-23	15073-15078	right	_	
98-24	15079-15082	and	_	
98-25	15083-15087	left	_	
98-26	15088-15095	caudate	_	
98-27	15095-15096	,	_	
98-28	15097-15104	putamen	_	
98-29	15104-15105	,	_	
98-30	15106-15109	and	_	
98-31	15110-15116	globus	_	
98-32	15117-15125	pallidus	_	
98-33	15125-15126	.	_	

#Text=When we analyzed the RSFC between the right habenula and striatal sub-regions, we found that the Right habenula/Left caudate RSFC was significantly higher in those with opioid use (0.14 ± 0.03) than those without (0.06 ± 0.01) (F(304,1) = 6.73, p<0.01, Figure 3B).
99-1	15127-15131	When	_	
99-2	15132-15134	we	_	
99-3	15135-15143	analyzed	_	
99-4	15144-15147	the	_	
99-5	15148-15152	RSFC	_	
99-6	15153-15160	between	_	
99-7	15161-15164	the	_	
99-8	15165-15170	right	_	
99-9	15171-15179	habenula	_	
99-10	15180-15183	and	_	
99-11	15184-15192	striatal	_	
99-12	15193-15204	sub-regions	_	
99-13	15204-15205	,	_	
99-14	15206-15208	we	_	
99-15	15209-15214	found	_	
99-16	15215-15219	that	_	
99-17	15220-15223	the	_	
99-18	15224-15229	Right	_	
99-19	15230-15238	habenula	_	
99-20	15238-15239	/	_	
99-21	15239-15243	Left	_	
99-22	15244-15251	caudate	_	
99-23	15252-15256	RSFC	_	
99-24	15257-15260	was	_	
99-25	15261-15274	significantly	_	
99-26	15275-15281	higher	_	
99-27	15282-15284	in	_	
99-28	15285-15290	those	_	
99-29	15291-15295	with	_	
99-30	15296-15302	opioid	_	
99-31	15303-15306	use	_	
99-32	15307-15308	(	_	
99-33	15308-15312	0.14	_	
99-34	15313-15314	±	_	
99-35	15315-15319	0.03	_	
99-36	15319-15320	)	_	
99-37	15321-15325	than	_	
99-38	15326-15331	those	_	
99-39	15332-15339	without	_	
99-40	15340-15341	(	_	
99-41	15341-15345	0.06	_	
99-42	15346-15347	±	_	
99-43	15348-15352	0.01	_	
99-44	15352-15353	)	_	
99-45	15354-15355	(	_	
99-46	15355-15356	F	_	
99-47	15356-15357	(	_	
99-48	15357-15362	304,1	_	
99-49	15362-15363	)	_	
99-50	15364-15365	=	_	
99-51	15366-15370	6.73	_	
99-52	15370-15371	,	_	
99-53	15372-15373	p	_	
99-54	15373-15374	<	_	
99-55	15374-15378	0.01	_	
99-56	15378-15379	,	_	
99-57	15380-15386	Figure	_	
99-58	15387-15389	3B	_	
99-59	15389-15390	)	_	
99-60	15390-15391	.	_	

#Text=The right caudate showed a similar, but not statistically significant, difference.
100-1	15392-15395	The	_	
100-2	15396-15401	right	_	
100-3	15402-15409	caudate	_	
100-4	15410-15416	showed	_	
100-5	15417-15418	a	_	
100-6	15419-15426	similar	_	
100-7	15426-15427	,	_	
100-8	15428-15431	but	_	
100-9	15432-15435	not	_	
100-10	15436-15449	statistically	_	
100-11	15450-15461	significant	_	
100-12	15461-15462	,	_	
100-13	15463-15473	difference	_	
100-14	15473-15474	.	_	

#Text=Both the putamen and the globus pallidus showed a trend in the same direction as the caudate.
101-1	15475-15479	Both	_	
101-2	15480-15483	the	_	
101-3	15484-15491	putamen	_	
101-4	15492-15495	and	_	
101-5	15496-15499	the	_	
101-6	15500-15506	globus	_	
101-7	15507-15515	pallidus	_	
101-8	15516-15522	showed	_	
101-9	15523-15524	a	_	
101-10	15525-15530	trend	_	
101-11	15531-15533	in	_	
101-12	15534-15537	the	_	
101-13	15538-15542	same	_	
101-14	15543-15552	direction	_	
101-15	15553-15555	as	_	
101-16	15556-15559	the	_	
101-17	15560-15567	caudate	_	
101-18	15567-15568	.	_	

#Text=Finally, the Right habenula/Left caudate RSFC difference remained significant when we included the additional drugs in the ANCOVA models.
102-1	15569-15576	Finally	_	
102-2	15576-15577	,	_	
102-3	15578-15581	the	_	
102-4	15582-15587	Right	_	
102-5	15588-15596	habenula	_	
102-6	15596-15597	/	_	
102-7	15597-15601	Left	_	
102-8	15602-15609	caudate	_	
102-9	15610-15614	RSFC	_	
102-10	15615-15625	difference	_	
102-11	15626-15634	remained	_	
102-12	15635-15646	significant	_	
102-13	15647-15651	when	_	
102-14	15652-15654	we	_	
102-15	15655-15663	included	_	
102-16	15664-15667	the	_	
102-17	15668-15678	additional	_	
102-18	15679-15684	drugs	_	
102-19	15685-15687	in	_	
102-20	15688-15691	the	_	
102-21	15692-15698	ANCOVA	_	
102-22	15699-15705	models	_	
102-23	15705-15706	.	_	

#Text=The nicotinic acetylcholine receptor variant rs16969968 moderates habenula/caudate connectivity in opioid users
#Text=Given the hypothesis that the CHRNA5 nicotinic acetylcholine receptor α5 subunit variant, rs16969968 may be a risk factor for higher opioid use, the sample was divided according to genotype into pooled AA or AG genotypes (high risk) and GG genotype (low risk).
103-1	15707-15710	The	_	
103-2	15711-15720	nicotinic	_	
103-3	15721-15734	acetylcholine	_	
103-4	15735-15743	receptor	_	
103-5	15744-15751	variant	_	
103-6	15752-15762	rs16969968	_	
103-7	15763-15772	moderates	_	
103-8	15773-15781	habenula	_	
103-9	15781-15782	/	_	
103-10	15782-15789	caudate	_	
103-11	15790-15802	connectivity	_	
103-12	15803-15805	in	_	
103-13	15806-15812	opioid	_	
103-14	15813-15818	users	_	
103-15	15819-15824	Given	_	
103-16	15825-15828	the	_	
103-17	15829-15839	hypothesis	_	
103-18	15840-15844	that	_	
103-19	15845-15848	the	_	
103-20	15849-15855	CHRNA5	_	
103-21	15856-15865	nicotinic	_	
103-22	15866-15879	acetylcholine	_	
103-23	15880-15888	receptor	_	
103-24	15889-15891	α5	_	
103-25	15892-15899	subunit	_	
103-26	15900-15907	variant	_	
103-27	15907-15908	,	_	
103-28	15909-15919	rs16969968	_	
103-29	15920-15923	may	_	
103-30	15924-15926	be	_	
103-31	15927-15928	a	_	
103-32	15929-15933	risk	_	
103-33	15934-15940	factor	_	
103-34	15941-15944	for	_	
103-35	15945-15951	higher	_	
103-36	15952-15958	opioid	_	
103-37	15959-15962	use	_	
103-38	15962-15963	,	_	
103-39	15964-15967	the	_	
103-40	15968-15974	sample	_	
103-41	15975-15978	was	_	
103-42	15979-15986	divided	_	
103-43	15987-15996	according	_	
103-44	15997-15999	to	_	
103-45	16000-16008	genotype	_	
103-46	16009-16013	into	_	
103-47	16014-16020	pooled	_	
103-48	16021-16023	AA	_	
103-49	16024-16026	or	_	
103-50	16027-16029	AG	_	
103-51	16030-16039	genotypes	_	
103-52	16040-16041	(	_	
103-53	16041-16045	high	_	
103-54	16046-16050	risk	_	
103-55	16050-16051	)	_	
103-56	16052-16055	and	_	
103-57	16056-16058	GG	_	
103-58	16059-16067	genotype	_	
103-59	16068-16069	(	_	
103-60	16069-16072	low	_	
103-61	16073-16077	risk	_	
103-62	16077-16078	)	_	
103-63	16078-16079	.	_	

#Text=Figure 3C shows that opioid users carrying the GG genotype have higher Right habenula/Left caudate RSFC (0.18 ± 0.05) compared to non-opioid users carrying the GG genotype (non-opioid GG) (0.05 ± 0.02) (F(288,1) = 3.17, p<0.03).
104-1	16080-16086	Figure	_	
104-2	16087-16089	3C	_	
104-3	16090-16095	shows	_	
104-4	16096-16100	that	_	
104-5	16101-16107	opioid	_	
104-6	16108-16113	users	_	
104-7	16114-16122	carrying	_	
104-8	16123-16126	the	_	
104-9	16127-16129	GG	_	
104-10	16130-16138	genotype	_	
104-11	16139-16143	have	_	
104-12	16144-16150	higher	_	
104-13	16151-16156	Right	_	
104-14	16157-16165	habenula	_	
104-15	16165-16166	/	_	
104-16	16166-16170	Left	_	
104-17	16171-16178	caudate	_	
104-18	16179-16183	RSFC	_	
104-19	16184-16185	(	_	
104-20	16185-16189	0.18	_	
104-21	16190-16191	±	_	
104-22	16192-16196	0.05	_	
104-23	16196-16197	)	_	
104-24	16198-16206	compared	_	
104-25	16207-16209	to	_	
104-26	16210-16220	non-opioid	_	
104-27	16221-16226	users	_	
104-28	16227-16235	carrying	_	
104-29	16236-16239	the	_	
104-30	16240-16242	GG	_	
104-31	16243-16251	genotype	_	
104-32	16252-16253	(	_	
104-33	16253-16263	non-opioid	_	
104-34	16264-16266	GG	_	
104-35	16266-16267	)	_	
104-36	16268-16269	(	_	
104-37	16269-16273	0.05	_	
104-38	16274-16275	±	_	
104-39	16276-16280	0.02	_	
104-40	16280-16281	)	_	
104-41	16282-16283	(	_	
104-42	16283-16284	F	_	
104-43	16284-16285	(	_	
104-44	16285-16290	288,1	_	
104-45	16290-16291	)	_	
104-46	16292-16293	=	_	
104-47	16294-16298	3.17	_	
104-48	16298-16299	,	_	
104-49	16300-16301	p	_	
104-50	16301-16302	<	_	
104-51	16302-16306	0.03	_	
104-52	16306-16307	)	_	
104-53	16307-16308	.	_	

#Text=Post-hoc comparisons showed significant differences (p<0.05 LSD corrected) between both opioid GG vs. non-opioid GG and opioid GG vs. non-opioid AA/AG.
105-1	16309-16317	Post-hoc	_	
105-2	16318-16329	comparisons	_	
105-3	16330-16336	showed	_	
105-4	16337-16348	significant	_	
105-5	16349-16360	differences	_	
105-6	16361-16362	(	_	
105-7	16362-16363	p	_	
105-8	16363-16364	<	_	
105-9	16364-16368	0.05	_	
105-10	16369-16372	LSD	_	
105-11	16373-16382	corrected	_	
105-12	16382-16383	)	_	
105-13	16384-16391	between	_	
105-14	16392-16396	both	_	
105-15	16397-16403	opioid	_	
105-16	16404-16406	GG	_	
105-17	16407-16409	vs	_	
105-18	16409-16410	.	_	
105-19	16411-16421	non-opioid	_	
105-20	16422-16424	GG	_	
105-21	16425-16428	and	_	
105-22	16429-16435	opioid	_	
105-23	16436-16438	GG	_	
105-24	16439-16441	vs	_	
105-25	16441-16442	.	_	
105-26	16443-16453	non-opioid	_	
105-27	16454-16456	AA	_	
105-28	16456-16457	/	_	
105-29	16457-16459	AG	_	
105-30	16459-16460	.	_	

#Text=There was no interaction between genotype and opioid use (F(285,1)=2.034, p=0.16).
106-1	16461-16466	There	_	
106-2	16467-16470	was	_	
106-3	16471-16473	no	_	
106-4	16474-16485	interaction	_	
106-5	16486-16493	between	_	
106-6	16494-16502	genotype	_	
106-7	16503-16506	and	_	
106-8	16507-16513	opioid	_	
106-9	16514-16517	use	_	
106-10	16518-16519	(	_	
106-11	16519-16520	F	_	
106-12	16520-16521	(	_	
106-13	16521-16526	285,1	_	
106-14	16526-16527	)	_	
106-15	16527-16528	=	_	
106-16	16528-16533	2.034	_	
106-17	16533-16534	,	_	
106-18	16535-16536	p	_	
106-19	16536-16537	=	_	
106-20	16537-16541	0.16	_	
106-21	16541-16542	)	_	
106-22	16542-16543	.	_	

#Text=For Right Hb/Left caudate, the Cohen’s d effect size for users vs. non-users was 0.26.
107-1	16544-16547	For	_	
107-2	16548-16553	Right	_	
107-3	16554-16556	Hb	_	
107-4	16556-16557	/	_	
107-5	16557-16561	Left	_	
107-6	16562-16569	caudate	_	
107-7	16569-16570	,	_	
107-8	16571-16574	the	_	
107-9	16575-16580	Cohen	_	
107-10	16580-16581	’	_	
107-11	16581-16582	s	_	
107-12	16583-16584	d	_	
107-13	16585-16591	effect	_	
107-14	16592-16596	size	_	
107-15	16597-16600	for	_	
107-16	16601-16606	users	_	
107-17	16607-16609	vs	_	
107-18	16609-16610	.	_	
107-19	16611-16620	non-users	_	
107-20	16621-16624	was	_	
107-21	16625-16629	0.26	_	
107-22	16629-16630	.	_	

#Text=The effect sizes for GG vs.
108-1	16631-16634	The	_	
108-2	16635-16641	effect	_	
108-3	16642-16647	sizes	_	
108-4	16648-16651	for	_	
108-5	16652-16654	GG	_	
108-6	16655-16657	vs	_	
108-7	16657-16658	.	_	

#Text=AG/AA were 0.49 (users) and 0.08 (non-users).
109-1	16659-16661	AG	_	
109-2	16661-16662	/	_	
109-3	16662-16664	AA	_	
109-4	16665-16669	were	_	
109-5	16670-16674	0.49	_	
109-6	16675-16676	(	_	
109-7	16676-16681	users	_	
109-8	16681-16682	)	_	
109-9	16683-16686	and	_	
109-10	16687-16691	0.08	_	
109-11	16692-16693	(	_	
109-12	16693-16702	non-users	_	
109-13	16702-16703	)	_	
109-14	16703-16704	.	_	

#Text=Exploratory analysis shows habenula/amygdala RSFC is possibly involved in opioid dependence
#Text=We studied a number of regions known or hypothesized to be part of the habenular circuit: superior, medial, and inferior frontal gyrus (s, m, iFG); insula; anterior cingulate cortex (ACC); nucleus accumbens; amygdala (right and left); septum verum; and locus coeruleus.
110-1	16705-16716	Exploratory	_	
110-2	16717-16725	analysis	_	
110-3	16726-16731	shows	_	
110-4	16732-16740	habenula	_	
110-5	16740-16741	/	_	
110-6	16741-16749	amygdala	_	
110-7	16750-16754	RSFC	_	
110-8	16755-16757	is	_	
110-9	16758-16766	possibly	_	
110-10	16767-16775	involved	_	
110-11	16776-16778	in	_	
110-12	16779-16785	opioid	_	
110-13	16786-16796	dependence	_	
110-14	16797-16799	We	_	
110-15	16800-16807	studied	_	
110-16	16808-16809	a	_	
110-17	16810-16816	number	_	
110-18	16817-16819	of	_	
110-19	16820-16827	regions	_	
110-20	16828-16833	known	_	
110-21	16834-16836	or	_	
110-22	16837-16849	hypothesized	_	
110-23	16850-16852	to	_	
110-24	16853-16855	be	_	
110-25	16856-16860	part	_	
110-26	16861-16863	of	_	
110-27	16864-16867	the	_	
110-28	16868-16877	habenular	_	
110-29	16878-16885	circuit	_	
110-30	16885-16886	:	_	
110-31	16887-16895	superior	_	
110-32	16895-16896	,	_	
110-33	16897-16903	medial	_	
110-34	16903-16904	,	_	
110-35	16905-16908	and	_	
110-36	16909-16917	inferior	_	
110-37	16918-16925	frontal	_	
110-38	16926-16931	gyrus	_	
110-39	16932-16933	(	_	
110-40	16933-16934	s	_	
110-41	16934-16935	,	_	
110-42	16936-16937	m	_	
110-43	16937-16938	,	_	
110-44	16939-16942	iFG	_	
110-45	16942-16943	)	_	
110-46	16943-16944	;	_	
110-47	16945-16951	insula	_	
110-48	16951-16952	;	_	
110-49	16953-16961	anterior	_	
110-50	16962-16971	cingulate	_	
110-51	16972-16978	cortex	_	
110-52	16979-16980	(	_	
110-53	16980-16983	ACC	_	
110-54	16983-16984	)	_	
110-55	16984-16985	;	_	
110-56	16986-16993	nucleus	_	
110-57	16994-17003	accumbens	_	
110-58	17003-17004	;	_	
110-59	17005-17013	amygdala	_	
110-60	17014-17015	(	_	
110-61	17015-17020	right	_	
110-62	17021-17024	and	_	
110-63	17025-17029	left	_	
110-64	17029-17030	)	_	
110-65	17030-17031	;	_	
110-66	17032-17038	septum	_	
110-67	17039-17044	verum	_	
110-68	17044-17045	;	_	
110-69	17046-17049	and	_	
110-70	17050-17055	locus	_	
110-71	17056-17065	coeruleus	_	
110-72	17065-17066	.	_	

#Text=When opioid users were compared to non-opioid users, significant differences in RSFC were observed between the following brain regions and habenula (p<0.05, not corrected for multiple comparisons): Right habenula/Left Insula, Right habenula/Right insula, Right habenula/Left ACC, and Left habenula/Left sFG.
111-1	17067-17071	When	_	
111-2	17072-17078	opioid	_	
111-3	17079-17084	users	_	
111-4	17085-17089	were	_	
111-5	17090-17098	compared	_	
111-6	17099-17101	to	_	
111-7	17102-17112	non-opioid	_	
111-8	17113-17118	users	_	
111-9	17118-17119	,	_	
111-10	17120-17131	significant	_	
111-11	17132-17143	differences	_	
111-12	17144-17146	in	_	
111-13	17147-17151	RSFC	_	
111-14	17152-17156	were	_	
111-15	17157-17165	observed	_	
111-16	17166-17173	between	_	
111-17	17174-17177	the	_	
111-18	17178-17187	following	_	
111-19	17188-17193	brain	_	
111-20	17194-17201	regions	_	
111-21	17202-17205	and	_	
111-22	17206-17214	habenula	_	
111-23	17215-17216	(	_	
111-24	17216-17217	p	_	
111-25	17217-17218	<	_	
111-26	17218-17222	0.05	_	
111-27	17222-17223	,	_	
111-28	17224-17227	not	_	
111-29	17228-17237	corrected	_	
111-30	17238-17241	for	_	
111-31	17242-17250	multiple	_	
111-32	17251-17262	comparisons	_	
111-33	17262-17263	)	_	
111-34	17263-17264	:	_	
111-35	17265-17270	Right	_	
111-36	17271-17279	habenula	_	
111-37	17279-17280	/	_	
111-38	17280-17284	Left	_	
111-39	17285-17291	Insula	_	
111-40	17291-17292	,	_	
111-41	17293-17298	Right	_	
111-42	17299-17307	habenula	_	
111-43	17307-17308	/	_	
111-44	17308-17313	Right	_	
111-45	17314-17320	insula	_	
111-46	17320-17321	,	_	
111-47	17322-17327	Right	_	
111-48	17328-17336	habenula	_	
111-49	17336-17337	/	_	
111-50	17337-17341	Left	_	
111-51	17342-17345	ACC	_	
111-52	17345-17346	,	_	
111-53	17347-17350	and	_	
111-54	17351-17355	Left	_	
111-55	17356-17364	habenula	_	
111-56	17364-17365	/	_	
111-57	17365-17369	Left	_	
111-58	17370-17373	sFG	_	
111-59	17373-17374	.	_	

#Text=Interestingly, the connectivity between the right and left habenula was also higher in opioid users than in non-opioid user patients.
112-1	17375-17388	Interestingly	_	
112-2	17388-17389	,	_	
112-3	17390-17393	the	_	
112-4	17394-17406	connectivity	_	
112-5	17407-17414	between	_	
112-6	17415-17418	the	_	
112-7	17419-17424	right	_	
112-8	17425-17428	and	_	
112-9	17429-17433	left	_	
112-10	17434-17442	habenula	_	
112-11	17443-17446	was	_	
112-12	17447-17451	also	_	
112-13	17452-17458	higher	_	
112-14	17459-17461	in	_	
112-15	17462-17468	opioid	_	
112-16	17469-17474	users	_	
112-17	17475-17479	than	_	
112-18	17480-17482	in	_	
112-19	17483-17493	non-opioid	_	
112-20	17494-17498	user	_	
112-21	17499-17507	patients	_	
112-22	17507-17508	.	_	

#Text=Both the habenula/insula and habenula/ACC RSFC data recapitulated the results found in the caudate, in that among those with a GG genotype, opioid-using participants had higher RSFC than non-using participants (not shown).
113-1	17509-17513	Both	_	
113-2	17514-17517	the	_	
113-3	17518-17526	habenula	_	
113-4	17526-17527	/	_	
113-5	17527-17533	insula	_	
113-6	17534-17537	and	_	
113-7	17538-17546	habenula	_	
113-8	17546-17547	/	_	
113-9	17547-17550	ACC	_	
113-10	17551-17555	RSFC	_	
113-11	17556-17560	data	_	
113-12	17561-17574	recapitulated	_	
113-13	17575-17578	the	_	
113-14	17579-17586	results	_	
113-15	17587-17592	found	_	
113-16	17593-17595	in	_	
113-17	17596-17599	the	_	
113-18	17600-17607	caudate	_	
113-19	17607-17608	,	_	
113-20	17609-17611	in	_	
113-21	17612-17616	that	_	
113-22	17617-17622	among	_	
113-23	17623-17628	those	_	
113-24	17629-17633	with	_	
113-25	17634-17635	a	_	
113-26	17636-17638	GG	_	
113-27	17639-17647	genotype	_	
113-28	17647-17648	,	_	
113-29	17649-17661	opioid-using	_	
113-30	17662-17674	participants	_	
113-31	17675-17678	had	_	
113-32	17679-17685	higher	_	
113-33	17686-17690	RSFC	_	
113-34	17691-17695	than	_	
113-35	17696-17705	non-using	_	
113-36	17706-17718	participants	_	
113-37	17719-17720	(	_	
113-38	17720-17723	not	_	
113-39	17724-17729	shown	_	
113-40	17729-17730	)	_	
113-41	17730-17731	.	_	

#Text=Discussion
#Text=RSFC between the habenula and sub-regions of the striatum, particularly the caudate, was greater in opioid-using participants than in non-users in our inpatient psychiatric sample.
114-1	17732-17742	Discussion	_	
114-2	17743-17747	RSFC	_	
114-3	17748-17755	between	_	
114-4	17756-17759	the	_	
114-5	17760-17768	habenula	_	
114-6	17769-17772	and	_	
114-7	17773-17784	sub-regions	_	
114-8	17785-17787	of	_	
114-9	17788-17791	the	_	
114-10	17792-17800	striatum	_	
114-11	17800-17801	,	_	
114-12	17802-17814	particularly	_	
114-13	17815-17818	the	_	
114-14	17819-17826	caudate	_	
114-15	17826-17827	,	_	
114-16	17828-17831	was	_	
114-17	17832-17839	greater	_	
114-18	17840-17842	in	_	
114-19	17843-17855	opioid-using	_	
114-20	17856-17868	participants	_	
114-21	17869-17873	than	_	
114-22	17874-17876	in	_	
114-23	17877-17886	non-users	_	
114-24	17887-17889	in	_	
114-25	17890-17893	our	_	
114-26	17894-17903	inpatient	_	
114-27	17904-17915	psychiatric	_	
114-28	17916-17922	sample	_	
114-29	17922-17923	.	_	

#Text=This increase was driven by patients with the CHRNA rs16969968 GG genotype, which is known to confer a lower risk of being a tobacco smoker in humans, and less severe opioid dependence.
115-1	17924-17928	This	_	
115-2	17929-17937	increase	_	
115-3	17938-17941	was	_	
115-4	17942-17948	driven	_	
115-5	17949-17951	by	_	
115-6	17952-17960	patients	_	
115-7	17961-17965	with	_	
115-8	17966-17969	the	_	
115-9	17970-17975	CHRNA	_	
115-10	17976-17986	rs16969968	_	
115-11	17987-17989	GG	_	
115-12	17990-17998	genotype	_	
115-13	17998-17999	,	_	
115-14	18000-18005	which	_	
115-15	18006-18008	is	_	
115-16	18009-18014	known	_	
115-17	18015-18017	to	_	
115-18	18018-18024	confer	_	
115-19	18025-18026	a	_	
115-20	18027-18032	lower	_	
115-21	18033-18037	risk	_	
115-22	18038-18040	of	_	
115-23	18041-18046	being	_	
115-24	18047-18048	a	_	
115-25	18049-18056	tobacco	_	
115-26	18057-18063	smoker	_	
115-27	18064-18066	in	_	
115-28	18067-18073	humans	_	
115-29	18073-18074	,	_	
115-30	18075-18078	and	_	
115-31	18079-18083	less	_	
115-32	18084-18090	severe	_	
115-33	18091-18097	opioid	_	
115-34	18098-18108	dependence	_	
115-35	18108-18109	.	_	

#Text=Less severe dependence and withdrawal symptoms when stopping opioids may make using opioids less aversive and consequently more attractive.
116-1	18110-18114	Less	_	
116-2	18115-18121	severe	_	
116-3	18122-18132	dependence	_	
116-4	18133-18136	and	_	
116-5	18137-18147	withdrawal	_	
116-6	18148-18156	symptoms	_	
116-7	18157-18161	when	_	
116-8	18162-18170	stopping	_	
116-9	18171-18178	opioids	_	
116-10	18179-18182	may	_	
116-11	18183-18187	make	_	
116-12	18188-18193	using	_	
116-13	18194-18201	opioids	_	
116-14	18202-18206	less	_	
116-15	18207-18215	aversive	_	
116-16	18216-18219	and	_	
116-17	18220-18232	consequently	_	
116-18	18233-18237	more	_	
116-19	18238-18248	attractive	_	
116-20	18248-18249	.	_	

#Text=We focused on the habenula due to the role this small brain structure plays in negative reinforcement.
117-1	18250-18252	We	_	
117-2	18253-18260	focused	_	
117-3	18261-18263	on	_	
117-4	18264-18267	the	_	
117-5	18268-18276	habenula	_	
117-6	18277-18280	due	_	
117-7	18281-18283	to	_	
117-8	18284-18287	the	_	
117-9	18288-18292	role	_	
117-10	18293-18297	this	_	
117-11	18298-18303	small	_	
117-12	18304-18309	brain	_	
117-13	18310-18319	structure	_	
117-14	18320-18325	plays	_	
117-15	18326-18328	in	_	
117-16	18329-18337	negative	_	
117-17	18338-18351	reinforcement	_	
117-18	18351-18352	.	_	

#Text=Following unexpectedly rewarding events, dopamine release in the striatum is hypothesized to be an important learning signal.
118-1	18353-18362	Following	_	
118-2	18363-18375	unexpectedly	_	
118-3	18376-18385	rewarding	_	
118-4	18386-18392	events	_	
118-5	18392-18393	,	_	
118-6	18394-18402	dopamine	_	
118-7	18403-18410	release	_	
118-8	18411-18413	in	_	
118-9	18414-18417	the	_	
118-10	18418-18426	striatum	_	
118-11	18427-18429	is	_	
118-12	18430-18442	hypothesized	_	
118-13	18443-18445	to	_	
118-14	18446-18448	be	_	
118-15	18449-18451	an	_	
118-16	18452-18461	important	_	
118-17	18462-18470	learning	_	
118-18	18471-18477	signal	_	
118-19	18477-18478	.	_	

#Text=Activation of habenula following negative prediction errors, however, decreases dopamine release in the striatum.
119-1	18479-18489	Activation	_	
119-2	18490-18492	of	_	
119-3	18493-18501	habenula	_	
119-4	18502-18511	following	_	
119-5	18512-18520	negative	_	
119-6	18521-18531	prediction	_	
119-7	18532-18538	errors	_	
119-8	18538-18539	,	_	
119-9	18540-18547	however	_	
119-10	18547-18548	,	_	
119-11	18549-18558	decreases	_	
119-12	18559-18567	dopamine	_	
119-13	18568-18575	release	_	
119-14	18576-18578	in	_	
119-15	18579-18582	the	_	
119-16	18583-18591	striatum	_	
119-17	18591-18592	.	_	

#Text=This same habenular signaling pathway is likely to be modulated by drugs of abuse.
120-1	18593-18597	This	_	
120-2	18598-18602	same	_	
120-3	18603-18612	habenular	_	
120-4	18613-18622	signaling	_	
120-5	18623-18630	pathway	_	
120-6	18631-18633	is	_	
120-7	18634-18640	likely	_	
120-8	18641-18643	to	_	
120-9	18644-18646	be	_	
120-10	18647-18656	modulated	_	
120-11	18657-18659	by	_	
120-12	18660-18665	drugs	_	
120-13	18666-18668	of	_	
120-14	18669-18674	abuse	_	
120-15	18674-18675	.	_	

#Text=We previously showed that habenular activity is, at least in mice, critical for the appearance of nicotine withdrawal.
121-1	18676-18678	We	_	
121-2	18679-18689	previously	_	
121-3	18690-18696	showed	_	
121-4	18697-18701	that	_	
121-5	18702-18711	habenular	_	
121-6	18712-18720	activity	_	
121-7	18721-18723	is	_	
121-8	18723-18724	,	_	
121-9	18725-18727	at	_	
121-10	18728-18733	least	_	
121-11	18734-18736	in	_	
121-12	18737-18741	mice	_	
121-13	18741-18742	,	_	
121-14	18743-18751	critical	_	
121-15	18752-18755	for	_	
121-16	18756-18759	the	_	
121-17	18760-18770	appearance	_	
121-18	18771-18773	of	_	
121-19	18774-18782	nicotine	_	
121-20	18783-18793	withdrawal	_	
121-21	18793-18794	.	_	

#Text=In nicotine treated mice, both systemic mecamylamine (a non-specific nicotinic acetylcholine receptor blocker) and systemic naloxone (a μ-opioid receptor competitive antagonist) precipitate withdrawal symptoms, pointing to cross-talk between the nicotinic and the opioid systems.
122-1	18795-18797	In	_	
122-2	18798-18806	nicotine	_	
122-3	18807-18814	treated	_	
122-4	18815-18819	mice	_	
122-5	18819-18820	,	_	
122-6	18821-18825	both	_	
122-7	18826-18834	systemic	_	
122-8	18835-18847	mecamylamine	_	
122-9	18848-18849	(	_	
122-10	18849-18850	a	_	
122-11	18851-18863	non-specific	_	
122-12	18864-18873	nicotinic	_	
122-13	18874-18887	acetylcholine	_	
122-14	18888-18896	receptor	_	
122-15	18897-18904	blocker	_	
122-16	18904-18905	)	_	
122-17	18906-18909	and	_	
122-18	18910-18918	systemic	_	
122-19	18919-18927	naloxone	_	
122-20	18928-18929	(	_	
122-21	18929-18930	a	_	
122-22	18931-18939	μ-opioid	_	
122-23	18940-18948	receptor	_	
122-24	18949-18960	competitive	_	
122-25	18961-18971	antagonist	_	
122-26	18971-18972	)	_	
122-27	18973-18984	precipitate	_	
122-28	18985-18995	withdrawal	_	
122-29	18996-19004	symptoms	_	
122-30	19004-19005	,	_	
122-31	19006-19014	pointing	_	
122-32	19015-19017	to	_	
122-33	19018-19028	cross-talk	_	
122-34	19029-19036	between	_	
122-35	19037-19040	the	_	
122-36	19041-19050	nicotinic	_	
122-37	19051-19054	and	_	
122-38	19055-19058	the	_	
122-39	19059-19065	opioid	_	
122-40	19066-19073	systems	_	
122-41	19073-19074	.	_	

#Text=Given the high habenular expression of both nicotinic receptors and μ-opioid receptors (Allen Brain Atlas, www.brain-map.org) and the fact that nicotine withdrawal can be precipitated by microinjection of mecamylamine in the habenula, we hypothesized that the habenula, and specifically nicotinic receptor activity within the habenula, may be associated with the effects of opioid use.
123-1	19075-19080	Given	_	
123-2	19081-19084	the	_	
123-3	19085-19089	high	_	
123-4	19090-19099	habenular	_	
123-5	19100-19110	expression	_	
123-6	19111-19113	of	_	
123-7	19114-19118	both	_	
123-8	19119-19128	nicotinic	_	
123-9	19129-19138	receptors	_	
123-10	19139-19142	and	_	
123-11	19143-19151	μ-opioid	_	
123-12	19152-19161	receptors	_	
123-13	19162-19163	(	_	
123-14	19163-19168	Allen	_	
123-15	19169-19174	Brain	_	
123-16	19175-19180	Atlas	_	
123-17	19180-19181	,	_	
123-18	19182-19199	www.brain-map.org	_	
123-19	19199-19200	)	_	
123-20	19201-19204	and	_	
123-21	19205-19208	the	_	
123-22	19209-19213	fact	_	
123-23	19214-19218	that	_	
123-24	19219-19227	nicotine	_	
123-25	19228-19238	withdrawal	_	
123-26	19239-19242	can	_	
123-27	19243-19245	be	_	
123-28	19246-19258	precipitated	_	
123-29	19259-19261	by	_	
123-30	19262-19276	microinjection	_	
123-31	19277-19279	of	_	
123-32	19280-19292	mecamylamine	_	
123-33	19293-19295	in	_	
123-34	19296-19299	the	_	
123-35	19300-19308	habenula	_	
123-36	19308-19309	,	_	
123-37	19310-19312	we	_	
123-38	19313-19325	hypothesized	_	
123-39	19326-19330	that	_	
123-40	19331-19334	the	_	
123-41	19335-19343	habenula	_	
123-42	19343-19344	,	_	
123-43	19345-19348	and	_	
123-44	19349-19361	specifically	_	
123-45	19362-19371	nicotinic	_	
123-46	19372-19380	receptor	_	
123-47	19381-19389	activity	_	
123-48	19390-19396	within	_	
123-49	19397-19400	the	_	
123-50	19401-19409	habenula	_	
123-51	19409-19410	,	_	
123-52	19411-19414	may	_	
123-53	19415-19417	be	_	
123-54	19418-19428	associated	_	
123-55	19429-19433	with	_	
123-56	19434-19437	the	_	
123-57	19438-19445	effects	_	
123-58	19446-19448	of	_	
123-59	19449-19455	opioid	_	
123-60	19456-19459	use	_	
123-61	19459-19460	.	_	

#Text=The A allele of rs16969968 in the CHRNA5 gene (nicotinic acetylcholine receptor α5 subunit) confers higher risk of tobacco abuse, greater opioid dependence severity and alcohol use.
124-1	19461-19464	The	_	
124-2	19465-19466	A	_	
124-3	19467-19473	allele	_	
124-4	19474-19476	of	_	
124-5	19477-19487	rs16969968	_	
124-6	19488-19490	in	_	
124-7	19491-19494	the	_	
124-8	19495-19501	CHRNA5	_	
124-9	19502-19506	gene	_	
124-10	19507-19508	(	_	
124-11	19508-19517	nicotinic	_	
124-12	19518-19531	acetylcholine	_	
124-13	19532-19540	receptor	_	
124-14	19541-19543	α5	_	
124-15	19544-19551	subunit	_	
124-16	19551-19552	)	_	
124-17	19553-19560	confers	_	
124-18	19561-19567	higher	_	
124-19	19568-19572	risk	_	
124-20	19573-19575	of	_	
124-21	19576-19583	tobacco	_	
124-22	19584-19589	abuse	_	
124-23	19589-19590	,	_	
124-24	19591-19598	greater	_	
124-25	19599-19605	opioid	_	
124-26	19606-19616	dependence	_	
124-27	19617-19625	severity	_	
124-28	19626-19629	and	_	
124-29	19630-19637	alcohol	_	
124-30	19638-19641	use	_	
124-31	19641-19642	.	_	

#Text=However, this same allele confers lower risk of cocaine abuse.
125-1	19643-19650	However	_	
125-2	19650-19651	,	_	
125-3	19652-19656	this	_	
125-4	19657-19661	same	_	
125-5	19662-19668	allele	_	
125-6	19669-19676	confers	_	
125-7	19677-19682	lower	_	
125-8	19683-19687	risk	_	
125-9	19688-19690	of	_	
125-10	19691-19698	cocaine	_	
125-11	19699-19704	abuse	_	
125-12	19704-19705	.	_	

#Text=We therefore examined if opioid use alters RSFC between the habenula and dopaminergic striatal regions.
126-1	19706-19708	We	_	
126-2	19709-19718	therefore	_	
126-3	19719-19727	examined	_	
126-4	19728-19730	if	_	
126-5	19731-19737	opioid	_	
126-6	19738-19741	use	_	
126-7	19742-19748	alters	_	
126-8	19749-19753	RSFC	_	
126-9	19754-19761	between	_	
126-10	19762-19765	the	_	
126-11	19766-19774	habenula	_	
126-12	19775-19778	and	_	
126-13	19779-19791	dopaminergic	_	
126-14	19792-19800	striatal	_	
126-15	19801-19808	regions	_	
126-16	19808-19809	.	_	

#Text=Higher habenula/striatum RSFC was observed in opioid-using participants, which could point to a role for the habenula in OUD.
127-1	19810-19816	Higher	_	
127-2	19817-19825	habenula	_	
127-3	19825-19826	/	_	
127-4	19826-19834	striatum	_	
127-5	19835-19839	RSFC	_	
127-6	19840-19843	was	_	
127-7	19844-19852	observed	_	
127-8	19853-19855	in	_	
127-9	19856-19868	opioid-using	_	
127-10	19869-19881	participants	_	
127-11	19881-19882	,	_	
127-12	19883-19888	which	_	
127-13	19889-19894	could	_	
127-14	19895-19900	point	_	
127-15	19901-19903	to	_	
127-16	19904-19905	a	_	
127-17	19906-19910	role	_	
127-18	19911-19914	for	_	
127-19	19915-19918	the	_	
127-20	19919-19927	habenula	_	
127-21	19928-19930	in	_	
127-22	19931-19934	OUD	_	
127-23	19934-19935	.	_	

#Text=Specifically, the effect was observed mainly between the right habenula and the caudate.
128-1	19936-19948	Specifically	_	
128-2	19948-19949	,	_	
128-3	19950-19953	the	_	
128-4	19954-19960	effect	_	
128-5	19961-19964	was	_	
128-6	19965-19973	observed	_	
128-7	19974-19980	mainly	_	
128-8	19981-19988	between	_	
128-9	19989-19992	the	_	
128-10	19993-19998	right	_	
128-11	19999-20007	habenula	_	
128-12	20008-20011	and	_	
128-13	20012-20015	the	_	
128-14	20016-20023	caudate	_	
128-15	20023-20024	.	_	

#Text=Habenular asymmetry is important for animal behaviors and has been observed in human healthy controls.
129-1	20025-20034	Habenular	_	
129-2	20035-20044	asymmetry	_	
129-3	20045-20047	is	_	
129-4	20048-20057	important	_	
129-5	20058-20061	for	_	
129-6	20062-20068	animal	_	
129-7	20069-20078	behaviors	_	
129-8	20079-20082	and	_	
129-9	20083-20086	has	_	
129-10	20087-20091	been	_	
129-11	20092-20100	observed	_	
129-12	20101-20103	in	_	
129-13	20104-20109	human	_	
129-14	20110-20117	healthy	_	
129-15	20118-20126	controls	_	
129-16	20126-20127	.	_	

#Text=Although most habenular fibers are lateralized, as evidenced by diffusion tensor imaging (DTI) measurements, the habenular commissure, which is very close to the posterior commissure (both are often observed as a single structure in MRI, see Figure 2E), likely transmits information between the hemispheres.
130-1	20128-20136	Although	_	
130-2	20137-20141	most	_	
130-3	20142-20151	habenular	_	
130-4	20152-20158	fibers	_	
130-5	20159-20162	are	_	
130-6	20163-20174	lateralized	_	
130-7	20174-20175	,	_	
130-8	20176-20178	as	_	
130-9	20179-20188	evidenced	_	
130-10	20189-20191	by	_	
130-11	20192-20201	diffusion	_	
130-12	20202-20208	tensor	_	
130-13	20209-20216	imaging	_	
130-14	20217-20218	(	_	
130-15	20218-20221	DTI	_	
130-16	20221-20222	)	_	
130-17	20223-20235	measurements	_	
130-18	20235-20236	,	_	
130-19	20237-20240	the	_	
130-20	20241-20250	habenular	_	
130-21	20251-20261	commissure	_	
130-22	20261-20262	,	_	
130-23	20263-20268	which	_	
130-24	20269-20271	is	_	
130-25	20272-20276	very	_	
130-26	20277-20282	close	_	
130-27	20283-20285	to	_	
130-28	20286-20289	the	_	
130-29	20290-20299	posterior	_	
130-30	20300-20310	commissure	_	
130-31	20311-20312	(	_	
130-32	20312-20316	both	_	
130-33	20317-20320	are	_	
130-34	20321-20326	often	_	
130-35	20327-20335	observed	_	
130-36	20336-20338	as	_	
130-37	20339-20340	a	_	
130-38	20341-20347	single	_	
130-39	20348-20357	structure	_	
130-40	20358-20360	in	_	
130-41	20361-20364	MRI	_	
130-42	20364-20365	,	_	
130-43	20366-20369	see	_	
130-44	20370-20376	Figure	_	
130-45	20377-20379	2E	_	
130-46	20379-20380	)	_	
130-47	20380-20381	,	_	
130-48	20382-20388	likely	_	
130-49	20389-20398	transmits	_	
130-50	20399-20410	information	_	
130-51	20411-20418	between	_	
130-52	20419-20422	the	_	
130-53	20423-20434	hemispheres	_	
130-54	20434-20435	.	_	

#Text=Indeed, we observed increased RSFC between the right and the left habenula in opioid users.
131-1	20436-20442	Indeed	_	
131-2	20442-20443	,	_	
131-3	20444-20446	we	_	
131-4	20447-20455	observed	_	
131-5	20456-20465	increased	_	
131-6	20466-20470	RSFC	_	
131-7	20471-20478	between	_	
131-8	20479-20482	the	_	
131-9	20483-20488	right	_	
131-10	20489-20492	and	_	
131-11	20493-20496	the	_	
131-12	20497-20501	left	_	
131-13	20502-20510	habenula	_	
131-14	20511-20513	in	_	
131-15	20514-20520	opioid	_	
131-16	20521-20526	users	_	
131-17	20526-20527	.	_	

#Text=The RSFC between the habenula and the striatum is not likely to reflect direct anatomical connections, but be dependent on indirect connectivity (e.g. habenula → rostromedial tegmental nucleus → ventral tegmental area/substantia nigra compacta → striatum).
132-1	20528-20531	The	_	
132-2	20532-20536	RSFC	_	
132-3	20537-20544	between	_	
132-4	20545-20548	the	_	
132-5	20549-20557	habenula	_	
132-6	20558-20561	and	_	
132-7	20562-20565	the	_	
132-8	20566-20574	striatum	_	
132-9	20575-20577	is	_	
132-10	20578-20581	not	_	
132-11	20582-20588	likely	_	
132-12	20589-20591	to	_	
132-13	20592-20599	reflect	_	
132-14	20600-20606	direct	_	
132-15	20607-20617	anatomical	_	
132-16	20618-20629	connections	_	
132-17	20629-20630	,	_	
132-18	20631-20634	but	_	
132-19	20635-20637	be	_	
132-20	20638-20647	dependent	_	
132-21	20648-20650	on	_	
132-22	20651-20659	indirect	_	
132-23	20660-20672	connectivity	_	
132-24	20673-20674	(	_	
132-25	20674-20677	e.g	_	
132-26	20677-20678	.	_	
132-27	20679-20687	habenula	_	
132-28	20688-20689	→	_	
132-29	20690-20702	rostromedial	_	
132-30	20703-20712	tegmental	_	
132-31	20713-20720	nucleus	_	
132-32	20721-20722	→	_	
132-33	20723-20730	ventral	_	
132-34	20731-20740	tegmental	_	
132-35	20741-20745	area	_	
132-36	20745-20746	/	_	
132-37	20746-20756	substantia	_	
132-38	20757-20762	nigra	_	
132-39	20763-20771	compacta	_	
132-40	20772-20773	→	_	
132-41	20774-20782	striatum	_	
132-42	20782-20783	)	_	
132-43	20783-20784	.	_	

#Text=The increase in Right habenula/Left caudate RSFC was greater in patients with the GG CHRNA5 genotype (lower tobacco, opioid, and alcohol risk), compared to A-allele carriers.
133-1	20785-20788	The	_	
133-2	20789-20797	increase	_	
133-3	20798-20800	in	_	
133-4	20801-20806	Right	_	
133-5	20807-20815	habenula	_	
133-6	20815-20816	/	_	
133-7	20816-20820	Left	_	
133-8	20821-20828	caudate	_	
133-9	20829-20833	RSFC	_	
133-10	20834-20837	was	_	
133-11	20838-20845	greater	_	
133-12	20846-20848	in	_	
133-13	20849-20857	patients	_	
133-14	20858-20862	with	_	
133-15	20863-20866	the	_	
133-16	20867-20869	GG	_	
133-17	20870-20876	CHRNA5	_	
133-18	20877-20885	genotype	_	
133-19	20886-20887	(	_	
133-20	20887-20892	lower	_	
133-21	20893-20900	tobacco	_	
133-22	20900-20901	,	_	
133-23	20902-20908	opioid	_	
133-24	20908-20909	,	_	
133-25	20910-20913	and	_	
133-26	20914-20921	alcohol	_	
133-27	20922-20926	risk	_	
133-28	20926-20927	)	_	
133-29	20927-20928	,	_	
133-30	20929-20937	compared	_	
133-31	20938-20940	to	_	
133-32	20941-20949	A-allele	_	
133-33	20950-20958	carriers	_	
133-34	20958-20959	.	_	

#Text=The current study suggests RSFC between habenula and striatal sub-regions is altered in opioid users, possibly the result of (or resulting from) differences in negative reinforcement among those who are dependent versus non-dependent as well as carriers of the GG versus the AA/AG CHRNA5 genotypes.
134-1	20960-20963	The	_	
134-2	20964-20971	current	_	
134-3	20972-20977	study	_	
134-4	20978-20986	suggests	_	
134-5	20987-20991	RSFC	_	
134-6	20992-20999	between	_	
134-7	21000-21008	habenula	_	
134-8	21009-21012	and	_	
134-9	21013-21021	striatal	_	
134-10	21022-21033	sub-regions	_	
134-11	21034-21036	is	_	
134-12	21037-21044	altered	_	
134-13	21045-21047	in	_	
134-14	21048-21054	opioid	_	
134-15	21055-21060	users	_	
134-16	21060-21061	,	_	
134-17	21062-21070	possibly	_	
134-18	21071-21074	the	_	
134-19	21075-21081	result	_	
134-20	21082-21084	of	_	
134-21	21085-21086	(	_	
134-22	21086-21088	or	_	
134-23	21089-21098	resulting	_	
134-24	21099-21103	from	_	
134-25	21103-21104	)	_	
134-26	21105-21116	differences	_	
134-27	21117-21119	in	_	
134-28	21120-21128	negative	_	
134-29	21129-21142	reinforcement	_	
134-30	21143-21148	among	_	
134-31	21149-21154	those	_	
134-32	21155-21158	who	_	
134-33	21159-21162	are	_	
134-34	21163-21172	dependent	_	
134-35	21173-21179	versus	_	
134-36	21180-21193	non-dependent	_	
134-37	21194-21196	as	_	
134-38	21197-21201	well	_	
134-39	21202-21204	as	_	
134-40	21205-21213	carriers	_	
134-41	21214-21216	of	_	
134-42	21217-21220	the	_	
134-43	21221-21223	GG	_	
134-44	21224-21230	versus	_	
134-45	21231-21234	the	_	
134-46	21235-21237	AA	_	
134-47	21237-21238	/	_	
134-48	21238-21240	AG	_	
134-49	21241-21247	CHRNA5	_	
134-50	21248-21257	genotypes	_	
134-51	21257-21258	.	_	

#Text=In rodents, habenular expression of α5-containing nicotinic receptors is necessary for the appearance of nicotine’s negative effects, including withdrawal symptoms.
135-1	21259-21261	In	_	
135-2	21262-21269	rodents	_	
135-3	21269-21270	,	_	
135-4	21271-21280	habenular	_	
135-5	21281-21291	expression	_	
135-6	21292-21294	of	_	
135-7	21295-21297	α5	_	
135-8	21297-21298	-	_	
135-9	21298-21308	containing	_	
135-10	21309-21318	nicotinic	_	
135-11	21319-21328	receptors	_	
135-12	21329-21331	is	_	
135-13	21332-21341	necessary	_	
135-14	21342-21345	for	_	
135-15	21346-21349	the	_	
135-16	21350-21360	appearance	_	
135-17	21361-21363	of	_	
135-18	21364-21372	nicotine	_	
135-19	21372-21373	’	_	
135-20	21373-21374	s	_	
135-21	21375-21383	negative	_	
135-22	21384-21391	effects	_	
135-23	21391-21392	,	_	
135-24	21393-21402	including	_	
135-25	21403-21413	withdrawal	_	
135-26	21414-21422	symptoms	_	
135-27	21422-21423	.	_	

#Text=For example, α5 subunit null mice self-administer enormous amounts of nicotine because they are sensitive to the positive (reward) but not to the negative (withdrawal) effects of nicotine use.
136-1	21424-21427	For	_	
136-2	21428-21435	example	_	
136-3	21435-21436	,	_	
136-4	21437-21439	α5	_	
136-5	21440-21447	subunit	_	
136-6	21448-21452	null	_	
136-7	21453-21457	mice	_	
136-8	21458-21473	self-administer	_	
136-9	21474-21482	enormous	_	
136-10	21483-21490	amounts	_	
136-11	21491-21493	of	_	
136-12	21494-21502	nicotine	_	
136-13	21503-21510	because	_	
136-14	21511-21515	they	_	
136-15	21516-21519	are	_	
136-16	21520-21529	sensitive	_	
136-17	21530-21532	to	_	
136-18	21533-21536	the	_	
136-19	21537-21545	positive	_	
136-20	21546-21547	(	_	
136-21	21547-21553	reward	_	
136-22	21553-21554	)	_	
136-23	21555-21558	but	_	
136-24	21559-21562	not	_	
136-25	21563-21565	to	_	
136-26	21566-21569	the	_	
136-27	21570-21578	negative	_	
136-28	21579-21580	(	_	
136-29	21580-21590	withdrawal	_	
136-30	21590-21591	)	_	
136-31	21592-21599	effects	_	
136-32	21600-21602	of	_	
136-33	21603-21611	nicotine	_	
136-34	21612-21615	use	_	
136-35	21615-21616	.	_	

#Text=Since the rs16969968 A-allele may decrease nicotinic receptor activity, it is tempting to speculate that the high risk for tobacco and opioid use associated with this allele may be due to decreased negative drug reinforcement.
137-1	21617-21622	Since	_	
137-2	21623-21626	the	_	
137-3	21627-21637	rs16969968	_	
137-4	21638-21646	A-allele	_	
137-5	21647-21650	may	_	
137-6	21651-21659	decrease	_	
137-7	21660-21669	nicotinic	_	
137-8	21670-21678	receptor	_	
137-9	21679-21687	activity	_	
137-10	21687-21688	,	_	
137-11	21689-21691	it	_	
137-12	21692-21694	is	_	
137-13	21695-21703	tempting	_	
137-14	21704-21706	to	_	
137-15	21707-21716	speculate	_	
137-16	21717-21721	that	_	
137-17	21722-21725	the	_	
137-18	21726-21730	high	_	
137-19	21731-21735	risk	_	
137-20	21736-21739	for	_	
137-21	21740-21747	tobacco	_	
137-22	21748-21751	and	_	
137-23	21752-21758	opioid	_	
137-24	21759-21762	use	_	
137-25	21763-21773	associated	_	
137-26	21774-21778	with	_	
137-27	21779-21783	this	_	
137-28	21784-21790	allele	_	
137-29	21791-21794	may	_	
137-30	21795-21797	be	_	
137-31	21798-21801	due	_	
137-32	21802-21804	to	_	
137-33	21805-21814	decreased	_	
137-34	21815-21823	negative	_	
137-35	21824-21828	drug	_	
137-36	21829-21842	reinforcement	_	
137-37	21842-21843	.	_	

#Text=We postulate that high-risk opioid users feel less negative reinforcement, which may result in increased use.
138-1	21844-21846	We	_	
138-2	21847-21856	postulate	_	
138-3	21857-21861	that	_	
138-4	21862-21871	high-risk	_	
138-5	21872-21878	opioid	_	
138-6	21879-21884	users	_	
138-7	21885-21889	feel	_	
138-8	21890-21894	less	_	
138-9	21895-21903	negative	_	
138-10	21904-21917	reinforcement	_	
138-11	21917-21918	,	_	
138-12	21919-21924	which	_	
138-13	21925-21928	may	_	
138-14	21929-21935	result	_	
138-15	21936-21938	in	_	
138-16	21939-21948	increased	_	
138-17	21949-21952	use	_	
138-18	21952-21953	.	_	

#Text=The functional significance of the ra16969968 variant is not completely clear but simplistically, it may work by decreasing the receptor’s response to nicotine.
139-1	21954-21957	The	_	
139-2	21958-21968	functional	_	
139-3	21969-21981	significance	_	
139-4	21982-21984	of	_	
139-5	21985-21988	the	_	
139-6	21989-21999	ra16969968	_	
139-7	22000-22007	variant	_	
139-8	22008-22010	is	_	
139-9	22011-22014	not	_	
139-10	22015-22025	completely	_	
139-11	22026-22031	clear	_	
139-12	22032-22035	but	_	
139-13	22036-22050	simplistically	_	
139-14	22050-22051	,	_	
139-15	22052-22054	it	_	
139-16	22055-22058	may	_	
139-17	22059-22063	work	_	
139-18	22064-22066	by	_	
139-19	22067-22077	decreasing	_	
139-20	22078-22081	the	_	
139-21	22082-22090	receptor	_	
139-22	22090-22091	’	_	
139-23	22091-22092	s	_	
139-24	22093-22101	response	_	
139-25	22102-22104	to	_	
139-26	22105-22113	nicotine	_	
139-27	22113-22114	.	_	

#Text=In that sense, humans carrying the rs16969968 A variant may be a mild version of α5 nicotinic receptor knock-out mice.
140-1	22115-22117	In	_	
140-2	22118-22122	that	_	
140-3	22123-22128	sense	_	
140-4	22128-22129	,	_	
140-5	22130-22136	humans	_	
140-6	22137-22145	carrying	_	
140-7	22146-22149	the	_	
140-8	22150-22160	rs16969968	_	
140-9	22161-22162	A	_	
140-10	22163-22170	variant	_	
140-11	22171-22174	may	_	
140-12	22175-22177	be	_	
140-13	22178-22179	a	_	
140-14	22180-22184	mild	_	
140-15	22185-22192	version	_	
140-16	22193-22195	of	_	
140-17	22196-22198	α5	_	
140-18	22199-22208	nicotinic	_	
140-19	22209-22217	receptor	_	
140-20	22218-22227	knock-out	_	
140-21	22228-22232	mice	_	
140-22	22232-22233	.	_	

#Text=These animals self-administer enormous amounts of nicotine and show no nicotine withdrawal signs.
141-1	22234-22239	These	_	
141-2	22240-22247	animals	_	
141-3	22248-22263	self-administer	_	
141-4	22264-22272	enormous	_	
141-5	22273-22280	amounts	_	
141-6	22281-22283	of	_	
141-7	22284-22292	nicotine	_	
141-8	22293-22296	and	_	
141-9	22297-22301	show	_	
141-10	22302-22304	no	_	
141-11	22305-22313	nicotine	_	
141-12	22314-22324	withdrawal	_	
141-13	22325-22330	signs	_	
141-14	22330-22331	.	_	

#Text=Our data showed a possible significant functional difference between the right and the left habenula in the context of opioid abuse.
142-1	22332-22335	Our	_	
142-2	22336-22340	data	_	
142-3	22341-22347	showed	_	
142-4	22348-22349	a	_	
142-5	22350-22358	possible	_	
142-6	22359-22370	significant	_	
142-7	22371-22381	functional	_	
142-8	22382-22392	difference	_	
142-9	22393-22400	between	_	
142-10	22401-22404	the	_	
142-11	22405-22410	right	_	
142-12	22411-22414	and	_	
142-13	22415-22418	the	_	
142-14	22419-22423	left	_	
142-15	22424-22432	habenula	_	
142-16	22433-22435	in	_	
142-17	22436-22439	the	_	
142-18	22440-22447	context	_	
142-19	22448-22450	of	_	
142-20	22451-22457	opioid	_	
142-21	22458-22463	abuse	_	
142-22	22463-22464	.	_	

#Text=Habenular asymmetry has been shown to be behaviorally important in vertebrates.
143-1	22465-22474	Habenular	_	
143-2	22475-22484	asymmetry	_	
143-3	22485-22488	has	_	
143-4	22489-22493	been	_	
143-5	22494-22499	shown	_	
143-6	22500-22502	to	_	
143-7	22503-22505	be	_	
143-8	22506-22518	behaviorally	_	
143-9	22519-22528	important	_	
143-10	22529-22531	in	_	
143-11	22532-22543	vertebrates	_	
143-12	22543-22544	.	_	

#Text=In humans, habenular RSFC has been shown to be asymmetric.
144-1	22545-22547	In	_	
144-2	22548-22554	humans	_	
144-3	22554-22555	,	_	
144-4	22556-22565	habenular	_	
144-5	22566-22570	RSFC	_	
144-6	22571-22574	has	_	
144-7	22575-22579	been	_	
144-8	22580-22585	shown	_	
144-9	22586-22588	to	_	
144-10	22589-22591	be	_	
144-11	22592-22602	asymmetric	_	
144-12	22602-22603	.	_	

#Text=However, the functional significance of this asymmetry is not clear.
145-1	22604-22611	However	_	
145-2	22611-22612	,	_	
145-3	22613-22616	the	_	
145-4	22617-22627	functional	_	
145-5	22628-22640	significance	_	
145-6	22641-22643	of	_	
145-7	22644-22648	this	_	
145-8	22649-22658	asymmetry	_	
145-9	22659-22661	is	_	
145-10	22662-22665	not	_	
145-11	22666-22671	clear	_	
145-12	22671-22672	.	_	

#Text=Our data opens questions about the possibility that habenular functional asymmetry may play a role in addiction.
146-1	22673-22676	Our	_	
146-2	22677-22681	data	_	
146-3	22682-22687	opens	_	
146-4	22688-22697	questions	_	
146-5	22698-22703	about	_	
146-6	22704-22707	the	_	
146-7	22708-22719	possibility	_	
146-8	22720-22724	that	_	
146-9	22725-22734	habenular	_	
146-10	22735-22745	functional	_	
146-11	22746-22755	asymmetry	_	
146-12	22756-22759	may	_	
146-13	22760-22764	play	_	
146-14	22765-22766	a	_	
146-15	22767-22771	role	_	
146-16	22772-22774	in	_	
146-17	22775-22784	addiction	_	
146-18	22784-22785	.	_	

#Text=The current sample consisted of opioid-using and non-using participants within an inpatient population at The Menninger Clinic, rather than between opioid-using participants and healthy controls.
147-1	22786-22789	The	_	
147-2	22790-22797	current	_	
147-3	22798-22804	sample	_	
147-4	22805-22814	consisted	_	
147-5	22815-22817	of	_	
147-6	22818-22830	opioid-using	_	
147-7	22831-22834	and	_	
147-8	22835-22844	non-using	_	
147-9	22845-22857	participants	_	
147-10	22858-22864	within	_	
147-11	22865-22867	an	_	
147-12	22868-22877	inpatient	_	
147-13	22878-22888	population	_	
147-14	22889-22891	at	_	
147-15	22892-22895	The	_	
147-16	22896-22905	Menninger	_	
147-17	22906-22912	Clinic	_	
147-18	22912-22913	,	_	
147-19	22914-22920	rather	_	
147-20	22921-22925	than	_	
147-21	22926-22933	between	_	
147-22	22934-22946	opioid-using	_	
147-23	22947-22959	participants	_	
147-24	22960-22963	and	_	
147-25	22964-22971	healthy	_	
147-26	22972-22980	controls	_	
147-27	22980-22981	.	_	

#Text=By using other patients as controls and including comorbidities as covariates in the analysis, we attempted to control for the possible confounding effects of multiple diagnoses.
148-1	22982-22984	By	_	
148-2	22985-22990	using	_	
148-3	22991-22996	other	_	
148-4	22997-23005	patients	_	
148-5	23006-23008	as	_	
148-6	23009-23017	controls	_	
148-7	23018-23021	and	_	
148-8	23022-23031	including	_	
148-9	23032-23045	comorbidities	_	
148-10	23046-23048	as	_	
148-11	23049-23059	covariates	_	
148-12	23060-23062	in	_	
148-13	23063-23066	the	_	
148-14	23067-23075	analysis	_	
148-15	23075-23076	,	_	
148-16	23077-23079	we	_	
148-17	23080-23089	attempted	_	
148-18	23090-23092	to	_	
148-19	23093-23100	control	_	
148-20	23101-23104	for	_	
148-21	23105-23108	the	_	
148-22	23109-23117	possible	_	
148-23	23118-23129	confounding	_	
148-24	23130-23137	effects	_	
148-25	23138-23140	of	_	
148-26	23141-23149	multiple	_	
148-27	23150-23159	diagnoses	_	
148-28	23159-23160	.	_	

#Text=In addition, by studying all consenting patients without excluding patients because of comorbidities when comparing user versus non-user participants, our sample arguably has higher ecological validity than the more traditional imaging approach, where a small sample of narrowly defined patients is compared to healthy controls.
149-1	23161-23163	In	_	
149-2	23164-23172	addition	_	
149-3	23172-23173	,	_	
149-4	23174-23176	by	_	
149-5	23177-23185	studying	_	
149-6	23186-23189	all	_	
149-7	23190-23200	consenting	_	
149-8	23201-23209	patients	_	
149-9	23210-23217	without	_	
149-10	23218-23227	excluding	_	
149-11	23228-23236	patients	_	
149-12	23237-23244	because	_	
149-13	23245-23247	of	_	
149-14	23248-23261	comorbidities	_	
149-15	23262-23266	when	_	
149-16	23267-23276	comparing	_	
149-17	23277-23281	user	_	
149-18	23282-23288	versus	_	
149-19	23289-23297	non-user	_	
149-20	23298-23310	participants	_	
149-21	23310-23311	,	_	
149-22	23312-23315	our	_	
149-23	23316-23322	sample	_	
149-24	23323-23331	arguably	_	
149-25	23332-23335	has	_	
149-26	23336-23342	higher	_	
149-27	23343-23353	ecological	_	
149-28	23354-23362	validity	_	
149-29	23363-23367	than	_	
149-30	23368-23371	the	_	
149-31	23372-23376	more	_	
149-32	23377-23388	traditional	_	
149-33	23389-23396	imaging	_	
149-34	23397-23405	approach	_	
149-35	23405-23406	,	_	
149-36	23407-23412	where	_	
149-37	23413-23414	a	_	
149-38	23415-23420	small	_	
149-39	23421-23427	sample	_	
149-40	23428-23430	of	_	
149-41	23431-23439	narrowly	_	
149-42	23440-23447	defined	_	
149-43	23448-23456	patients	_	
149-44	23457-23459	is	_	
149-45	23460-23468	compared	_	
149-46	23469-23471	to	_	
149-47	23472-23479	healthy	_	
149-48	23480-23488	controls	_	
149-49	23488-23489	.	_	

#Text=Our sample included comorbid diagnoses and abusers of multiple dugs.
150-1	23490-23493	Our	_	
150-2	23494-23500	sample	_	
150-3	23501-23509	included	_	
150-4	23510-23518	comorbid	_	
150-5	23519-23528	diagnoses	_	
150-6	23529-23532	and	_	
150-7	23533-23540	abusers	_	
150-8	23541-23543	of	_	
150-9	23544-23552	multiple	_	
150-10	23553-23557	dugs	_	
150-11	23557-23558	.	_	

#Text=Despite this heterogeneity, opioid use was the one variable that influenced RSFC between habenula and striatal sub-regions.
151-1	23559-23566	Despite	_	
151-2	23567-23571	this	_	
151-3	23572-23585	heterogeneity	_	
151-4	23585-23586	,	_	
151-5	23587-23593	opioid	_	
151-6	23594-23597	use	_	
151-7	23598-23601	was	_	
151-8	23602-23605	the	_	
151-9	23606-23609	one	_	
151-10	23610-23618	variable	_	
151-11	23619-23623	that	_	
151-12	23624-23634	influenced	_	
151-13	23635-23639	RSFC	_	
151-14	23640-23647	between	_	
151-15	23648-23656	habenula	_	
151-16	23657-23660	and	_	
151-17	23661-23669	striatal	_	
151-18	23670-23681	sub-regions	_	
151-19	23681-23682	.	_	

#Text=Given the small size of the habenula, comparable to the size of the functional voxel we used, it is difficult to be confident that the observed results are indeed differences in habenular connectivity.
152-1	23683-23688	Given	_	
152-2	23689-23692	the	_	
152-3	23693-23698	small	_	
152-4	23699-23703	size	_	
152-5	23704-23706	of	_	
152-6	23707-23710	the	_	
152-7	23711-23719	habenula	_	
152-8	23719-23720	,	_	
152-9	23721-23731	comparable	_	
152-10	23732-23734	to	_	
152-11	23735-23738	the	_	
152-12	23739-23743	size	_	
152-13	23744-23746	of	_	
152-14	23747-23750	the	_	
152-15	23751-23761	functional	_	
152-16	23762-23767	voxel	_	
152-17	23768-23770	we	_	
152-18	23771-23775	used	_	
152-19	23775-23776	,	_	
152-20	23777-23779	it	_	
152-21	23780-23782	is	_	
152-22	23783-23792	difficult	_	
152-23	23793-23795	to	_	
152-24	23796-23798	be	_	
152-25	23799-23808	confident	_	
152-26	23809-23813	that	_	
152-27	23814-23817	the	_	
152-28	23818-23826	observed	_	
152-29	23827-23834	results	_	
152-30	23835-23838	are	_	
152-31	23839-23845	indeed	_	
152-32	23846-23857	differences	_	
152-33	23858-23860	in	_	
152-34	23861-23870	habenular	_	
152-35	23871-23883	connectivity	_	
152-36	23883-23884	.	_	

#Text=The thalamus is in close proximity and much larger than the habenula, so thalamic contamination could influence the results.
153-1	23885-23888	The	_	
153-2	23889-23897	thalamus	_	
153-3	23898-23900	is	_	
153-4	23901-23903	in	_	
153-5	23904-23909	close	_	
153-6	23910-23919	proximity	_	
153-7	23920-23923	and	_	
153-8	23924-23928	much	_	
153-9	23929-23935	larger	_	
153-10	23936-23940	than	_	
153-11	23941-23944	the	_	
153-12	23945-23953	habenula	_	
153-13	23953-23954	,	_	
153-14	23955-23957	so	_	
153-15	23958-23966	thalamic	_	
153-16	23967-23980	contamination	_	
153-17	23981-23986	could	_	
153-18	23987-23996	influence	_	
153-19	23997-24000	the	_	
153-20	24001-24008	results	_	
153-21	24008-24009	.	_	

#Text=Although this is a possibility, we believe it is unlikely for a number of reasons.
154-1	24010-24018	Although	_	
154-2	24019-24023	this	_	
154-3	24024-24026	is	_	
154-4	24027-24028	a	_	
154-5	24029-24040	possibility	_	
154-6	24040-24041	,	_	
154-7	24042-24044	we	_	
154-8	24045-24052	believe	_	
154-9	24053-24055	it	_	
154-10	24056-24058	is	_	
154-11	24059-24067	unlikely	_	
154-12	24068-24071	for	_	
154-13	24072-24073	a	_	
154-14	24074-24080	number	_	
154-15	24081-24083	of	_	
154-16	24084-24091	reasons	_	
154-17	24091-24092	.	_	

#Text=First, the habenula is known to be (indirectly) connected to the striatum, and habenula/striatum connectivity is known to affect reward processes.
155-1	24093-24098	First	_	
155-2	24098-24099	,	_	
155-3	24100-24103	the	_	
155-4	24104-24112	habenula	_	
155-5	24113-24115	is	_	
155-6	24116-24121	known	_	
155-7	24122-24124	to	_	
155-8	24125-24127	be	_	
155-9	24128-24129	(	_	
155-10	24129-24139	indirectly	_	
155-11	24139-24140	)	_	
155-12	24141-24150	connected	_	
155-13	24151-24153	to	_	
155-14	24154-24157	the	_	
155-15	24158-24166	striatum	_	
155-16	24166-24167	,	_	
155-17	24168-24171	and	_	
155-18	24172-24180	habenula	_	
155-19	24180-24181	/	_	
155-20	24181-24189	striatum	_	
155-21	24190-24202	connectivity	_	
155-22	24203-24205	is	_	
155-23	24206-24211	known	_	
155-24	24212-24214	to	_	
155-25	24215-24221	affect	_	
155-26	24222-24228	reward	_	
155-27	24229-24238	processes	_	
155-28	24238-24239	.	_	

#Text=Second, the habenula expresses nicotinic receptor alpha 5 subunit mRNA, which is absent in the thalamus, and mu-opioid receptors.
156-1	24240-24246	Second	_	
156-2	24246-24247	,	_	
156-3	24248-24251	the	_	
156-4	24252-24260	habenula	_	
156-5	24261-24270	expresses	_	
156-6	24271-24280	nicotinic	_	
156-7	24281-24289	receptor	_	
156-8	24290-24295	alpha	_	
156-9	24296-24297	5	_	
156-10	24298-24305	subunit	_	
156-11	24306-24310	mRNA	_	
156-12	24310-24311	,	_	
156-13	24312-24317	which	_	
156-14	24318-24320	is	_	
156-15	24321-24327	absent	_	
156-16	24328-24330	in	_	
156-17	24331-24334	the	_	
156-18	24335-24343	thalamus	_	
156-19	24343-24344	,	_	
156-20	24345-24348	and	_	
156-21	24349-24358	mu-opioid	_	
156-22	24359-24368	receptors	_	
156-23	24368-24369	.	_	

#Text=Third, habenular resting state connectivity has been studied using a smaller voxel, and the results are qualitatively very similar to ours: Although in this manuscript we focused only on the striatum and areas known or hypothesized to be important for the habenular reward-related circuit, high habenular connectivity with thalamus, anterior cingulate, posterior cingulate, superior frontal gyrus, and high "negative connectivity" with lingual gyrus and cuneus were observed both in the Ely manuscript and in our data (not shown).
157-1	24370-24375	Third	_	
157-2	24375-24376	,	_	
157-3	24377-24386	habenular	_	
157-4	24387-24394	resting	_	
157-5	24395-24400	state	_	
157-6	24401-24413	connectivity	_	
157-7	24414-24417	has	_	
157-8	24418-24422	been	_	
157-9	24423-24430	studied	_	
157-10	24431-24436	using	_	
157-11	24437-24438	a	_	
157-12	24439-24446	smaller	_	
157-13	24447-24452	voxel	_	
157-14	24452-24453	,	_	
157-15	24454-24457	and	_	
157-16	24458-24461	the	_	
157-17	24462-24469	results	_	
157-18	24470-24473	are	_	
157-19	24474-24487	qualitatively	_	
157-20	24488-24492	very	_	
157-21	24493-24500	similar	_	
157-22	24501-24503	to	_	
157-23	24504-24508	ours	_	
157-24	24508-24509	:	_	
157-25	24510-24518	Although	_	
157-26	24519-24521	in	_	
157-27	24522-24526	this	_	
157-28	24527-24537	manuscript	_	
157-29	24538-24540	we	_	
157-30	24541-24548	focused	_	
157-31	24549-24553	only	_	
157-32	24554-24556	on	_	
157-33	24557-24560	the	_	
157-34	24561-24569	striatum	_	
157-35	24570-24573	and	_	
157-36	24574-24579	areas	_	
157-37	24580-24585	known	_	
157-38	24586-24588	or	_	
157-39	24589-24601	hypothesized	_	
157-40	24602-24604	to	_	
157-41	24605-24607	be	_	
157-42	24608-24617	important	_	
157-43	24618-24621	for	_	
157-44	24622-24625	the	_	
157-45	24626-24635	habenular	_	
157-46	24636-24650	reward-related	_	
157-47	24651-24658	circuit	_	
157-48	24658-24659	,	_	
157-49	24660-24664	high	_	
157-50	24665-24674	habenular	_	
157-51	24675-24687	connectivity	_	
157-52	24688-24692	with	_	
157-53	24693-24701	thalamus	_	
157-54	24701-24702	,	_	
157-55	24703-24711	anterior	_	
157-56	24712-24721	cingulate	_	
157-57	24721-24722	,	_	
157-58	24723-24732	posterior	_	
157-59	24733-24742	cingulate	_	
157-60	24742-24743	,	_	
157-61	24744-24752	superior	_	
157-62	24753-24760	frontal	_	
157-63	24761-24766	gyrus	_	
157-64	24766-24767	,	_	
157-65	24768-24771	and	_	
157-66	24772-24776	high	_	
157-67	24777-24778	"	_	
157-68	24778-24786	negative	_	
157-69	24787-24799	connectivity	_	
157-70	24799-24800	"	_	
157-71	24801-24805	with	_	
157-72	24806-24813	lingual	_	
157-73	24814-24819	gyrus	_	
157-74	24820-24823	and	_	
157-75	24824-24830	cuneus	_	
157-76	24831-24835	were	_	
157-77	24836-24844	observed	_	
157-78	24845-24849	both	_	
157-79	24850-24852	in	_	
157-80	24853-24856	the	_	
157-81	24857-24860	Ely	_	
157-82	24861-24871	manuscript	_	
157-83	24872-24875	and	_	
157-84	24876-24878	in	_	
157-85	24879-24882	our	_	
157-86	24883-24887	data	_	
157-87	24888-24889	(	_	
157-88	24889-24892	not	_	
157-89	24893-24898	shown	_	
157-90	24898-24899	)	_	
157-91	24899-24900	.	_	

#Text=We believe that only a qualitative comparison between both sets of data should be done, since there are many differences between both manuscripts, including scanner, imaging parameters, data processing, and importantly sample characteristics.
158-1	24901-24903	We	_	
158-2	24904-24911	believe	_	
158-3	24912-24916	that	_	
158-4	24917-24921	only	_	
158-5	24922-24923	a	_	
158-6	24924-24935	qualitative	_	
158-7	24936-24946	comparison	_	
158-8	24947-24954	between	_	
158-9	24955-24959	both	_	
158-10	24960-24964	sets	_	
158-11	24965-24967	of	_	
158-12	24968-24972	data	_	
158-13	24973-24979	should	_	
158-14	24980-24982	be	_	
158-15	24983-24987	done	_	
158-16	24987-24988	,	_	
158-17	24989-24994	since	_	
158-18	24995-25000	there	_	
158-19	25001-25004	are	_	
158-20	25005-25009	many	_	
158-21	25010-25021	differences	_	
158-22	25022-25029	between	_	
158-23	25030-25034	both	_	
158-24	25035-25046	manuscripts	_	
158-25	25046-25047	,	_	
158-26	25048-25057	including	_	
158-27	25058-25065	scanner	_	
158-28	25065-25066	,	_	
158-29	25067-25074	imaging	_	
158-30	25075-25085	parameters	_	
158-31	25085-25086	,	_	
158-32	25087-25091	data	_	
158-33	25092-25102	processing	_	
158-34	25102-25103	,	_	
158-35	25104-25107	and	_	
158-36	25108-25119	importantly	_	
158-37	25120-25126	sample	_	
158-38	25127-25142	characteristics	_	
158-39	25142-25143	.	_	

#Text=A limitation of this work is the fact that we can't separate the medial from the lateral habenula at the resolution achieved in our MRI.
159-1	25144-25145	A	_	
159-2	25146-25156	limitation	_	
159-3	25157-25159	of	_	
159-4	25160-25164	this	_	
159-5	25165-25169	work	_	
159-6	25170-25172	is	_	
159-7	25173-25176	the	_	
159-8	25177-25181	fact	_	
159-9	25182-25186	that	_	
159-10	25187-25189	we	_	
159-11	25190-25195	can't	_	
159-12	25196-25204	separate	_	
159-13	25205-25208	the	_	
159-14	25209-25215	medial	_	
159-15	25216-25220	from	_	
159-16	25221-25224	the	_	
159-17	25225-25232	lateral	_	
159-18	25233-25241	habenula	_	
159-19	25242-25244	at	_	
159-20	25245-25248	the	_	
159-21	25249-25259	resolution	_	
159-22	25260-25268	achieved	_	
159-23	25269-25271	in	_	
159-24	25272-25275	our	_	
159-25	25276-25279	MRI	_	
159-26	25279-25280	.	_	

#Text=The medial and the lateral habenula are functionally and transcriptionally very different, and both the alpha 5 subunit of the nicotinic receptor and the mu-opioid receptor are expressed predominantly in the medial habenula.
160-1	25281-25284	The	_	
160-2	25285-25291	medial	_	
160-3	25292-25295	and	_	
160-4	25296-25299	the	_	
160-5	25300-25307	lateral	_	
160-6	25308-25316	habenula	_	
160-7	25317-25320	are	_	
160-8	25321-25333	functionally	_	
160-9	25334-25337	and	_	
160-10	25338-25355	transcriptionally	_	
160-11	25356-25360	very	_	
160-12	25361-25370	different	_	
160-13	25370-25371	,	_	
160-14	25372-25375	and	_	
160-15	25376-25380	both	_	
160-16	25381-25384	the	_	
160-17	25385-25390	alpha	_	
160-18	25391-25392	5	_	
160-19	25393-25400	subunit	_	
160-20	25401-25403	of	_	
160-21	25404-25407	the	_	
160-22	25408-25417	nicotinic	_	
160-23	25418-25426	receptor	_	
160-24	25427-25430	and	_	
160-25	25431-25434	the	_	
160-26	25435-25444	mu-opioid	_	
160-27	25445-25453	receptor	_	
160-28	25454-25457	are	_	
160-29	25458-25467	expressed	_	
160-30	25468-25481	predominantly	_	
160-31	25482-25484	in	_	
160-32	25485-25488	the	_	
160-33	25489-25495	medial	_	
160-34	25496-25504	habenula	_	
160-35	25504-25505	.	_	

#Text=Thus, we hypothesize that our results may be associated to medial habenular connectivity, but major improvements on equipment and/or analysis techniques are necessary to explore that question.
161-1	25506-25510	Thus	_	
161-2	25510-25511	,	_	
161-3	25512-25514	we	_	
161-4	25515-25526	hypothesize	_	
161-5	25527-25531	that	_	
161-6	25532-25535	our	_	
161-7	25536-25543	results	_	
161-8	25544-25547	may	_	
161-9	25548-25550	be	_	
161-10	25551-25561	associated	_	
161-11	25562-25564	to	_	
161-12	25565-25571	medial	_	
161-13	25572-25581	habenular	_	
161-14	25582-25594	connectivity	_	
161-15	25594-25595	,	_	
161-16	25596-25599	but	_	
161-17	25600-25605	major	_	
161-18	25606-25618	improvements	_	
161-19	25619-25621	on	_	
161-20	25622-25631	equipment	_	
161-21	25632-25635	and	_	
161-22	25635-25636	/	_	
161-23	25636-25638	or	_	
161-24	25639-25647	analysis	_	
161-25	25648-25658	techniques	_	
161-26	25659-25662	are	_	
161-27	25663-25672	necessary	_	
161-28	25673-25675	to	_	
161-29	25676-25683	explore	_	
161-30	25684-25688	that	_	
161-31	25689-25697	question	_	
161-32	25697-25698	.	_	

#Text=An additional limitation of this work is the use of a particularly short scan time.
162-1	25699-25701	An	_	
162-2	25702-25712	additional	_	
162-3	25713-25723	limitation	_	
162-4	25724-25726	of	_	
162-5	25727-25731	this	_	
162-6	25732-25736	work	_	
162-7	25737-25739	is	_	
162-8	25740-25743	the	_	
162-9	25744-25747	use	_	
162-10	25748-25750	of	_	
162-11	25751-25752	a	_	
162-12	25753-25765	particularly	_	
162-13	25766-25771	short	_	
162-14	25772-25776	scan	_	
162-15	25777-25781	time	_	
162-16	25781-25782	.	_	

#Text=We collected resting state data over only 5 minutes, which may lead to high within-subject variability in our sample.
163-1	25783-25785	We	_	
163-2	25786-25795	collected	_	
163-3	25796-25803	resting	_	
163-4	25804-25809	state	_	
163-5	25810-25814	data	_	
163-6	25815-25819	over	_	
163-7	25820-25824	only	_	
163-8	25825-25826	5	_	
163-9	25827-25834	minutes	_	
163-10	25834-25835	,	_	
163-11	25836-25841	which	_	
163-12	25842-25845	may	_	
163-13	25846-25850	lead	_	
163-14	25851-25853	to	_	
163-15	25854-25858	high	_	
163-16	25859-25873	within-subject	_	
163-17	25874-25885	variability	_	
163-18	25886-25888	in	_	
163-19	25889-25892	our	_	
163-20	25893-25899	sample	_	
163-21	25899-25900	.	_	

#Text=Previous work has shown that a resting state of at least 7 minutes is preferable to reduce variability and strengthen the statistical power of our analyses.
164-1	25901-25909	Previous	_	
164-2	25910-25914	work	_	
164-3	25915-25918	has	_	
164-4	25919-25924	shown	_	
164-5	25925-25929	that	_	
164-6	25930-25931	a	_	
164-7	25932-25939	resting	_	
164-8	25940-25945	state	_	
164-9	25946-25948	of	_	
164-10	25949-25951	at	_	
164-11	25952-25957	least	_	
164-12	25958-25959	7	_	
164-13	25960-25967	minutes	_	
164-14	25968-25970	is	_	
164-15	25971-25981	preferable	_	
164-16	25982-25984	to	_	
164-17	25985-25991	reduce	_	
164-18	25992-26003	variability	_	
164-19	26004-26007	and	_	
164-20	26008-26018	strengthen	_	
164-21	26019-26022	the	_	
164-22	26023-26034	statistical	_	
164-23	26035-26040	power	_	
164-24	26041-26043	of	_	
164-25	26044-26047	our	_	
164-26	26048-26056	analyses	_	
164-27	26056-26057	.	_	

#Text=A longer scan time of 7–10 minutes may significantly reduce within-subject variability.
165-1	26058-26059	A	_	
165-2	26060-26066	longer	_	
165-3	26067-26071	scan	_	
165-4	26072-26076	time	_	
165-5	26077-26079	of	_	
165-6	26080-26081	7	_	
165-7	26081-26082	–	_	
165-8	26082-26084	10	_	
165-9	26085-26092	minutes	_	
165-10	26093-26096	may	_	
165-11	26097-26110	significantly	_	
165-12	26111-26117	reduce	_	
165-13	26118-26132	within-subject	_	
165-14	26133-26144	variability	_	
165-15	26144-26145	.	_	

#Text=Our initial finding of increased right habenula/striatum RSFC in opioid users compared to non-users was statistically not very strong.
166-1	26146-26149	Our	_	
166-2	26150-26157	initial	_	
166-3	26158-26165	finding	_	
166-4	26166-26168	of	_	
166-5	26169-26178	increased	_	
166-6	26179-26184	right	_	
166-7	26185-26193	habenula	_	
166-8	26193-26194	/	_	
166-9	26194-26202	striatum	_	
166-10	26203-26207	RSFC	_	
166-11	26208-26210	in	_	
166-12	26211-26217	opioid	_	
166-13	26218-26223	users	_	
166-14	26224-26232	compared	_	
166-15	26233-26235	to	_	
166-16	26236-26245	non-users	_	
166-17	26246-26249	was	_	
166-18	26250-26263	statistically	_	
166-19	26264-26267	not	_	
166-20	26268-26272	very	_	
166-21	26273-26279	strong	_	
166-22	26279-26280	.	_	

#Text=Furthermore, we did not correct for multiple comparisons of laterality and subregions of the striatum.
167-1	26281-26292	Furthermore	_	
167-2	26292-26293	,	_	
167-3	26294-26296	we	_	
167-4	26297-26300	did	_	
167-5	26301-26304	not	_	
167-6	26305-26312	correct	_	
167-7	26313-26316	for	_	
167-8	26317-26325	multiple	_	
167-9	26326-26337	comparisons	_	
167-10	26338-26340	of	_	
167-11	26341-26351	laterality	_	
167-12	26352-26355	and	_	
167-13	26356-26366	subregions	_	
167-14	26367-26369	of	_	
167-15	26370-26373	the	_	
167-16	26374-26382	striatum	_	
167-17	26382-26383	.	_	

#Text=Additional studies or replications of the analysis will be needed to strengthen these findings.
168-1	26384-26394	Additional	_	
168-2	26395-26402	studies	_	
168-3	26403-26405	or	_	
168-4	26406-26418	replications	_	
168-5	26419-26421	of	_	
168-6	26422-26425	the	_	
168-7	26426-26434	analysis	_	
168-8	26435-26439	will	_	
168-9	26440-26442	be	_	
168-10	26443-26449	needed	_	
168-11	26450-26452	to	_	
168-12	26453-26463	strengthen	_	
168-13	26464-26469	these	_	
168-14	26470-26478	findings	_	
168-15	26478-26479	.	_	

#Text=As with most human brain imaging studies, our results must be interpreted with care.
169-1	26480-26482	As	_	
169-2	26483-26487	with	_	
169-3	26488-26492	most	_	
169-4	26493-26498	human	_	
169-5	26499-26504	brain	_	
169-6	26505-26512	imaging	_	
169-7	26513-26520	studies	_	
169-8	26520-26521	,	_	
169-9	26522-26525	our	_	
169-10	26526-26533	results	_	
169-11	26534-26538	must	_	
169-12	26539-26541	be	_	
169-13	26542-26553	interpreted	_	
169-14	26554-26558	with	_	
169-15	26559-26563	care	_	
169-16	26563-26564	.	_	

#Text=The use of a heterogeneous sample of psychiatric inpatients diagnosed with several different disorders, without the use of a control sample limits this work.
170-1	26565-26568	The	_	
170-2	26569-26572	use	_	
170-3	26573-26575	of	_	
170-4	26576-26577	a	_	
170-5	26578-26591	heterogeneous	_	
170-6	26592-26598	sample	_	
170-7	26599-26601	of	_	
170-8	26602-26613	psychiatric	_	
170-9	26614-26624	inpatients	_	
170-10	26625-26634	diagnosed	_	
170-11	26635-26639	with	_	
170-12	26640-26647	several	_	
170-13	26648-26657	different	_	
170-14	26658-26667	disorders	_	
170-15	26667-26668	,	_	
170-16	26669-26676	without	_	
170-17	26677-26680	the	_	
170-18	26681-26684	use	_	
170-19	26685-26687	of	_	
170-20	26688-26689	a	_	
170-21	26690-26697	control	_	
170-22	26698-26704	sample	_	
170-23	26705-26711	limits	_	
170-24	26712-26716	this	_	
170-25	26717-26721	work	_	
170-26	26721-26722	.	_	

#Text=Although the study population provides insight into the role of the habenula in opioid use in a psychiatric population, it may be difficult to interpret the findings without a healthy sample of controls with which to compare results.
171-1	26723-26731	Although	_	
171-2	26732-26735	the	_	
171-3	26736-26741	study	_	
171-4	26742-26752	population	_	
171-5	26753-26761	provides	_	
171-6	26762-26769	insight	_	
171-7	26770-26774	into	_	
171-8	26775-26778	the	_	
171-9	26779-26783	role	_	
171-10	26784-26786	of	_	
171-11	26787-26790	the	_	
171-12	26791-26799	habenula	_	
171-13	26800-26802	in	_	
171-14	26803-26809	opioid	_	
171-15	26810-26813	use	_	
171-16	26814-26816	in	_	
171-17	26817-26818	a	_	
171-18	26819-26830	psychiatric	_	
171-19	26831-26841	population	_	
171-20	26841-26842	,	_	
171-21	26843-26845	it	_	
171-22	26846-26849	may	_	
171-23	26850-26852	be	_	
171-24	26853-26862	difficult	_	
171-25	26863-26865	to	_	
171-26	26866-26875	interpret	_	
171-27	26876-26879	the	_	
171-28	26880-26888	findings	_	
171-29	26889-26896	without	_	
171-30	26897-26898	a	_	
171-31	26899-26906	healthy	_	
171-32	26907-26913	sample	_	
171-33	26914-26916	of	_	
171-34	26917-26925	controls	_	
171-35	26926-26930	with	_	
171-36	26931-26936	which	_	
171-37	26937-26939	to	_	
171-38	26940-26947	compare	_	
171-39	26948-26955	results	_	
171-40	26955-26956	.	_	

#Text=Furthermore, despite the relatively large number of patients analyzed, false positives and hard to replicate data are common in these types of studies.
172-1	26957-26968	Furthermore	_	
172-2	26968-26969	,	_	
172-3	26970-26977	despite	_	
172-4	26978-26981	the	_	
172-5	26982-26992	relatively	_	
172-6	26993-26998	large	_	
172-7	26999-27005	number	_	
172-8	27006-27008	of	_	
172-9	27009-27017	patients	_	
172-10	27018-27026	analyzed	_	
172-11	27026-27027	,	_	
172-12	27028-27033	false	_	
172-13	27034-27043	positives	_	
172-14	27044-27047	and	_	
172-15	27048-27052	hard	_	
172-16	27053-27055	to	_	
172-17	27056-27065	replicate	_	
172-18	27066-27070	data	_	
172-19	27071-27074	are	_	
172-20	27075-27081	common	_	
172-21	27082-27084	in	_	
172-22	27085-27090	these	_	
172-23	27091-27096	types	_	
172-24	27097-27099	of	_	
172-25	27100-27107	studies	_	
172-26	27107-27108	.	_	

#Text=In addition, we can only speculate about causality between habenular RSFC and opioid abuse.
173-1	27109-27111	In	_	
173-2	27112-27120	addition	_	
173-3	27120-27121	,	_	
173-4	27122-27124	we	_	
173-5	27125-27128	can	_	
173-6	27129-27133	only	_	
173-7	27134-27143	speculate	_	
173-8	27144-27149	about	_	
173-9	27150-27159	causality	_	
173-10	27160-27167	between	_	
173-11	27168-27177	habenular	_	
173-12	27178-27182	RSFC	_	
173-13	27183-27186	and	_	
173-14	27187-27193	opioid	_	
173-15	27194-27199	abuse	_	
173-16	27199-27200	.	_	

#Text=However, we believe that the inclusion of genotypic data in imaging research moves us closer to being able to infer causality in some studies, particularly for brain regions expressing high levels of particular genes of interest.
174-1	27201-27208	However	_	
174-2	27208-27209	,	_	
174-3	27210-27212	we	_	
174-4	27213-27220	believe	_	
174-5	27221-27225	that	_	
174-6	27226-27229	the	_	
174-7	27230-27239	inclusion	_	
174-8	27240-27242	of	_	
174-9	27243-27252	genotypic	_	
174-10	27253-27257	data	_	
174-11	27258-27260	in	_	
174-12	27261-27268	imaging	_	
174-13	27269-27277	research	_	
174-14	27278-27283	moves	_	
174-15	27284-27286	us	_	
174-16	27287-27293	closer	_	
174-17	27294-27296	to	_	
174-18	27297-27302	being	_	
174-19	27303-27307	able	_	
174-20	27308-27310	to	_	
174-21	27311-27316	infer	_	
174-22	27317-27326	causality	_	
174-23	27327-27329	in	_	
174-24	27330-27334	some	_	
174-25	27335-27342	studies	_	
174-26	27342-27343	,	_	
174-27	27344-27356	particularly	_	
174-28	27357-27360	for	_	
174-29	27361-27366	brain	_	
174-30	27367-27374	regions	_	
174-31	27375-27385	expressing	_	
174-32	27386-27390	high	_	
174-33	27391-27397	levels	_	
174-34	27398-27400	of	_	
174-35	27401-27411	particular	_	
174-36	27412-27417	genes	_	
174-37	27418-27420	of	_	
174-38	27421-27429	interest	_	
174-39	27429-27430	.	_	

#Text=Finally, all these patients were medicated at the time of MRI.
175-1	27431-27438	Finally	_	
175-2	27438-27439	,	_	
175-3	27440-27443	all	_	
175-4	27444-27449	these	_	
175-5	27450-27458	patients	_	
175-6	27459-27463	were	_	
175-7	27464-27473	medicated	_	
175-8	27474-27476	at	_	
175-9	27477-27480	the	_	
175-10	27481-27485	time	_	
175-11	27486-27488	of	_	
175-12	27489-27492	MRI	_	
175-13	27492-27493	.	_	

#Text=Since we used controls with roughly the same diagnoses as the opioid users (see table 1), any effects of medications on imaging parameters are very likely to cancel each other.
176-1	27494-27499	Since	_	
176-2	27500-27502	we	_	
176-3	27503-27507	used	_	
176-4	27508-27516	controls	_	
176-5	27517-27521	with	_	
176-6	27522-27529	roughly	_	
176-7	27530-27533	the	_	
176-8	27534-27538	same	_	
176-9	27539-27548	diagnoses	_	
176-10	27549-27551	as	_	
176-11	27552-27555	the	_	
176-12	27556-27562	opioid	_	
176-13	27563-27568	users	_	
176-14	27569-27570	(	_	
176-15	27570-27573	see	_	
176-16	27574-27579	table	_	
176-17	27580-27581	1	_	
176-18	27581-27582	)	_	
176-19	27582-27583	,	_	
176-20	27584-27587	any	_	
176-21	27588-27595	effects	_	
176-22	27596-27598	of	_	
176-23	27599-27610	medications	_	
176-24	27611-27613	on	_	
176-25	27614-27621	imaging	_	
176-26	27622-27632	parameters	_	
176-27	27633-27636	are	_	
176-28	27637-27641	very	_	
176-29	27642-27648	likely	_	
176-30	27649-27651	to	_	
176-31	27652-27658	cancel	_	
176-32	27659-27663	each	_	
176-33	27664-27669	other	_	
176-34	27669-27670	.	_	

#Text=In conclusion, we have shown that RSFC between the habenula and caudate is increased in opioid users and further mediated by a coding variant in the CHRNA α5 nicotinic acetylcholine subunit receptor rs16969968 A allele.
177-1	27671-27673	In	_	
177-2	27674-27684	conclusion	_	
177-3	27684-27685	,	_	
177-4	27686-27688	we	_	
177-5	27689-27693	have	_	
177-6	27694-27699	shown	_	
177-7	27700-27704	that	_	
177-8	27705-27709	RSFC	_	
177-9	27710-27717	between	_	
177-10	27718-27721	the	_	
177-11	27722-27730	habenula	_	
177-12	27731-27734	and	_	
177-13	27735-27742	caudate	_	
177-14	27743-27745	is	_	
177-15	27746-27755	increased	_	
177-16	27756-27758	in	_	
177-17	27759-27765	opioid	_	
177-18	27766-27771	users	_	
177-19	27772-27775	and	_	
177-20	27776-27783	further	_	
177-21	27784-27792	mediated	_	
177-22	27793-27795	by	_	
177-23	27796-27797	a	_	
177-24	27798-27804	coding	_	
177-25	27805-27812	variant	_	
177-26	27813-27815	in	_	
177-27	27816-27819	the	_	
177-28	27820-27825	CHRNA	_	
177-29	27826-27828	α5	_	
177-30	27829-27838	nicotinic	_	
177-31	27839-27852	acetylcholine	_	
177-32	27853-27860	subunit	_	
177-33	27861-27869	receptor	_	
177-34	27870-27880	rs16969968	_	
177-35	27881-27882	A	_	
177-36	27883-27889	allele	_	
177-37	27889-27890	.	_	

#Text=Declaration of Interest         
#Text=The authors report no conflicts of interest.
178-1	27902-27913	Declaration	_	
178-2	27914-27916	of	_	
178-3	27917-27925	Interest	_	
178-4	27935-27938	The	_	
178-5	27939-27946	authors	_	
178-6	27947-27953	report	_	
178-7	27954-27956	no	_	
178-8	27957-27966	conflicts	_	
178-9	27967-27969	of	_	
178-10	27970-27978	interest	_	
178-11	27978-27979	.	_	

#Text=Wide-ranging Online Data for Epidemiologic Research (WONDER), Multiple-Cause-of-Death file, 2000–2014
#Text=Should protracted withdrawal from drugs be included in DSM-IV?
179-1	27980-27992	Wide-ranging	_	
179-2	27993-27999	Online	_	
179-3	28000-28004	Data	_	
179-4	28005-28008	for	_	
179-5	28009-28022	Epidemiologic	_	
179-6	28023-28031	Research	_	
179-7	28032-28033	(	_	
179-8	28033-28039	WONDER	_	
179-9	28039-28040	)	_	
179-10	28040-28041	,	_	
179-11	28042-28065	Multiple-Cause-of-Death	_	
179-12	28066-28070	file	_	
179-13	28070-28071	,	_	
179-14	28072-28076	2000	_	
179-15	28076-28077	–	_	
179-16	28077-28081	2014	_	
179-17	28082-28088	Should	_	
179-18	28089-28099	protracted	_	
179-19	28100-28110	withdrawal	_	
179-20	28111-28115	from	_	
179-21	28116-28121	drugs	_	
179-22	28122-28124	be	_	
179-23	28125-28133	included	_	
179-24	28134-28136	in	_	
179-25	28137-28143	DSM-IV	_	
179-26	28143-28144	?	_	

#Text=The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat
#Text=Naloxone precipitates nicotine abstinence syndrome in the rat
#Text=Modification of precipitated morphine withdrawal syndrome by drugs affecting cholinergic mechanisms
#Text=Genome-wide atlas of gene expression in the adult mouse brain
#Text=Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit
#Text=Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice
#Text=Altered anxiety-related responses in mutant mice lacking the beta4 subunit of the nicotinic receptor
#Text=The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice
#Text=The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo
#Text=Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1
#Text=Variants in nicotinic receptors and risk for nicotine dependence
#Text=Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence
#Text=Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity
#Text=A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence
#Text=Lateral habenula as a source of negative reward signals in dopamine neurons
#Text=Habenular and interpeduncularis nuclei: shared components in multiple-function networks
#Text=Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake
#Text=Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula
#Text=The role of the habenula in drug addiction
#Text=Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient
#Text=Fear and anxiety regulation by conserved affective circuits
#Text=Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors
#Text=Unmasking the mysteries of the habenula in pain and analgesia
#Text=A novel approach to identifying a neuroimaging biomarker for patients with serious mental illness
#Text=Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations
#Text=Interhemispheric insular and inferior frontal connectivity are associated with substance abuse in a psychiatric population
#Text=
#Text=
#Text=Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST)
#Text=Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=DBH gene as predictor of response in a cocaine vaccine clinical trial
#Text=Proportioning whole-genome single-nucleotide-polymorphism diversity for the identification of geographic population structure and genetic ancestry
#Text=BOLD Responses to Negative Reward Prediction Errors in Human Habenula
#Text=Asymmetry in functional connectivity of the human habenula revealed by high-resolution cardiac-gated resting state imaging
#Text=Characterizing white matter changes in cigarette smokers via diffusion tensor imaging
#Text=Affective and cognitive prefrontal cortex projections to the lateral habenula in humans
#Text=Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5
#Text=Habenula and the asymmetric development of the vertebrate brain
#Text=Resting-state functional connectivity of the human habenula in healthy individuals: Associations with subclinical depression
#Text=Asymmetry in functional connectivity of the human habenula revealed by high-resolution cardiac-gated resting state imaging
#Text=The medial habenula: still neglected
#Text=Temporal Evolution of Brain Functional Connectivity Metrics: Could 7 Min of Rest be Enough?
180-1	28145-28148	The	_	
180-2	28149-28158	nicotinic	_	
180-3	28159-28169	antagonist	_	
180-4	28170-28182	mecamylamine	_	
180-5	28183-28195	precipitates	_	
180-6	28196-28204	nicotine	_	
180-7	28205-28215	abstinence	_	
180-8	28216-28224	syndrome	_	
180-9	28225-28227	in	_	
180-10	28228-28231	the	_	
180-11	28232-28235	rat	_	
180-12	28236-28244	Naloxone	_	
180-13	28245-28257	precipitates	_	
180-14	28258-28266	nicotine	_	
180-15	28267-28277	abstinence	_	
180-16	28278-28286	syndrome	_	
180-17	28287-28289	in	_	
180-18	28290-28293	the	_	
180-19	28294-28297	rat	_	
180-20	28298-28310	Modification	_	
180-21	28311-28313	of	_	
180-22	28314-28326	precipitated	_	
180-23	28327-28335	morphine	_	
180-24	28336-28346	withdrawal	_	
180-25	28347-28355	syndrome	_	
180-26	28356-28358	by	_	
180-27	28359-28364	drugs	_	
180-28	28365-28374	affecting	_	
180-29	28375-28386	cholinergic	_	
180-30	28387-28397	mechanisms	_	
180-31	28398-28409	Genome-wide	_	
180-32	28410-28415	atlas	_	
180-33	28416-28418	of	_	
180-34	28419-28423	gene	_	
180-35	28424-28434	expression	_	
180-36	28435-28437	in	_	
180-37	28438-28441	the	_	
180-38	28442-28447	adult	_	
180-39	28448-28453	mouse	_	
180-40	28454-28459	brain	_	
180-41	28460-28469	Decreased	_	
180-42	28470-28475	signs	_	
180-43	28476-28478	of	_	
180-44	28479-28487	nicotine	_	
180-45	28488-28498	withdrawal	_	
180-46	28499-28501	in	_	
180-47	28502-28506	mice	_	
180-48	28507-28511	null	_	
180-49	28512-28515	for	_	
180-50	28516-28519	the	_	
180-51	28520-28525	beta4	_	
180-52	28526-28535	nicotinic	_	
180-53	28536-28549	acetylcholine	_	
180-54	28550-28558	receptor	_	
180-55	28559-28566	subunit	_	
180-56	28567-28576	Nicotinic	_	
180-57	28577-28586	receptors	_	
180-58	28587-28589	in	_	
180-59	28590-28593	the	_	
180-60	28594-28618	habenulo-interpeduncular	_	
180-61	28619-28625	system	_	
180-62	28626-28629	are	_	
180-63	28630-28639	necessary	_	
180-64	28640-28643	for	_	
180-65	28644-28652	nicotine	_	
180-66	28653-28663	withdrawal	_	
180-67	28664-28666	in	_	
180-68	28667-28671	mice	_	
180-69	28672-28679	Altered	_	
180-70	28680-28695	anxiety-related	_	
180-71	28696-28705	responses	_	
180-72	28706-28708	in	_	
180-73	28709-28715	mutant	_	
180-74	28716-28720	mice	_	
180-75	28721-28728	lacking	_	
180-76	28729-28732	the	_	
180-77	28733-28738	beta4	_	
180-78	28739-28746	subunit	_	
180-79	28747-28749	of	_	
180-80	28750-28753	the	_	
180-81	28754-28763	nicotinic	_	
180-82	28764-28772	receptor	_	
180-83	28773-28776	The	_	
180-84	28777-28783	alpha3	_	
180-85	28784-28787	and	_	
180-86	28788-28793	beta4	_	
180-87	28794-28803	nicotinic	_	
180-88	28804-28817	acetylcholine	_	
180-89	28818-28826	receptor	_	
180-90	28827-28835	subunits	_	
180-91	28836-28839	are	_	
180-92	28840-28849	necessary	_	
180-93	28850-28853	for	_	
180-94	28854-28870	nicotine-induced	_	
180-95	28871-28879	seizures	_	
180-96	28880-28883	and	_	
180-97	28884-28898	hypolocomotion	_	
180-98	28899-28901	in	_	
180-99	28902-28906	mice	_	
180-100	28907-28910	The	_	
180-101	28911-28920	nicotinic	_	
180-102	28921-28934	acetylcholine	_	
180-103	28935-28943	receptor	_	
180-104	28944-28951	subunit	_	
180-105	28952-28957	alpha	_	
180-106	28958-28959	5	_	
180-107	28960-28968	mediates	_	
180-108	28969-28979	short-term	_	
180-109	28980-28987	effects	_	
180-110	28988-28990	of	_	
180-111	28991-28999	nicotine	_	
180-112	29000-29002	in	_	
180-113	29003-29007	vivo	_	
180-114	29008-29019	Genome-wide	_	
180-115	29020-29031	association	_	
180-116	29032-29036	scan	_	
180-117	29037-29039	of	_	
180-118	29040-29043	tag	_	
180-119	29044-29048	SNPs	_	
180-120	29049-29059	identifies	_	
180-121	29060-29061	a	_	
180-122	29062-29076	susceptibility	_	
180-123	29077-29082	locus	_	
180-124	29083-29086	for	_	
180-125	29087-29091	lung	_	
180-126	29092-29098	cancer	_	
180-127	29099-29101	at	_	
180-128	29102-29109	15q25.1	_	
180-129	29110-29118	Variants	_	
180-130	29119-29121	in	_	
180-131	29122-29131	nicotinic	_	
180-132	29132-29141	receptors	_	
180-133	29142-29145	and	_	
180-134	29146-29150	risk	_	
180-135	29151-29154	for	_	
180-136	29155-29163	nicotine	_	
180-137	29164-29174	dependence	_	
180-138	29175-29182	Genetic	_	
180-139	29183-29192	variation	_	
180-140	29193-29195	in	_	
180-141	29196-29199	the	_	
180-142	29200-29206	CHRNA5	_	
180-143	29207-29211	gene	_	
180-144	29212-29219	affects	_	
180-145	29220-29224	mRNA	_	
180-146	29225-29231	levels	_	
180-147	29232-29235	and	_	
180-148	29236-29238	is	_	
180-149	29239-29249	associated	_	
180-150	29250-29254	with	_	
180-151	29255-29259	risk	_	
180-152	29260-29263	for	_	
180-153	29264-29271	alcohol	_	
180-154	29272-29282	dependence	_	
180-155	29283-29292	Nicotinic	_	
180-156	29293-29306	acetylcholine	_	
180-157	29307-29315	receptor	_	
180-158	29316-29321	genes	_	
180-159	29322-29324	on	_	
180-160	29325-29335	chromosome	_	
180-161	29336-29343	15q25.1	_	
180-162	29344-29347	are	_	
180-163	29348-29358	associated	_	
180-164	29359-29363	with	_	
180-165	29364-29372	nicotine	_	
180-166	29373-29376	and	_	
180-167	29377-29383	opioid	_	
180-168	29384-29394	dependence	_	
180-169	29395-29403	severity	_	
180-170	29404-29405	A	_	
180-171	29406-29410	risk	_	
180-172	29411-29417	allele	_	
180-173	29418-29421	for	_	
180-174	29422-29430	nicotine	_	
180-175	29431-29441	dependence	_	
180-176	29442-29444	in	_	
180-177	29445-29451	CHRNA5	_	
180-178	29452-29454	is	_	
180-179	29455-29456	a	_	
180-180	29457-29467	protective	_	
180-181	29468-29474	allele	_	
180-182	29475-29478	for	_	
180-183	29479-29486	cocaine	_	
180-184	29487-29497	dependence	_	
180-185	29498-29505	Lateral	_	
180-186	29506-29514	habenula	_	
180-187	29515-29517	as	_	
180-188	29518-29519	a	_	
180-189	29520-29526	source	_	
180-190	29527-29529	of	_	
180-191	29530-29538	negative	_	
180-192	29539-29545	reward	_	
180-193	29546-29553	signals	_	
180-194	29554-29556	in	_	
180-195	29557-29565	dopamine	_	
180-196	29566-29573	neurons	_	
180-197	29574-29583	Habenular	_	
180-198	29584-29587	and	_	
180-199	29588-29605	interpeduncularis	_	
180-200	29606-29612	nuclei	_	
180-201	29612-29613	:	_	
180-202	29614-29620	shared	_	
180-203	29621-29631	components	_	
180-204	29632-29634	in	_	
180-205	29635-29652	multiple-function	_	
180-206	29653-29661	networks	_	
180-207	29662-29671	Habenular	_	
180-208	29672-29678	alpha5	_	
180-209	29679-29688	nicotinic	_	
180-210	29689-29697	receptor	_	
180-211	29698-29705	subunit	_	
180-212	29706-29716	signalling	_	
180-213	29717-29725	controls	_	
180-214	29726-29734	nicotine	_	
180-215	29735-29741	intake	_	
180-216	29742-29750	Aversion	_	
180-217	29751-29753	to	_	
180-218	29754-29762	nicotine	_	
180-219	29763-29765	is	_	
180-220	29766-29775	regulated	_	
180-221	29776-29778	by	_	
180-222	29779-29782	the	_	
180-223	29783-29791	balanced	_	
180-224	29792-29800	activity	_	
180-225	29801-29803	of	_	
180-226	29804-29809	beta4	_	
180-227	29810-29813	and	_	
180-228	29814-29820	alpha5	_	
180-229	29821-29830	nicotinic	_	
180-230	29831-29839	receptor	_	
180-231	29840-29848	subunits	_	
180-232	29849-29851	in	_	
180-233	29852-29855	the	_	
180-234	29856-29862	medial	_	
180-235	29863-29871	habenula	_	
180-236	29872-29875	The	_	
180-237	29876-29880	role	_	
180-238	29881-29883	of	_	
180-239	29884-29887	the	_	
180-240	29888-29896	habenula	_	
180-241	29897-29899	in	_	
180-242	29900-29904	drug	_	
180-243	29905-29914	addiction	_	
180-244	29915-29924	Remission	_	
180-245	29925-29927	of	_	
180-246	29928-29933	major	_	
180-247	29934-29944	depression	_	
180-248	29945-29950	under	_	
180-249	29951-29955	deep	_	
180-250	29956-29961	brain	_	
180-251	29962-29973	stimulation	_	
180-252	29974-29976	of	_	
180-253	29977-29980	the	_	
180-254	29981-29988	lateral	_	
180-255	29989-29997	habenula	_	
180-256	29998-30000	in	_	
180-257	30001-30002	a	_	
180-258	30003-30021	therapy-refractory	_	
180-259	30022-30029	patient	_	
180-260	30030-30034	Fear	_	
180-261	30035-30038	and	_	
180-262	30039-30046	anxiety	_	
180-263	30047-30057	regulation	_	
180-264	30058-30060	by	_	
180-265	30061-30070	conserved	_	
180-266	30071-30080	affective	_	
180-267	30081-30089	circuits	_	
180-268	30090-30098	Habenula	_	
180-269	30099-30110	cholinergic	_	
180-270	30111-30118	neurons	_	
180-271	30119-30127	regulate	_	
180-272	30128-30135	anxiety	_	
180-273	30136-30142	during	_	
180-274	30143-30151	nicotine	_	
180-275	30152-30162	withdrawal	_	
180-276	30163-30166	via	_	
180-277	30167-30176	nicotinic	_	
180-278	30177-30190	acetylcholine	_	
180-279	30191-30200	receptors	_	
180-280	30201-30210	Unmasking	_	
180-281	30211-30214	the	_	
180-282	30215-30224	mysteries	_	
180-283	30225-30227	of	_	
180-284	30228-30231	the	_	
180-285	30232-30240	habenula	_	
180-286	30241-30243	in	_	
180-287	30244-30248	pain	_	
180-288	30249-30252	and	_	
180-289	30253-30262	analgesia	_	
180-290	30263-30264	A	_	
180-291	30265-30270	novel	_	
180-292	30271-30279	approach	_	
180-293	30280-30282	to	_	
180-294	30283-30294	identifying	_	
180-295	30295-30296	a	_	
180-296	30297-30309	neuroimaging	_	
180-297	30310-30319	biomarker	_	
180-298	30320-30323	for	_	
180-299	30324-30332	patients	_	
180-300	30333-30337	with	_	
180-301	30338-30345	serious	_	
180-302	30346-30352	mental	_	
180-303	30353-30360	illness	_	
180-304	30361-30369	Enhanced	_	
180-305	30370-30379	Olfactory	_	
180-306	30380-30386	Cortex	_	
180-307	30387-30399	Connectivity	_	
180-308	30400-30402	in	_	
180-309	30403-30404	a	_	
180-310	30405-30412	Patient	_	
180-311	30413-30417	With	_	
180-312	30418-30422	PTSD	_	
180-313	30423-30427	With	_	
180-314	30428-30437	Olfactory	_	
180-315	30438-30452	Hallucinations	_	
180-316	30453-30469	Interhemispheric	_	
180-317	30470-30477	insular	_	
180-318	30478-30481	and	_	
180-319	30482-30490	inferior	_	
180-320	30491-30498	frontal	_	
180-321	30499-30511	connectivity	_	
180-322	30512-30515	are	_	
180-323	30516-30526	associated	_	
180-324	30527-30531	with	_	
180-325	30532-30541	substance	_	
180-326	30542-30547	abuse	_	
180-327	30548-30550	in	_	
180-328	30551-30552	a	_	
180-329	30553-30564	psychiatric	_	
180-330	30565-30575	population	_	
180-331	30578-30588	Validation	_	
180-332	30589-30591	of	_	
180-333	30592-30595	the	_	
180-334	30596-30603	Alcohol	_	
180-335	30603-30604	,	_	
180-336	30605-30612	Smoking	_	
180-337	30613-30616	And	_	
180-338	30617-30626	Substance	_	
180-339	30627-30638	Involvement	_	
180-340	30639-30648	Screening	_	
180-341	30649-30653	Test	_	
180-342	30654-30655	(	_	
180-343	30655-30661	ASSIST	_	
180-344	30661-30662	)	_	
180-345	30663-30667	Conn	_	
180-346	30667-30668	:	_	
180-347	30669-30670	a	_	
180-348	30671-30681	functional	_	
180-349	30682-30694	connectivity	_	
180-350	30695-30702	toolbox	_	
180-351	30703-30706	for	_	
180-352	30707-30717	correlated	_	
180-353	30718-30721	and	_	
180-354	30722-30736	anticorrelated	_	
180-355	30737-30742	brain	_	
180-356	30743-30751	networks	_	
180-357	30752-30756	AFNI	_	
180-358	30756-30757	:	_	
180-359	30758-30766	software	_	
180-360	30767-30770	for	_	
180-361	30771-30779	analysis	_	
180-362	30780-30783	and	_	
180-363	30784-30797	visualization	_	
180-364	30798-30800	of	_	
180-365	30801-30811	functional	_	
180-366	30812-30820	magnetic	_	
180-367	30821-30830	resonance	_	
180-368	30831-30842	neuroimages	_	
180-369	30843-30846	DBH	_	
180-370	30847-30851	gene	_	
180-371	30852-30854	as	_	
180-372	30855-30864	predictor	_	
180-373	30865-30867	of	_	
180-374	30868-30876	response	_	
180-375	30877-30879	in	_	
180-376	30880-30881	a	_	
180-377	30882-30889	cocaine	_	
180-378	30890-30897	vaccine	_	
180-379	30898-30906	clinical	_	
180-380	30907-30912	trial	_	
180-381	30913-30926	Proportioning	_	
180-382	30927-30939	whole-genome	_	
180-383	30940-30970	single-nucleotide-polymorphism	_	
180-384	30971-30980	diversity	_	
180-385	30981-30984	for	_	
180-386	30985-30988	the	_	
180-387	30989-31003	identification	_	
180-388	31004-31006	of	_	
180-389	31007-31017	geographic	_	
180-390	31018-31028	population	_	
180-391	31029-31038	structure	_	
180-392	31039-31042	and	_	
180-393	31043-31050	genetic	_	
180-394	31051-31059	ancestry	_	
180-395	31060-31064	BOLD	_	
180-396	31065-31074	Responses	_	
180-397	31075-31077	to	_	
180-398	31078-31086	Negative	_	
180-399	31087-31093	Reward	_	
180-400	31094-31104	Prediction	_	
180-401	31105-31111	Errors	_	
180-402	31112-31114	in	_	
180-403	31115-31120	Human	_	
180-404	31121-31129	Habenula	_	
180-405	31130-31139	Asymmetry	_	
180-406	31140-31142	in	_	
180-407	31143-31153	functional	_	
180-408	31154-31166	connectivity	_	
180-409	31167-31169	of	_	
180-410	31170-31173	the	_	
180-411	31174-31179	human	_	
180-412	31180-31188	habenula	_	
180-413	31189-31197	revealed	_	
180-414	31198-31200	by	_	
180-415	31201-31216	high-resolution	_	
180-416	31217-31230	cardiac-gated	_	
180-417	31231-31238	resting	_	
180-418	31239-31244	state	_	
180-419	31245-31252	imaging	_	
180-420	31253-31267	Characterizing	_	
180-421	31268-31273	white	_	
180-422	31274-31280	matter	_	
180-423	31281-31288	changes	_	
180-424	31289-31291	in	_	
180-425	31292-31301	cigarette	_	
180-426	31302-31309	smokers	_	
180-427	31310-31313	via	_	
180-428	31314-31323	diffusion	_	
180-429	31324-31330	tensor	_	
180-430	31331-31338	imaging	_	
180-431	31339-31348	Affective	_	
180-432	31349-31352	and	_	
180-433	31353-31362	cognitive	_	
180-434	31363-31373	prefrontal	_	
180-435	31374-31380	cortex	_	
180-436	31381-31392	projections	_	
180-437	31393-31395	to	_	
180-438	31396-31399	the	_	
180-439	31400-31407	lateral	_	
180-440	31408-31416	habenula	_	
180-441	31417-31419	in	_	
180-442	31420-31426	humans	_	
180-443	31427-31431	Risk	_	
180-444	31432-31435	for	_	
180-445	31436-31444	nicotine	_	
180-446	31445-31455	dependence	_	
180-447	31456-31459	and	_	
180-448	31460-31464	lung	_	
180-449	31465-31471	cancer	_	
180-450	31472-31474	is	_	
180-451	31475-31484	conferred	_	
180-452	31485-31487	by	_	
180-453	31488-31492	mRNA	_	
180-454	31493-31503	expression	_	
180-455	31504-31510	levels	_	
180-456	31511-31514	and	_	
180-457	31515-31520	amino	_	
180-458	31521-31525	acid	_	
180-459	31526-31532	change	_	
180-460	31533-31535	in	_	
180-461	31536-31542	CHRNA5	_	
180-462	31543-31551	Habenula	_	
180-463	31552-31555	and	_	
180-464	31556-31559	the	_	
180-465	31560-31570	asymmetric	_	
180-466	31571-31582	development	_	
180-467	31583-31585	of	_	
180-468	31586-31589	the	_	
180-469	31590-31600	vertebrate	_	
180-470	31601-31606	brain	_	
180-471	31607-31620	Resting-state	_	
180-472	31621-31631	functional	_	
180-473	31632-31644	connectivity	_	
180-474	31645-31647	of	_	
180-475	31648-31651	the	_	
180-476	31652-31657	human	_	
180-477	31658-31666	habenula	_	
180-478	31667-31669	in	_	
180-479	31670-31677	healthy	_	
180-480	31678-31689	individuals	_	
180-481	31689-31690	:	_	
180-482	31691-31703	Associations	_	
180-483	31704-31708	with	_	
180-484	31709-31720	subclinical	_	
180-485	31721-31731	depression	_	
180-486	31732-31741	Asymmetry	_	
180-487	31742-31744	in	_	
180-488	31745-31755	functional	_	
180-489	31756-31768	connectivity	_	
180-490	31769-31771	of	_	
180-491	31772-31775	the	_	
180-492	31776-31781	human	_	
180-493	31782-31790	habenula	_	
180-494	31791-31799	revealed	_	
180-495	31800-31802	by	_	
180-496	31803-31818	high-resolution	_	
180-497	31819-31832	cardiac-gated	_	
180-498	31833-31840	resting	_	
180-499	31841-31846	state	_	
180-500	31847-31854	imaging	_	
180-501	31855-31858	The	_	
180-502	31859-31865	medial	_	
180-503	31866-31874	habenula	_	
180-504	31874-31875	:	_	
180-505	31876-31881	still	_	
180-506	31882-31891	neglected	_	
180-507	31892-31900	Temporal	_	
180-508	31901-31910	Evolution	_	
180-509	31911-31913	of	_	
180-510	31914-31919	Brain	_	
180-511	31920-31930	Functional	_	
180-512	31931-31943	Connectivity	_	
180-513	31944-31951	Metrics	_	
180-514	31951-31952	:	_	
180-515	31953-31958	Could	_	
180-516	31959-31960	7	_	
180-517	31961-31964	Min	_	
180-518	31965-31967	of	_	
180-519	31968-31972	Rest	_	
180-520	31973-31975	be	_	
180-521	31976-31982	Enough	_	
180-522	31982-31983	?	_	

#Text=Regions of interest.
181-1	31984-31991	Regions	_	
181-2	31992-31994	of	_	
181-3	31995-32003	interest	_	
181-4	32003-32004	.	_	

#Text=A) Striatum (Str) (subdivided into caudate (Caud), putamen (Put) and globus pallidus (GP) on different colors on the left side).
182-1	32005-32006	A	_	
182-2	32006-32007	)	_	
182-3	32008-32016	Striatum	_	
182-4	32017-32018	(	_	
182-5	32018-32021	Str	_	
182-6	32021-32022	)	_	
182-7	32023-32024	(	_	
182-8	32024-32034	subdivided	_	
182-9	32035-32039	into	_	
182-10	32040-32047	caudate	_	
182-11	32048-32049	(	_	
182-12	32049-32053	Caud	_	
182-13	32053-32054	)	_	
182-14	32054-32055	,	_	
182-15	32056-32063	putamen	_	
182-16	32064-32065	(	_	
182-17	32065-32068	Put	_	
182-18	32068-32069	)	_	
182-19	32070-32073	and	_	
182-20	32074-32080	globus	_	
182-21	32081-32089	pallidus	_	
182-22	32090-32091	(	_	
182-23	32091-32093	GP	_	
182-24	32093-32094	)	_	
182-25	32095-32097	on	_	
182-26	32098-32107	different	_	
182-27	32108-32114	colors	_	
182-28	32115-32117	on	_	
182-29	32118-32121	the	_	
182-30	32122-32126	left	_	
182-31	32127-32131	side	_	
182-32	32131-32132	)	_	
182-33	32132-32133	.	_	

#Text=B) Habenula region of interest was one 3×3×3 cube on each side, manually located using the T1 and functional images as guide.
183-1	32134-32135	B	_	
183-2	32135-32136	)	_	
183-3	32137-32145	Habenula	_	
183-4	32146-32152	region	_	
183-5	32153-32155	of	_	
183-6	32156-32164	interest	_	
183-7	32165-32168	was	_	
183-8	32169-32172	one	_	
183-9	32173-32174	3	_	
183-10	32174-32175	×	_	
183-11	32175-32176	3	_	
183-12	32176-32177	×	_	
183-13	32177-32178	3	_	
183-14	32179-32183	cube	_	
183-15	32184-32186	on	_	
183-16	32187-32191	each	_	
183-17	32192-32196	side	_	
183-18	32196-32197	,	_	
183-19	32198-32206	manually	_	
183-20	32207-32214	located	_	
183-21	32215-32220	using	_	
183-22	32221-32224	the	_	
183-23	32225-32227	T1	_	
183-24	32228-32231	and	_	
183-25	32232-32242	functional	_	
183-26	32243-32249	images	_	
183-27	32250-32252	as	_	
183-28	32253-32258	guide	_	
183-29	32258-32259	.	_	

#Text=C), D), E) Exploratory ROIs: C) superior, medial, inferior frontal gyri (s, m, i), insula (Ins), anterior cingulate cortex (ACC); D) nucleus accumbens (nAcc), amygdala (Amy); E) Septum verum (SV), Locus coeruleus (LC).
184-1	32260-32261	C	_	
184-2	32261-32262	)	_	
184-3	32262-32263	,	_	
184-4	32264-32265	D	_	
184-5	32265-32266	)	_	
184-6	32266-32267	,	_	
184-7	32268-32269	E	_	
184-8	32269-32270	)	_	
184-9	32271-32282	Exploratory	_	
184-10	32283-32287	ROIs	_	
184-11	32287-32288	:	_	
184-12	32289-32290	C	_	
184-13	32290-32291	)	_	
184-14	32292-32300	superior	_	
184-15	32300-32301	,	_	
184-16	32302-32308	medial	_	
184-17	32308-32309	,	_	
184-18	32310-32318	inferior	_	
184-19	32319-32326	frontal	_	
184-20	32327-32331	gyri	_	
184-21	32332-32333	(	_	
184-22	32333-32334	s	_	
184-23	32334-32335	,	_	
184-24	32336-32337	m	_	
184-25	32337-32338	,	_	
184-26	32339-32340	i	_	
184-27	32340-32341	)	_	
184-28	32341-32342	,	_	
184-29	32343-32349	insula	_	
184-30	32350-32351	(	_	
184-31	32351-32354	Ins	_	
184-32	32354-32355	)	_	
184-33	32355-32356	,	_	
184-34	32357-32365	anterior	_	
184-35	32366-32375	cingulate	_	
184-36	32376-32382	cortex	_	
184-37	32383-32384	(	_	
184-38	32384-32387	ACC	_	
184-39	32387-32388	)	_	
184-40	32388-32389	;	_	
184-41	32390-32391	D	_	
184-42	32391-32392	)	_	
184-43	32393-32400	nucleus	_	
184-44	32401-32410	accumbens	_	
184-45	32411-32412	(	_	
184-46	32412-32416	nAcc	_	
184-47	32416-32417	)	_	
184-48	32417-32418	,	_	
184-49	32419-32427	amygdala	_	
184-50	32428-32429	(	_	
184-51	32429-32432	Amy	_	
184-52	32432-32433	)	_	
184-53	32433-32434	;	_	
184-54	32435-32436	E	_	
184-55	32436-32437	)	_	
184-56	32438-32444	Septum	_	
184-57	32445-32450	verum	_	
184-58	32451-32452	(	_	
184-59	32452-32454	SV	_	
184-60	32454-32455	)	_	
184-61	32455-32456	,	_	
184-62	32457-32462	Locus	_	
184-63	32463-32472	coeruleus	_	
184-64	32473-32474	(	_	
184-65	32474-32476	LC	_	
184-66	32476-32477	)	_	
184-67	32477-32478	.	_	

#Text=Sample description.
185-1	32479-32485	Sample	_	
185-2	32486-32497	description	_	
185-3	32497-32498	.	_	

#Text=A) Number of patients that were positive for moderate/high use for each drug of abuse according to the ASSIST questionnaire.
186-1	32499-32500	A	_	
186-2	32500-32501	)	_	
186-3	32502-32508	Number	_	
186-4	32509-32511	of	_	
186-5	32512-32520	patients	_	
186-6	32521-32525	that	_	
186-7	32526-32530	were	_	
186-8	32531-32539	positive	_	
186-9	32540-32543	for	_	
186-10	32544-32552	moderate	_	
186-11	32552-32553	/	_	
186-12	32553-32557	high	_	
186-13	32558-32561	use	_	
186-14	32562-32565	for	_	
186-15	32566-32570	each	_	
186-16	32571-32575	drug	_	
186-17	32576-32578	of	_	
186-18	32579-32584	abuse	_	
186-19	32585-32594	according	_	
186-20	32595-32597	to	_	
186-21	32598-32601	the	_	
186-22	32602-32608	ASSIST	_	
186-23	32609-32622	questionnaire	_	
186-24	32622-32623	.	_	

#Text=Both total positives (gray bars) and unique positives (white bars, patients who were positive for only one drug) are shown.
187-1	32624-32628	Both	_	
187-2	32629-32634	total	_	
187-3	32635-32644	positives	_	
187-4	32645-32646	(	_	
187-5	32646-32650	gray	_	
187-6	32651-32655	bars	_	
187-7	32655-32656	)	_	
187-8	32657-32660	and	_	
187-9	32661-32667	unique	_	
187-10	32668-32677	positives	_	
187-11	32678-32679	(	_	
187-12	32679-32684	white	_	
187-13	32685-32689	bars	_	
187-14	32689-32690	,	_	
187-15	32691-32699	patients	_	
187-16	32700-32703	who	_	
187-17	32704-32708	were	_	
187-18	32709-32717	positive	_	
187-19	32718-32721	for	_	
187-20	32722-32726	only	_	
187-21	32727-32730	one	_	
187-22	32731-32735	drug	_	
187-23	32735-32736	)	_	
187-24	32737-32740	are	_	
187-25	32741-32746	shown	_	
187-26	32746-32747	.	_	

#Text=B) Number of patient positive use of for none, one, or more drugs (according to ASSIST questionnaire).
188-1	32748-32749	B	_	
188-2	32749-32750	)	_	
188-3	32751-32757	Number	_	
188-4	32758-32760	of	_	
188-5	32761-32768	patient	_	
188-6	32769-32777	positive	_	
188-7	32778-32781	use	_	
188-8	32782-32784	of	_	
188-9	32785-32788	for	_	
188-10	32789-32793	none	_	
188-11	32793-32794	,	_	
188-12	32795-32798	one	_	
188-13	32798-32799	,	_	
188-14	32800-32802	or	_	
188-15	32803-32807	more	_	
188-16	32808-32813	drugs	_	
188-17	32814-32815	(	_	
188-18	32815-32824	according	_	
188-19	32825-32827	to	_	
188-20	32828-32834	ASSIST	_	
188-21	32835-32848	questionnaire	_	
188-22	32848-32849	)	_	
188-23	32849-32850	.	_	

#Text=C) Number of patients diagnosed for each of the four most common DSM-IV diagnoses in the sample: Major depressive disorder (MDD), substance use disorder (SUD), anxiety disorders (ANX), and personality disorders (PD).
189-1	32851-32852	C	_	
189-2	32852-32853	)	_	
189-3	32854-32860	Number	_	
189-4	32861-32863	of	_	
189-5	32864-32872	patients	_	
189-6	32873-32882	diagnosed	_	
189-7	32883-32886	for	_	
189-8	32887-32891	each	_	
189-9	32892-32894	of	_	
189-10	32895-32898	the	_	
189-11	32899-32903	four	_	
189-12	32904-32908	most	_	
189-13	32909-32915	common	_	
189-14	32916-32922	DSM-IV	_	
189-15	32923-32932	diagnoses	_	
189-16	32933-32935	in	_	
189-17	32936-32939	the	_	
189-18	32940-32946	sample	_	
189-19	32946-32947	:	_	
189-20	32948-32953	Major	_	
189-21	32954-32964	depressive	_	
189-22	32965-32973	disorder	_	
189-23	32974-32975	(	_	
189-24	32975-32978	MDD	_	
189-25	32978-32979	)	_	
189-26	32979-32980	,	_	
189-27	32981-32990	substance	_	
189-28	32991-32994	use	_	
189-29	32995-33003	disorder	_	
189-30	33004-33005	(	_	
189-31	33005-33008	SUD	_	
189-32	33008-33009	)	_	
189-33	33009-33010	,	_	
189-34	33011-33018	anxiety	_	
189-35	33019-33028	disorders	_	
189-36	33029-33030	(	_	
189-37	33030-33033	ANX	_	
189-38	33033-33034	)	_	
189-39	33034-33035	,	_	
189-40	33036-33039	and	_	
189-41	33040-33051	personality	_	
189-42	33052-33061	disorders	_	
189-43	33062-33063	(	_	
189-44	33063-33065	PD	_	
189-45	33065-33066	)	_	
189-46	33066-33067	.	_	

#Text=Both total diagnosed (gray bars) and unique positives (white bars, patients who had only one diagnosis) are shown.
190-1	33068-33072	Both	_	
190-2	33073-33078	total	_	
190-3	33079-33088	diagnosed	_	
190-4	33089-33090	(	_	
190-5	33090-33094	gray	_	
190-6	33095-33099	bars	_	
190-7	33099-33100	)	_	
190-8	33101-33104	and	_	
190-9	33105-33111	unique	_	
190-10	33112-33121	positives	_	
190-11	33122-33123	(	_	
190-12	33123-33128	white	_	
190-13	33129-33133	bars	_	
190-14	33133-33134	,	_	
190-15	33135-33143	patients	_	
190-16	33144-33147	who	_	
190-17	33148-33151	had	_	
190-18	33152-33156	only	_	
190-19	33157-33160	one	_	
190-20	33161-33170	diagnosis	_	
190-21	33170-33171	)	_	
190-22	33172-33175	are	_	
190-23	33176-33181	shown	_	
190-24	33181-33182	.	_	

#Text=D) Number of patient with none, one, or more diagnoses (counting only the four most common diagnoses, therefore zero are patients other than MDD, SUD, ANX or PD).
191-1	33183-33184	D	_	
191-2	33184-33185	)	_	
191-3	33186-33192	Number	_	
191-4	33193-33195	of	_	
191-5	33196-33203	patient	_	
191-6	33204-33208	with	_	
191-7	33209-33213	none	_	
191-8	33213-33214	,	_	
191-9	33215-33218	one	_	
191-10	33218-33219	,	_	
191-11	33220-33222	or	_	
191-12	33223-33227	more	_	
191-13	33228-33237	diagnoses	_	
191-14	33238-33239	(	_	
191-15	33239-33247	counting	_	
191-16	33248-33252	only	_	
191-17	33253-33256	the	_	
191-18	33257-33261	four	_	
191-19	33262-33266	most	_	
191-20	33267-33273	common	_	
191-21	33274-33283	diagnoses	_	
191-22	33283-33284	,	_	
191-23	33285-33294	therefore	_	
191-24	33295-33299	zero	_	
191-25	33300-33303	are	_	
191-26	33304-33312	patients	_	
191-27	33313-33318	other	_	
191-28	33319-33323	than	_	
191-29	33324-33327	MDD	_	
191-30	33327-33328	,	_	
191-31	33329-33332	SUD	_	
191-32	33332-33333	,	_	
191-33	33334-33337	ANX	_	
191-34	33338-33340	or	_	
191-35	33341-33343	PD	_	
191-36	33343-33344	)	_	
191-37	33344-33345	.	_	

#Text=Habenula/striatum resting state functional connectivity (Hb/Str RSFC) in opioid users and psychiatric patient controls.
192-1	33346-33354	Habenula	_	
192-2	33354-33355	/	_	
192-3	33355-33363	striatum	_	
192-4	33364-33371	resting	_	
192-5	33372-33377	state	_	
192-6	33378-33388	functional	_	
192-7	33389-33401	connectivity	_	
192-8	33402-33403	(	_	
192-9	33403-33405	Hb	_	
192-10	33405-33406	/	_	
192-11	33406-33409	Str	_	
192-12	33410-33414	RSFC	_	
192-13	33414-33415	)	_	
192-14	33416-33418	in	_	
192-15	33419-33425	opioid	_	
192-16	33426-33431	users	_	
192-17	33432-33435	and	_	
192-18	33436-33447	psychiatric	_	
192-19	33448-33455	patient	_	
192-20	33456-33464	controls	_	
192-21	33464-33465	.	_	

#Text=A) RSFC between the right and the left habenula (RHb, LHb) and the whole striatum (composed of caudate, putamen and globus pallidus).
193-1	33466-33467	A	_	
193-2	33467-33468	)	_	
193-3	33469-33473	RSFC	_	
193-4	33474-33481	between	_	
193-5	33482-33485	the	_	
193-6	33486-33491	right	_	
193-7	33492-33495	and	_	
193-8	33496-33499	the	_	
193-9	33500-33504	left	_	
193-10	33505-33513	habenula	_	
193-11	33514-33515	(	_	
193-12	33515-33518	RHb	_	
193-13	33518-33519	,	_	
193-14	33520-33523	LHb	_	
193-15	33523-33524	)	_	
193-16	33525-33528	and	_	
193-17	33529-33532	the	_	
193-18	33533-33538	whole	_	
193-19	33539-33547	striatum	_	
193-20	33548-33549	(	_	
193-21	33549-33557	composed	_	
193-22	33558-33560	of	_	
193-23	33561-33568	caudate	_	
193-24	33568-33569	,	_	
193-25	33570-33577	putamen	_	
193-26	33578-33581	and	_	
193-27	33582-33588	globus	_	
193-28	33589-33597	pallidus	_	
193-29	33597-33598	)	_	
193-30	33598-33599	.	_	

#Text=B) RSFC between the right and the left habenula and each sub-region of the striatum.
194-1	33600-33601	B	_	
194-2	33601-33602	)	_	
194-3	33603-33607	RSFC	_	
194-4	33608-33615	between	_	
194-5	33616-33619	the	_	
194-6	33620-33625	right	_	
194-7	33626-33629	and	_	
194-8	33630-33633	the	_	
194-9	33634-33638	left	_	
194-10	33639-33647	habenula	_	
194-11	33648-33651	and	_	
194-12	33652-33656	each	_	
194-13	33657-33667	sub-region	_	
194-14	33668-33670	of	_	
194-15	33671-33674	the	_	
194-16	33675-33683	striatum	_	
194-17	33683-33684	.	_	

#Text=No op: patients with no opioid use, Op: patients with opioid use. * p<0.05.
195-1	33685-33687	No	_	
195-2	33688-33690	op	_	
195-3	33690-33691	:	_	
195-4	33692-33700	patients	_	
195-5	33701-33705	with	_	
195-6	33706-33708	no	_	
195-7	33709-33715	opioid	_	
195-8	33716-33719	use	_	
195-9	33719-33720	,	_	
195-10	33721-33723	Op	_	
195-11	33723-33724	:	_	
195-12	33725-33733	patients	_	
195-13	33734-33738	with	_	
195-14	33739-33745	opioid	_	
195-15	33746-33749	use	_	
195-16	33749-33750	.	_	
195-17	33751-33752	*	_	
195-18	33753-33754	p	_	
195-19	33754-33755	<	_	
195-20	33755-33759	0.05	_	
195-21	33759-33760	.	_	

#Text=C) Right habenula/left caudate connectivity and alpha 5 nicotinic acetylcholine receptor subunit genetic variant rs16969968 genotype.
196-1	33761-33762	C	_	
196-2	33762-33763	)	_	
196-3	33764-33769	Right	_	
196-4	33770-33778	habenula	_	
196-5	33778-33779	/	_	
196-6	33779-33783	left	_	
196-7	33784-33791	caudate	_	
196-8	33792-33804	connectivity	_	
196-9	33805-33808	and	_	
196-10	33809-33814	alpha	_	
196-11	33815-33816	5	_	
196-12	33817-33826	nicotinic	_	
196-13	33827-33840	acetylcholine	_	
196-14	33841-33849	receptor	_	
196-15	33850-33857	subunit	_	
196-16	33858-33865	genetic	_	
196-17	33866-33873	variant	_	
196-18	33874-33884	rs16969968	_	
196-19	33885-33893	genotype	_	
196-20	33893-33894	.	_	

#Text=The low risk GG genotype shows increased connectivity in opioid-dependent patients compared to those carrying an A-allele and non-opioid users with GG genotype.
197-1	33895-33898	The	_	
197-2	33899-33902	low	_	
197-3	33903-33907	risk	_	
197-4	33908-33910	GG	_	
197-5	33911-33919	genotype	_	
197-6	33920-33925	shows	_	
197-7	33926-33935	increased	_	
197-8	33936-33948	connectivity	_	
197-9	33949-33951	in	_	
197-10	33952-33968	opioid-dependent	_	
197-11	33969-33977	patients	_	
197-12	33978-33986	compared	_	
197-13	33987-33989	to	_	
197-14	33990-33995	those	_	
197-15	33996-34004	carrying	_	
197-16	34005-34007	an	_	
197-17	34008-34016	A-allele	_	
197-18	34017-34020	and	_	
197-19	34021-34031	non-opioid	_	
197-20	34032-34037	users	_	
197-21	34038-34042	with	_	
197-22	34043-34045	GG	_	
197-23	34046-34054	genotype	_	
197-24	34054-34055	.	_	

#Text=No opi: patients with no opioid use, opi, patients with opioid use. * p<0.05 (LSD).
198-1	34056-34058	No	_	
198-2	34059-34062	opi	_	
198-3	34062-34063	:	_	
198-4	34064-34072	patients	_	
198-5	34073-34077	with	_	
198-6	34078-34080	no	_	
198-7	34081-34087	opioid	_	
198-8	34088-34091	use	_	
198-9	34091-34092	,	_	
198-10	34093-34096	opi	_	
198-11	34096-34097	,	_	
198-12	34098-34106	patients	_	
198-13	34107-34111	with	_	
198-14	34112-34118	opioid	_	
198-15	34119-34122	use	_	
198-16	34122-34123	.	_	
198-17	34124-34125	*	_	
198-18	34126-34127	p	_	
198-19	34127-34128	<	_	
198-20	34128-34132	0.05	_	
198-21	34133-34134	(	_	
198-22	34134-34137	LSD	_	
198-23	34137-34138	)	_	
198-24	34138-34139	.	_	

#Text=Demographic characteristics of the sample.
199-1	34140-34151	Demographic	_	
199-2	34152-34167	characteristics	_	
199-3	34168-34170	of	_	
199-4	34171-34174	the	_	
199-5	34175-34181	sample	_	
199-6	34181-34182	.	_	

#Text=No differences were statistically significant between the two groups (Chi square test).
200-1	34183-34185	No	_	
200-2	34186-34197	differences	_	
200-3	34198-34202	were	_	
200-4	34203-34216	statistically	_	
200-5	34217-34228	significant	_	
200-6	34229-34236	between	_	
200-7	34237-34240	the	_	
200-8	34241-34244	two	_	
200-9	34245-34251	groups	_	
200-10	34252-34253	(	_	
200-11	34253-34256	Chi	_	
200-12	34257-34263	square	_	
200-13	34264-34268	test	_	
200-14	34268-34269	)	_	
200-15	34269-34270	.	_	

#Text=OpioidNon-Users\tOpioidUsers\t \tN\t254\t51\t \tGender (% male)\t53\t75\t \tAge (years; SD)\t31.4; 12.4\t28.1; 11.4\t \tMDD Spectrum (%)\t64\t57\t \tAnxiety Spectrum (%)\t56\t63\t \tAny PD (%)\t34\t43\t \trs16969968 GG (%)\t50\t51\t \t
#Text=PD: personality disorders.
201-1	34272-34287	OpioidNon-Users	_	
201-2	34288-34299	OpioidUsers	_	
201-3	34302-34303	N	_	
201-4	34304-34307	254	_	
201-5	34308-34310	51	_	
201-6	34313-34319	Gender	_	
201-7	34320-34321	(	_	
201-8	34321-34322	%	_	
201-9	34323-34327	male	_	
201-10	34327-34328	)	_	
201-11	34329-34331	53	_	
201-12	34332-34334	75	_	
201-13	34337-34340	Age	_	
201-14	34341-34342	(	_	
201-15	34342-34347	years	_	
201-16	34347-34348	;	_	
201-17	34349-34351	SD	_	
201-18	34351-34352	)	_	
201-19	34353-34357	31.4	_	
201-20	34357-34358	;	_	
201-21	34359-34363	12.4	_	
201-22	34364-34368	28.1	_	
201-23	34368-34369	;	_	
201-24	34370-34374	11.4	_	
201-25	34377-34380	MDD	_	
201-26	34381-34389	Spectrum	_	
201-27	34390-34391	(	_	
201-28	34391-34392	%	_	
201-29	34392-34393	)	_	
201-30	34394-34396	64	_	
201-31	34397-34399	57	_	
201-32	34402-34409	Anxiety	_	
201-33	34410-34418	Spectrum	_	
201-34	34419-34420	(	_	
201-35	34420-34421	%	_	
201-36	34421-34422	)	_	
201-37	34423-34425	56	_	
201-38	34426-34428	63	_	
201-39	34431-34434	Any	_	
201-40	34435-34437	PD	_	
201-41	34438-34439	(	_	
201-42	34439-34440	%	_	
201-43	34440-34441	)	_	
201-44	34442-34444	34	_	
201-45	34445-34447	43	_	
201-46	34450-34460	rs16969968	_	
201-47	34461-34463	GG	_	
201-48	34464-34465	(	_	
201-49	34465-34466	%	_	
201-50	34466-34467	)	_	
201-51	34468-34470	50	_	
201-52	34471-34473	51	_	
201-53	34477-34479	PD	_	
201-54	34479-34480	:	_	
201-55	34481-34492	personality	_	
201-56	34493-34502	disorders	_	
201-57	34502-34503	.	_	
